How long have these symptoms been present?
All diseases should be treated this way, especially at your age.
and a fever.
You will also need to have your cholesterol monitored for hypertension.
Do you have a fever now?
Do you have a cold now?
Do you also have breathing problems?
Can you tell me about any other symptoms you have with this?
how was your fever?
I have a cough too.
I have a report of colds and coughs.
And I actually have a little bit of a terrible fever today.
It's the perfect time for your samba.
had a severe case of pneumonia
I think I have a little bit of a hangover.
I want you to describe the symptoms of mesothelioma.
They also have the fever data.
and your family history.
You know, it feels like my heart is breaking.
You know, people cough all the time.
Do you have a tick bite?
You said there's a pressure in your chest.
any family member with heart disease, stroke, heart problems, heart problems, high cholesterol, high blood pressure
any other symptoms or problems with your muscle pain?
Are there other people who are just as sick as you are and are in your home with the same symptoms?
Do you have any symptoms like this?
Do you have a shortness of breath?
Do you still have the flu?
Because it's the winter season.
But we also had to rule out chest pains and heart attacks.
But another problem that is very important right now is the epidemic bite.
But I have a problem with my breathing.
But I know a lot of people have been turned off by me.
But we need to address every pain with the utmost honesty.
But you're breathing fine now, right?
I was completely oblivious to the pain in my back.
Does it feel like someone is kicking you in the chest?
It still feels like it's breathing a little too slowly.
Are they worried that they are suffering from the same symptoms?
Do you have any chronic pain disorder, like high blood pressure or anything?
Do you have any other chronic pain problems like multiple sclerosis?
Do you have any symptoms of respiratory failure?
Do you have high blood pressure?
Do you have any respiratory symptoms associated with this?
Do you know what the symptoms are?
Do you see the scenery?
A lot of liquid today.
Anyway, I'm taking the tests, you know.
However, it has the same symptoms as mine.
How high is your fever?
How's your blood pressure?
if you have a persistent high fever
if you have a fever of 102 or higher
if you think your symptoms or problems deserve attention
I had a fever yesterday.
He had a little bit of information, too.
I had fever yesterday.
I have a scar right here on my chest.
I also had some breathing problems.
I'll send it to the magazine.
I have a heart-attack report today.
I have a little bit of headache data and a little bit of sore throat data today.
And this, to my mind, is a cold.
I think this is a small flu.
It's like there's a heavy, heavy, heavy person sitting on my chest.
It all started with a headache and a fever all at the same time.
It hurts the center of my chest.
It's like stress, like a sore thumb.
It's in my heart.
It's right in the middle of my heart.
It's in the middle of the chest.
I had a pain in my chest.
I'm very concerned about the impact of this disease.
I want you to be able to describe this disorder.
such as high blood pressure or diabetes
It's like the right side of my chest.
Now you can take the tachipirina for a sweet.
how many days have you had the symptoms
You just said that you have a pain in your thigh.
Sometimes I have this pain in my knee.
Well, do you have any accompanying symptoms other than the pain?
Is there someone sitting on your chest?
It's more like fever and coughs, headaches and muscle aches.
Right side of the middle of my chest.
Show me where you feel the pain in the picture.
until you had the fever
So do you think that some of these symptoms are related to being pregnant?
So do your kids have that same set of symptoms?
Tell me about your pain.
Night fever is worse.
the fever I've had for the past two days.
The fever starts to get worse.
This is Dr. Porter in the emergency room of the ICU.
So can you tell me a little bit more about your pain management system?
So I have a little bit of pain in my upper body, here in my chest.
I had this really bad, bad, pain in my jaw.
Well, when I have this pain in my chest,
So what kind of pain do you have in your chest?
How did the pain start?
Where is the pain in your knee?
where you feel this throbbing pain in your chest
You feel your hips touch each other.
You know, I had the flu and stuff.
You said you had this sickness of the thigh.
Rapid spread of total coronavirus disease (COVID-19) cases within the European Union/European Economic Area and the United Kingdom, from 1 January to 15 March 2020
The overall incidence of coronavirus (COVID-19) cases shows similar patterns to the European Union/European Economic Area and the United Kingdom confirming the same, while at different stages depending on the country, the global COVID-19 epidemic is spreading rapidly across the country.
Based on the experience of Italy, countries, hospitals and acute care units should increase their preparedness to pursue COVID-19 patients who require medical care, especially acute care.
On 31 December 2020, a cluster of cases of unknown origin was reported in Wuhan, Hubei Province, China.
On 9 January 2020, the Chinese Center for Disease Control and Prevention reported the cause of the novel coronavirus, now called severe respiratory syndrome coronavirus 2 (SARS-CoV-2).
Until now, the SARS-CoV-2 infectious disease was known as the coronavirus disease (COVID-19).
Evidence suggests that up to 80% of people with COVID-19 have a mild illness, such as a chronic respiratory infection or chronic bronchitis, and usually recover.
In about 14% of cases, COVID-19 progresses to a severe illness requiring treatment, while in the remaining 6% of cases, it develops to a severe illness requiring immediate care.
The mortality rate for COVID-19 patients undergoing treatment is approximately 4%.
In this study, we assessed the trends in all COVID-19 cases in each country in the European Union/European Economic Area (EU/EEA) and the United Kingdom (UK) and compared them to Hubei Province, China.
We also compare the current number of COVID-19 cases in the EU/EEA and the United Kingdom with the number in Italy between 31 January and 15 March 2020.
COVID-19 cases within the EU/EEA and the United Kingdom UK
After China, COVID-19 has spread to more geographically-spaced areas and the speed of the COVID-19 pandemic in the rest of the world is now similar to that of this country.
11 March 2020, the Director-General of the World Health Organization (WHO) has declared COVID-19 a global disease.
On 5 March 2020, Eurosurveilance, Spiteri et al. reported the first case of COVID-19 in Europe as defined by the World Health Organization WHO.
Within the European Union/European Economic Area, the first three confirmed cases were reported on 24 January 2020 from a person returning from Wuhan, Hubei Province, China.
On 15 March 2020, the first COVID-19 cases were detected in all 30 countries of the European Union/European Economic Area EU/EEA and the United Kingdom (UK), while between 31 December 2019 and the date mentioned, 39,768 cases and 1,727 deaths were reported, with 17,750 cases and 1,441 deaths in Italy alone.
Total number of COVID-19 cases and incidence
The European Center for Disease Control and Prevention (ECDC), the number of reported COVID-19 cases in each country in the world, as determined by official sources such as national ministries of health, national and regional health authorities and the World Health Organization, is published daily at 8:00 am.
This data was used to assess the variation of COVID-19 within the EU/EEA and the UK and to compare it with that in Italy.
As the lead case reporting for COVID-19, we calculated a 14-day decline in the overall number of COVID-19 cases, thus taking into account the natural course of COVID-19 in each EU/EEA country and the UK, over the period 1 January-15 March 2020.
We present the total number of cases detected in each country on 15 March 2020 at 8:00 a.m. compared to Italy for the period 31 January-15 March 2020.
COVID-19 trends within the EU/EEA and the UK
The 14-day variations in the sum of the reported total number of COVID-19 cases within the EU/EEA and UK are mainly concentrated in Hubei Province (China) (Table 1).
Across the EU/EEA and the UK, the total number of COVID-19 cases began to rise around 21 February and then increased rapidly around 28 February 2020 (Help Source).
This is due to the rapid spread of the number of cases reported in Italy, but all other EU/EEA countries and the UK are showing an increasing trend in the total number of COVID-19 cases (Table 1).
Chart 2 shows the total number of COVID-19 cases within the EU/EEA and UK compared to Italy from 31 January to 15 March 2020
It shows that, as of 8am on 15 March, 15 other EU/EEA countries and the UK had already announced a total number of cases that is comparable to that of Italy just two weeks earlier or less.
Our results indicate that the number of detected COVID-19 cases is increasing rapidly within the EU/EEA and the UK.
The observed variation in overall COVID-19 cases suggests that the global disease is spreading at a similar rate to all countries.
This comes as countries have different standards, differences in national public health response, and the possibility of defining different cases in different countries and different protocols for selecting which patients should be tested for COVID-19, including in the catch-up test.
In early March 2020, doctors in the affected regions of Italy reported a situation where 10% of COVID-19 patients required the intensive care unit while media sources reported that hospitals and care facilities in these regions had reached their maximum capacity.
Data on COVID-19 case registration in hospitals and/or emergency departments is currently available at EU/EEU level for only 6% and 1% of cases, respectively (data not shown).
It should, however, be collected in a systematic manner to replace the current surveillance data which focuses on the number of reported cases and the number of deaths.
A 2010-11 study showed widespread variation in the availability of emergency care and central care beds in Europe, ranging from 29.2 in Germany to 4.2 beds per 100,000 in the Portuguese community.
This means that these countries can have income more or less than Italy (12.5 acute care and central care beds per 100,000 population in 2010-11)
The design stages for the healthcare volume convergence, with estimates for each EU/EEA country and the UK prioritizing hospitalized cases of COVID-19 related to a >90% risk of exceeding the bed volume in acute care, are reflected in the sixth update of ECDC's COVID-19 emergency risk assessment.
As cases are increasing to some extent in some regions of the EU/EEA and the United Kingdom, and hospitals and acute care units normally cater for the integration of a specific regional community, information on cases and acute care beds should be made available as a priority in the NUTS level 2 (Statistical Unit Reference Area) data.
The experience of Italy and current trends in other countries show that the global COVID-19 epidemic is progressing faster in the EU/EEA and the UK.
Fields, hospitals and acute care units should be prepared for the possibility of sustained community transmission of SARS-CoV-2 and the increase in the number of COVID-19 patients requiring medical care, and especially acute care, such as that occurring in the affected regions of Italy.
As noted in the recent rapid risk assessment, a rapid, comprehensive response is essential to delay the spread of SARS-COV-2, moving from containment to mitigation, with the expected rapid increase in the number of cases likely to not give decision makers and hospitals the time to understand, accept and adapt their response appropriately if not implemented in advance.
The Rapid Risk Assessment also lists public health measures to mitigate the impact of the global pandemic.
There is little opportunity for countries with potential to increase their containment efforts to reduce the spread of SARS-COV-2 and reduce the pressure on health care.
Failing this, it is likely that healthcare systems in other EU/EEA countries will face a huge increase in patients requiring urgent care in the coming days or weeks.
The outbreak of Coronavirus Disease 2019 (COVID-19), caused by the severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2), has so far killed over 3,000 people and infected over 80,000 in China and other parts of the world, causing a humanitarian catastrophe.
Like its cousin, SARS-CoV, which caused SARS in thousands of people in 2003, SARS-CoV-2 can also pass through the sensors and cause similar symptoms by following a similar mechanism.
However, COVID-19 has a lower severity and mortality than SARS but is more transmissible and affects more adults than youth and more men than women.
In response to the rapidly growing number of emerging disease publications, this article attempts to provide a comprehensive and up-to-date view of this easily evolving research topic.
We cover the basics of the pathogenesis of infectious diseases, the origin of the disease, virology, diagnosis, treatment, prognosis of the cause, and prevention.
Although there are still many questions that need to be answered, we hope that this insight will help to understand and mitigate the devastating consequences.
The Spring Festival on January 25, 2020 became an unprecedented and unforgettable memory for all Chinese who were told to stay indoors for the entire holiday after weeks of outbreak of the new virus.
The virus is very similar to the coronavirus (CoV) that caused the severe acute respiratory syndrome (SARS) outbreak in 2003; as a result, it was named SARS-CoV-2 by the World Health Organization (WHO) on February 11, 2020, and the related disease was named CoV disease-19 (COVID-19).
The epidemic started in Wuhan, China, and has spread rapidly throughout the country and to nearly 50 other countries around the world.
As of March 2, 2020, the virus has caused more than 80,000 confirmed cases of COVID-19, with more than 40,000 patients recovering and more than 3,000 patients dying from it.
The World Health Organization warns that COVID-19 is the "number one public enemy" and is likely to be more powerful than terrorism.
According to PubMed (https://www.ncbi.nlm.nih.gov/pubmed/), in less than two months, more than 200 papers have been published on COVID-19 including its viral genome, studying its viral genome, studying its origin, diagnosis, and treatment since it was first reported on January 7, 2020 which showed similarities in how the virus can be detected in patients.
This article attempts to summarize the research progress in this emerging field.
Whenever possible, we try to compare COVID-19 to SARS and another disease caused by the CoV, Middle East Respiratory Syndrome (MERS, outbreak 2012).
We will also discuss what we have learned so far in terms of the detection and prediction of the causes of pain, as well as other outstanding and urgent questions.
CoVs have traditionally been known as non-lethal infections, often causing about 15% of cases in humans.
However, in this century, we have encountered two major human pathogenic CoVs, such as SARS-CoV and MERS-CoV, which caused an outbreak that started in China in 2003 and Saudi Arabia in 2012, respectively, and quickly spread to many other countries with poor health and mortality.
Thus, COVID-19 is now the third CoV outbreak in recorded human history.
As shown in Figure 1.1, groups of bacteria whose origins are unknown were first reported in Wuhan on 31 December 2019 to the National Health Commission of China.
Seven days after the CoV was detected, it was released.
On 15 January 2020, the first death in Wuhan was reported.
At the same time, the pandemic spread rapidly to neighboring cities, provinces and territories.
On 20 January, infection was reported by healthcare workers, suggesting that human transmission is possible.
On January 23, a lockdown was imposed in Wuhan and all public transport was suspended.
On 24 January, the first clinical study of the disease reported that of 41 confirmed cases, only 21 had direct contact with the seafood market in Wuhan, which is thought to be the site of the unknown animal source of the outbreak.
On January 30, the World Health Organization declared the outbreak to be a global public health emergency.
At the time of this report, the disease has spread from China to nearly 50 countries around the world.
As the situation is changing rapidly, the latest extent and severity of the outbreak is now in sight.
On February 11, 2020, a multi-institutional study of 8,866 patients including 4,021 confirmed COVID-19 patients presented a much-updated picture of the infectious disease as follows (https://mp.weixin.qq.com/s/UIBi-HX_rHPXa1qHA2bhdA).
SARS-CoV-2 infected people of any age, but most likely aged 30-65.
Almost half (47.7%) of the infected people were over 50 years old, a very small number were under 20, and only 14 of the infected people were under 10 years old.
SARS-CoV-2 has infected more men (0.31/100,000) than women (0.27/100,000).
COVID-19 has spread in clusters mostly in and around Hubei.
COVID-19 took an average of 5 (2-9) days from the onset to the diagnosis.
The average length of stay was 4.8 (3.0-7.2) days.
The average time from incubation to death was 9.5 to 13 days.
The baseline reproductive index (RO) was 3.77 (95% Cl: 3.51-4.05), and the modified RO was 2.23-4.82.
The number of cases rose sharply before 23 January 2020, during the hectic Chinese Spring Festival season.
Mortality in patients with confirmed cases was 1.44% (95% CI: 1.10-1.86%), and the modified mortality in patients was 3.06% (95% CI: 202-4.59%).
The three main risk factors for COVID-19 were sex (gender), age (>=60), and worsening of the collarbone.
CoVs are a subfamily of large membrane viruses that consist of a single strand of RNA.
It can be divided into four categories, namely, alpha, beta, gamma and delta, which are known to occur in humans.
The superheated S-glycoprotein binds to its cell to the angiotensin-converting enzyme 2 (ACE2) and dipeptidyl peptidase 4 (DPP4) for SARS-CoV and MERS-CoV, in a series, and then the clumping occurs.
Genome RNA containing the virus is released in the cytoplasm; after replication of the virus genome, genomic RNA is accompanied by the membrane.
The first genome sequence of SARS-CoV-2 was reported on January 10, 2020.
SARS-CoV-2 was identified as a new beta-CoV strain with over 99.98% genematic identification from 10 sequential tests collected at the site of the initial outbreak, the Huanan seafood market in Wuhan.
SARS-CoV-2 is genetically similar to SARS-CoV compared to MERS-CoV
Through electron microscope transmission, SARS-CoV-2 spores were detected in a very thin layer of the human respiratory tract.
Human ACE2 has been found to be a receptor for SARS-CoV-2 as well as SARS-CoV.
However, the S protein of SARS-CoV-2 binds to ACE2 in humans much more weakly than SARS-CoV, which is in contradiction to the fact that SARS-CoV-2 causes less severe infection in patients than SARS-CoV.
SARS-CoV-2 can also produce an abnormally short protein with orf3b and a secreted protein with orf8.
orf3b in SARS-CoV-2 may play a role in virus infection and inhibition of IFNB expression; however, orf8 has no known active site.
On February 18, 2020, Zhou, et al., reported the cryo-EM pattern of complete expansion of ACE2 in humans to the 2.9 A dilute concentration of the amino acid transporter BAT01.
They found that the gene, which opens and closes the locus, we classified as weak and ADCE2-B0AT1 can bind to two S proteins, which indicate the identity of the CoV and the infection.
B0AT1 could be a therapeutic target for investigational drugs to inhibit SARS-CoV-2 infection.
Primary and intermediate migraine.
Both SARS-CoV and MERS-CoV have been found to have evolved from the virus and transmitted to humans through cats and camels respectively.
Through a comparison of the biological lineage history of SARS-CoV-2 and other CoVs, the viruses were identified as the original carrier pathogen of SARS-CoV-2 as the new virus is 96% identical to two other SARS-CoVs found in the viruses named viruses SL-CoVX45 and viruses SL-CoVZX21.
However, the mechanism that helped the virus cross the biological barrier to infect humans is unknown, and the pathway through which it did so is unclear.
Ji et al. suggest that snakes are the carriers of the virus and transmit it to humans, which contains the same internal S protein sequence.
According to a study, researchers in Gangzhou, China, suggested that the secret, fermented milk throat swabs - often used in traditional Chinese medicine - are the most likely intermediate pathways for SARS-CoV-2 infection by carrying 99% of the identical CoV genes identified in the SARS-CoV-2 strain.
However, the 1% variance is spread across both sets of genetic material and remains a significant variance, so mixed results from the hard evidence are awaited (Figure 33).
The chemical mechanisms of SARS-CoV-2 are still largely unknown.
SARS-CoV and MERS-CoV can survive in vitro for 48 hours in dry environments and up to 5 days below 20C and 40%-50% humidity.
SARS-CoV-2 may have a similar mechanism.
SARS-CoV-2 is reportedly sensitive to sunlight and heat of 56°C for 30 minutes, ether, 75% ethanol, disinfectants containing chlorine, paracetic acid, chloroform, and other lipid compounds, but not chlorhexidine, can effectively eliminate the virus.
The entire human population has a lowered immunity to SARS-CoV-2 and is therefore vulnerable to the new virus.
Currently, no detailed studies have been reported based on the immunological response to SARS-CoV-2.
Therefore, we can only refer to previous studies of other CoVs, especially SARS-CoV and MERS-CoV (Fig. (Fig.4) 4).
Generally, after a virus attacks a host, it is first recognized by the body's natural immune system by a sensor recognition pattern (PRR) including C-type lectin reticular sensors, Toll-like sensors (TLR), NOD-like sensors (NLR) and RIG-l-like sensors (RLR).
Through various mechanisms, the virus causes inflammation, growth of dendritic nerve cells, and the formation of type I interferons (IFN i) that inhibit the viral spread and the rapidity of macrophage phagocoytosis against the viral antigen.
However, the N protein in SARS-CoV can help the virus escape the immune response.
Recently, the adaptive immune response has been incorporated into the fight against the virus.
White blood cells T including CD4+ and CD8+ T cells play an important role in immunity.
CD4+ cells stimulate B cells to release antibodies specific to the virus, and CD8+ T cells that directly kill the infected cells.
T helper cells produce anti-inflammatory cytokines to aid in cell defense.
However, CoV can inhibit T cell function and cause T cells to die.
The human immune system, including antibodies such as C3a and C5a and antibodies are also essential in treating viral infections.
For example, antibodies from a recovered patient interfere with MERS-CoV.
On the other hand, overreactivation of the immune system produces multiple cells that act in the same way locally which can cause serious damage to the heart and other organs, and, in the worst case, multiple organ failure and even death.
SARS-CoV-2 infection, which is diagnosed in a control group, is more likely to be transmitted to older people with pre-existing disease and pregnant women.
It is common that people who are susceptible to a high number of viruses or who have a low functional immunity have a higher chance of contracting the infection when they are exposed to others.
The estimated average incubation period for SARS-CoV-2 is 1-14 days, most 3-7 days according to the study of the previous 425 cases in Wuhan.
However, a study of 1,099 cases indicates that the incubation period was 3 days on average, ranging from 0 to 24 days.
A more recent study, as described above, indicates that the incubation period was 4.8 (3.0-7.2) days based on a statistic of 8,866 cases.
It is very important for health authorities to improve the effective periodic quarantine during the period of the clinic, which prevents self-infection but also transmission of the virus to others by people who do not have symptoms.
As a rule, susceptible or infected persons usually need to be quarantined for 14 days.
Can the period of quarantine be extended to 24 days?
Fever is often the first and most prominent symptom of COVID-19, which can be accompanied by asymptomatic or other symptoms such as dry cough, shortness of breath, muscle pain, lethargy, headache, ankle pain, frequent diarrhoea, sore throat, diarrhoea, nausea, and sputum.
Some patients have been battling with respiratory depression and oxygen deprivation just one week after the onset of the disease.
In severe cases, patients progress rapidly to symptoms of severe respiratory distress, infection of the central arteries, acid reflux and bleeding.
Patients with fever and/or symptoms of bronchial asthma and chronic fever, even if they have not been screened for blood vessel disorders, should be tested for the virus by rapid viral testing.
A statistical study conducted in late December 2019 showed that the symptoms of asthma were 98% cough, 78% cough, 55% shortness of breath, and 3% diarrhea; 8% of patients required ventilation.
Similar results were reported in two recent studies of a family group where the group caused transmission of the disease to a person who was asymptomatic.
In comparison, a 2012 census study showed that MERS-CoV patients also had fever (98%), dry cough (47%), and shortness of breath (55%) as the main symptoms.
However, 80% of them require respiratory support, in addition to COVID-19 patients and a persistent risk of MERS death compared to COVID-19.
Diarrhoea (26%) and rheumatoid arthritis (21%) were also seen in patients with MERS.
In SARS patients, fever (99%-100%), dry cough (29%-75%), shortness of breath (40%-2%), diarrhea (20%-25%) and analgesia (13%-25%) were reported as the main symptoms and respiratory support, estimated to be 14%-20% of patients.
On 14 February, the COVID-19 mortality rate was 2% with 66,576 confirmed cases worldwide.
By comparison, the mortality rate of SARS in November 2002 is 10% of the 8,096 confirmed cases.
According to MERS, based on a study statistic from June 2012, deaths accounted for 37% of the 2,494 confirmed cases.
An earlier study stated that the R0 for SARS-CoV was higher than 6.47 with a 95% confidence interval (CI) of 5.71-7.23, while the R0 for SRAS-CoV was only scaled from 2 to 4.
Comparison of SARS-CoV-2 with MERS-CoV-2 and SARA-CoV with respect to their symptoms, mortality, and R0 is presented in Table 1.1.
The above figures suggest that SARS-CoV-2 has a much higher transmissivity compared to MERS-CoV and SARS-CoV, but a lower mortality than both.
As a result, it is much more difficult to control the SARS-CoV-2 outbreak compared to others such as MERS-CoV and SARS-CoV.
The current grouping is usually within the same household or in a single location or vehicle such as a cruise ship.
Patients with a history of travel or stay in Wuhan or other affected areas or who have been in contact with infected people or patients in the two weeks prior to the current outbreak.
However, it has been reported that people can carry the virus without showing symptoms for more than two weeks and treated patients discharged from hospital can carry the virus again, which raises concerns about the extension of the quarantine period.
Patients have a normal or decreased red blood cell count (especially red blood cells) in the early stage.
For example, a decrease in white blood cell count <4x109/L including white blood cell count 1×109/L, and an increase in aspartate aminotransferase and verimia levels were found in 1,099 COVID-19 patients.
The level of liver-muscle plasma and myoglobin was increased in the blood of some patients, and the high-reactive protein C and red blood cell count were increased in the blood of most patients.
In patients with high-risk cases, the D-dimmer levels, the decreased production of fibrin in the blood, were increased, and the white blood cell count was dramatically reduced.
Chest mapping defects have been identified in most COVID-19 patients as small angular lesions or lack of luminosity in the heart.
The patient usually suffers from a stroke, a severe heart attack, and signs of acute respiratory distress syndrome (ARDS).
When ARDS occurs, uncontrolled swelling, fluid buildup, and bacterial growth can seriously disrupt the respiratory system.
Impaired organ function of type-I and type-II pneumocytes reduces the rate of respiration and also increases the area tension, which reduces the capacity of the heart to expand, indicating a higher risk of cardiovascular death.
So the worst outcomes for imaging d
On 18 February 2020, laboratory analysis of COVID-19 showed the elimination of pneumocytes, formation of hyaline membranes, and the integration of white blood cells, and syncytial pluripotent cells in the heart of patients who died from the disease, the regularity of laboratory tests for viral infections and ARDs were similar to those in patients with SARS and MERS.
Detection of SARS-CoV-2 RNA by reverse-transcriptase polymerase chain reaction (RT-PCR) was used as the main criteria for COVID-19 detection.
However, due to the high false positive rate, which could accelerate the spread of the pandemic, the clinical indicators began to be used for tests (which cannot be exclusively compared to RT-PCR) in China on February 13, 2020.
A similar situation occurred in a SARS-related study.
Therefore, the combination of the history of the fetus, clinical evidence, laboratory tests and imaging results are fundamental and necessary to make the test effective.
On February 14, 2020, the Feng Zhang team described a method to use CRISPR-based SHERLOCK technique to detect SARS-CoV-2, by detecting SARS-CoV-2 RNA fragments from 20 x 10- 18mol/L to 200 x 10- 18 mol/L (10-100 copies per microliter of water) using a long rod that lasts less than an hour and requires no large equipment.
Hopefully, the new technology could suddenly boost sensitivity and fitness if confirmed in clinical trials.
Due to lack of experience with the new CoV, doctors can usually only provide supportive care to COVID-19 patients, while trying different treatments that have been previously used or recommended for the treatment of other CoVs such as SARS-CoV and MERS-CoV and viral diseases (Table (Table20.2).
Treatment includes the possibility of currently receiving treatment with antiviral drugs, immune system inhibitors, steroid yo, plasma from recovered patients, Chinese medicine and psychological support.
Even plasma from recovered patients has been proposed for use as a medicine.
Pharmaceutical companies are racing to develop antibodies and vaccines against the virus.
SARS-CoV-2 primarily infects the heart in the early stages and also infects, to a lesser extent, other ACE2-defining organs, such as the gastrointestinal tract and kidneys.
However, respiratory failure and death is the biggest fear of patients and the leading cause of death.
As a result, respiratory support is potentially life-saving for symptom relief including general oxygen therapy, hyper-oxygenation, without the use of a respirator, and with the use of a mechanical respirator depending on the severity of the disease.
Patients with severe respiratory symptoms should be supplemented with extracorporeal membrane oxygenation (ECMO). which is an upgraded form of the short-acting vascular technique used to treat life-threatening arterial hypertension or pulmonary arterial occlusion.
In addition, maintaining electrolyte balance, preventing and treating high-grade infections and activator infections, and immunizing critical pituitary function are also fundamental for SARS-CoV-2 patients.
It has been found that cytokine storm is caused by an overreaction of the immune system in SARS and MERS patients.
A cytokine storm is a type of systemic pain reaction that is followed by the release of a series of cytokines including TNFα, IL-1β, IL-2, IL-6, IFNα, IFNβ, IFNγ, and MCP-1.
These cytokines cause immune cells to release large amounts of free radicals, which is a major cause of ARDS and multi-cellular retirement.
The reduction of immunity is fundamental for the treatment of cytokine storms, especially in debilitated patients.
Corticosteroid and tocilizumb, an IL6 monoclonal antibody, were used to treat cytokine activation.
Other cytokine receptor immunotherapy includes inhibiting the T cell line of the immune response; inhibiting IFN-y, IL-1, and TNF; inhibiting JAK; blinatumomab; inhibiting cytokine signaling 4; and inhibiting HDAC.
Steroids, as immuno-immunotherapy, were widely used in the treatment of SARS to reduce the severity of the infection.
However, steroids taken in large doses did not help with severe lung damage in SARS and COVID-19 patients.
Instead, they can cause other serious side effects, especially avascular osteonecrosis, which significantly affects the prognosis of the cause of the disease.
Similarly, short-term corticosteroids for medicinal purposes are recommended for use with caution in patients with severe COVID-19.
At the time of writing, there is no proven antiviral therapy that works.
However, intravenous administration of remdesivir, a nucleotide analogue, has been found to be effective in US patients with COVID-19.
Remdesivir is a new antiviral drug developed by Gilead and originally intended for the treatment of diseases caused by Ebola and Marlburg virus.
Later, remdesivir also showed potential inhibition of other RNA strand virus including MERS and SARS viruses.
Based on these, Gilead brought the site to China to conduct several tests on people infected with SARS-CoV-2, the results are highly anticipated.
In addition, baricitinb, interferon-α, lopinavir/ritonavir, and ribavirin have been proposed as potential treatments for patients with symptoms of acute respiratory syndrome.
Fever, nausea, vomiting, heart damage, and more severe adverse reactions may occur with the prescribed treatment with lopinavir/ritonavir.
Interaction with other medicines should be carefully monitored.
Plasma from recovered patients and antibody generation.
The collection of blood from patients who have recovered from a contagious disease to treat other patients with the same disease or to prevent healthy people from contracting the disease has a long history.
In fact, most recovered patients have high levels of antibodies that protect them against infection in their blood.
Antibodies are immunoglobin (Ig) produced by white blood cells B to fight infections and other foreign invaders and to identify specific antigens in the infection and kill them directly.
Based on the data, plasma was collected from the blood of a group of patients who had recovered from COVID-19 and injected into 10 patients who were in critical condition.
Their symptoms resolved within 24 hours, with reduced inflammation and viral activity and increased oxygen levels in the blood.
However, the clarification and definition is important to suggest a method for widespread use before a specific treatment has been developed.
In addition, given the effects of treatment, some problems with plasma must be considered with caution.
For example, anti-inflammatory drugs can over-stimulate the immune system response and cause cytokine release symptoms, potentially causing autoimmunity.
The antibodies in the body are very low in plasma and the need for the plasma is very large to treat patients in severe pain.
It is difficult to develop and manufacture specific antibodies quickly enough to combat the pandemic.
As a result, it is difficult to directly remove B cells from recovered patients and determine the genetic code by inserting an effective antibody or a screen with an effective antibody that can fight the virus's underlying protein.
So here, we can imagine the production of anti-spike.
TCM has been used to treat various diseases in China for thousands of years.
However, its effectiveness is largely dependent on the complexity of the mutation rather than on the disease diagnosis based on the concepts of TCM.
The most useful items are often unknown or so rare that they are difficult to identify and verify as either a single item or a combination of items.
Currently, due to the lack of effective treatment specific to COVID-19, TCM has become the main option for treating patients with mild to moderate symptoms or those who have recovered from severe levels.
For example, Shu Feng Jie Du capsules and Lian Hua Qing Wen capsules have been found to be effective in treating COVID-19.
The highest rate of drug efficacy in treating COVID-19 was observed in several Chinese provinces that used TCM on 87% of their patients, including Gansu (63.7%), Ningxia (50%), and Hunan (50%), while Hubei Province, which used TCM on only 30% of their COVID-19 patients, had the lowest rate of drug efficacy (13%).
However, this is a very small negative comparison as other factors such as the number and risk of patients should be included in the assessment.
On February 18,2020, Boli Zhang and colleagues published a study comparing Western medicine therapy (WM) alone and a combination of WM and TCM therapy.
They saw how long your body needed to recover from heat, how little symptoms appeared, and how effective the treatment was for the WM+TCM group than for the WM alone.
Surprisingly, the deterioration rate for people who exhibited symptoms (mild to severe) was significantly lower in the WM+TCM group than in the WM alone group (7.4% vs. 46%), and the mortality rate was lower in the WM+TCM group than in the MW alone (8.8% vs. 39%).
However, the efficacy and safety of TCM are still awaiting highly controlled trials in many ways and in many facilities.
It would also be interesting to characterize the mechanical mechanisms of action and to demonstrate the efficacy of the therapeutic techniques of TCM or their combination if possible.
Suspected or confirmed COVID-19 patients often deal with the greater fear of the disease's contagion and even death, as well as people in quarantine deal with boredom, loneliness, and anger.
In addition, symptoms of infection such as fever, hypoxia, and cough as well as the side effects of treatment such as insomnia caused by corticosteroids can cause severe anxiety and migraine.
In the early stages of SARS, categories of mental illness including chronic verbal abuse, anxiety, fear, psychiatric origins, parental symptoms, illnesses causing emotional distress and even suicide have been reported.
Forced contact and isolation training, as part of the public health response to the COVID-19 outbreak, can make people feel anxious and guilty about the impact of this pandemic, and criticize their families and friends.
Therefore, medical mask care should be provided to COVID-19 patients, suspected, and contacted persons and other persons who may require it.
The conduct of laboratory tests should include the creation of integrated mental health teams, clear communication with monitoring of the clinic and ongoing treatment plans for SARS-CoV-2 and the use of professional electronic devices and the practice of maintaining close contact with each other.
Effective vaccines are the basis for fighting the chain of transmission from animal and human sources of infection to susceptible organisms and often extending viral therapy by controlling the infectious disease caused by emerging viruses.
Efforts have been made to develop vaccines based on S protein to produce long-lasting and potent antibody mediators and/or immunity against SARS-CoV.
Anti-viral vaccines have been evaluated against animal strains of SARS.
However, its effectiveness in older and at-risk populations and protection against infection from the animal virus has yet to be determined before clinical studies can be initiated.
This is because SARS has been declining for 17 years and there are no new cases reported so far.
In contrast, sporadic and localized cases of MERS continue to occur in the Middle East and spread to other regions with the exception of persistent infection within these areas.
Vaccine strategies have been developed for MERS using inactivated viruses, DNA plasmid, viral vectors, nanoparticles, virus-like compounds and micro-protein molecule combinations, some of which have been cloned from animal molecules.
The development of a safe and effective vaccine against SARS-CoV-2 for people without adequate immunity is a rapid and difficult task to contain the ongoing pandemic.
However, it is difficult to overcome the complications due to the long time (on average 18 months) required for vaccine development and the variants of the CoV.
As a new disease, COVID-19 has only just begun to emerge clearly in comprehensive clinical tests of thousands of patients.
In most cases, patients recover gradually from the absence of previous pain symptoms.
However, like SARS and MERS, COVID-19 is also a disease associated with the increase in people with additional infections and death in patients with complicated cases.
Therefore, building a mental approach to health care in the disease is the basis for health care institutions to prioritize their service, especially in resource-poor settings.
Based on the health studies discussed so far, the following factors may influence or be associated with the health care outlook of patients with COVID-19 (Table 33):
Age: Age was the most important factor in causing SARS, which is also true for COVID-19.
COVID-19 occurs mostly in the 30-65 age group with 47.7% of patients being over 50 in the 8,866 case studies mentioned above.
Patients who required palliative care were more likely to have previously dealt with other illnesses and critical conditions and were significantly older than those who did not (mean age of 66 versus 51), suggesting age as a factor in the outcome of COVID-19 patients.
Sex: SARS-CoV-2 infected more men than women (0./100,000 compared to 0.27/100,000) as noted above.
In the emergency department, patients are more likely to suffer from severe heart damage and abnormal heartbeat.
Heart attacks were also the leading cause of death in SARS patients.
It has been reported that SARS-CoV-2 can also infect ACE2-positive cholangiocytes, which can cause cardiac arrest in COVID-19 patients.
It should be noted that age and the persistence of the disease are strongly linked and cannot interfere with each other.
Unusual laboratory results: The level of C-reactive protein (CRP) in the blood reflects the severity of tissue damage and has been suggested as a factor in possible disease causation, treatment response, and ultimately cure.
The relationship of CRP levels with severity and causation of COVID-19 has also been suggested.
In addition, increased lactate dehydrogenase (LDH), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and creatine kinase (CK) may also help predict outcome.
These enzymes are highly expressed in several tissues, especially in the heart and liver, and are released during cell damage.
It is therefore a cultural indicator of cardiac or hepatic retirement.
Primary health symptoms: chest pain and timing of clinical symptoms should be considered along with other factors to predict outcome and adverse conditions of COVID-19.
Steroid use: as mentioned above, steroids are immunosuppressants that are commonly used as adjuvant therapy for inflammatory diseases to reduce the severity of the injury.
As corticosteroid agonists were widely used in SARS patients, many of those recovered suffered from avascular osteonecrosis with long-term disability and reduced quality of life.
Therefore, if necessary, steroids should be used in low dosage and for a short time in COVID-19 patients.
Brain noise: as noted above, during the COVID-19 outbreak many patients suffered from the same excessive speech as they often endure long periods of quarantine and inadequate housing and witnessed the death of close family members and fellow patients.
It is important to provide psychological counseling and long-term support to help these patients recover from the trauma and return to normal life.
According to demographic studies to date, COVID-19 appears to have different pathogenicity than SARS.
In addition to spreading through the lower respiratory tract, SARS-CoV-2 spreads more effectively in the upper respiratory tract causing no or mild symptoms in the frontal phase of infection, similar to other CoVs that cause colds.
Thus, patients who have been infected in the past or for an unknown period of time may produce a large number of viruses during daily activities, causing a high resistance to infection.
However, transmission of SARS-CoV has been found to occur when patients are becoming very ill, whereas transmission does not usually occur in the early phase.
Therefore, the current COVID-19 outbreak is more severe and difficult to control than the SARS outbreak.
Massive efforts are currently underway in China, including restrictions in Wuhan and nearby cities and ongoing quarantine in almost all communities in an attempt to disrupt transmission of SARS-CoV-2.
While these actions have severely damaged the economy and other parts of the country, the number of new cases is declining, indicating a decline in the epidemic.
The most optimistic estimate is that the recession will end by the end of March and that the recession will last for 3-4 months.
However, other experts do not see it that way.
Paul Hunter, et al., estimate that COVID-19, which appears to be more infectious than SARS, will not be extinct by 2020.
The epidemiology and the epidemiology of SARS-CoV-2 suggest that SARS-CoV-2 may be present in three parts of the global population.
A Canadian team reports that SARS-CoV-2 was found in both the nasal and throat fluids of recovered patients who were discharged from the hospital 2 weeks ago, suggesting that the newly identified virus may be a cyclic influenza-like event.
However, promising signs have occurred in Shinaha in light of the decline in the number of new cases, which suggests that the current strategies may have worked.
Ebola was originally predicted to cause a million cases and another half a million deaths.
However, through strict quarantine and isolation, the disease was eventually brought under control.
It is possible, similar to SARS-CoV, that SARS-CoV-2 could weaken in the course of infection and eventually die or become a micro-infectious virus that can co-exist with humans.
A comparison of COVID-19 infections with SARS and MERS is shown below (Figure 55).
SARS-CoV-2 is mainly transmitted through coughing and sneezing, and possibly also through direct contact with objects that have been exposed to the virus.
The virus has also been found in feces, which opens up a new possibility of passing from feces into the mouth.
A recent study of 138 cases reported that 41% of the cases were likely nosocomial infections, including 17 patients with other pre-existing conditions and 40 healthcare providers.
Therefore, great care must be used to protect people, especially health care providers, social workers, family members, friends, and bystanders who have been in contact with infected people or patients.
The first protective measure that can be used to reduce the risk of infection is by wearing a face mask; both the use of surgical masks and the use of N95 (series #1860) respiratory masks helps control the spread of viruses.
Surgical masks prevent the transmission of fluid droplets from a person who may have been infected by air travel or touching a site where it could not be transmitted to another person.
However, only N95 (series # 1860 yo) oral masks can maintain the absorption of a virus as small as 10 to 80 nm during inhalation, and potentially only 5% of the virus is able to transmit completely; SARS-CoV-2 is similar to SARS-CoV in both dimensions and is approximately 85 nm.
As microorganisms can pass through even five surgically sewn masks, healthcare providers who deal directly with patients are required to wear N95 (series #1860) masks but not surgical masks.
In addition to masks, healthcare providers should wear full protective gear to prevent exposure to viruses.
The virus can enter the eye through the eyes.
On January 22, 2020, a doctor was infected with SARS-CoV-2 despite wearing an N95 mouthguard, it is possible that he contracted the virus through his eyes.
Therefore, healthcare providers must wear a face mask when working with patients.
The public in affected and potentially affected areas are strongly advised to wash their hands with disinfectant soap more often, stay at home to self-quarantine and minimize contact with potentially infected people.
Three checkpoints were identified as the most suitable distance for patients to stay away from.
This is an effective way to reduce the risk of infection and prevent the spread of the virus.
Although SARS-CoV-2 has emerged as a new virus in the human world, it is very similar to SARS-CoV as reported on 7 January 2020 and has caused high alertness in China based on the deep memory of the 2003 SARS outbreak.
However, until 19 January 2020, the director of the Wuhan Center for Disease Control did not reassure the public that the new virus has a lower capacity to spread and control reproduction in humans and that it is not a problem to prevent and stop the disease.
The message dramatically eased public anxiety, especially as the whole country was preparing for the Spring Festival, and a crucial moment was set aside to contain the disease almost to the point of a mini-outbreak in Wuhan.
Chinese disease control agencies may take this hard lesson and make big breakthroughs in the future.
For example, these institutions should (1) take extra care when making public announcements as any word spoken to the public can change their feelings and attitudes; (2) react and react more to unusual information coming from health facilities while waiting for an official word from doctors and authorities; (3) take more restrictions to stop the possible spread of the epidemic in its early stages rather than trying to reassure the public; and (4) additionally distribute targeted and effective resources to increase public awareness of the pandemic and to test and improve the community's response to it in a timely manner.
The COVID-19 outbreak caused by the novel SARS-CoV-2 virus began in late December 2019.
In less than two months, it spread throughout China and to more than 50 countries around the world during this experiment.
As the virus is very similar to SARS-CoV and the symptoms are similar to COVID-19 and SARS, the COVID-19 outbreak has created a back-to-SARS sensation.
However, there are significant differences between COVID-19 and SARS, which are fundamental to stopping the pandemic and treating patients.
COVID-19 affects older people more than younger people and men more than women, and the risk and mortality rates are also higher in older people than in young children.
SARS has a much higher mortality rate than COVID-19 (10.91% versus 1.44%).
COVID-19 patients transmit the virus even when they have no symptoms whereas SARS patients did the same when they were very sick, which causes a major problem in stopping the spread of COVID-19 in relation to SARS.
This partly explains why SARS-CoV-2 is more virulent and more transmissible than SARS-CoV.
The persistent RNA test for SARS-CoV-2 may be negative for some COVID-19 patients.
On the other hand, patients who have been treated may develop the disease again.
The results increase the risk of viral spread dramatically.
Given the rapid progress in COVID-19 testing, many issues will be resolved, such as:
Where did SARS-CoV-2 come from?
Although 96% genetic similarity was found between SARS-CoV-2 and two SARS-CoV viruses, we cannot conclude that SARS-CoV-2 is from a virus.
What animal is the intermediary of the virus that has spread disease, say, from the hippopotamus, to the human being?
Without knowing answers #1 and 2, we can't effectively cut the transmission and the spread can get worse at any time.
Although molecular and biochemical tests have shown that SARS-CoV-2 is encoded by ACE2, how exactly does the virus enter the cell membrane and cause mutation in rapid tests?
Does the virus bind to ACE2 cell-defining proteins of other carriers?
Without clear answers to these questions, we cannot achieve rapid, accurate diagnostics and effective treatment.
How long will the outbreak last?
How does the virus genetically progress during transmission between humans?
Will it become a global pandemic, a slowdown like SARS or a chronic exacerbation like influenza?
It is important, but it may take some time to find the answers to the above questions and other questions.
However, whatever the cost, we have no choice but to stop this pandemic as soon as possible and return to normal life.
The origin of the zoonotic coronavirus
Genetic mutation and adaptation have brought about the emergence of the coronavirus (CoV) and its eight diseases, including humans, for thousands of years.
Prior to 2003, two CoVs (HCoVs) infecting humans were known to cause mild illness, such as the common cold.
The development of severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) has transformed the influenza pandemic into a highly virulent and life-threatening HCoV infection.
The emergence of SARS-CoV-2 in central China in late 2019 has again reduced the chances of CoVs and surprised us with its very high transmissivity but slowed down the spread compared to its sister SARS-CoV.
Human coronavirus infection (HCoV) is a disease transmitted from animals to humans by understanding the origin of human coronavirus infections (HCoVs).
Most HCoVs originate from mosquitoes but are not highly contagious.
Some HCoVs are also known as central nervous system disease.
Identifying the host animal has a direct impact on preventing human disease.
Studying interaction with animal CoV carriers may also provide important insights into the development of CoV infection in humans.
In retrospect, we present an overview of the knowledge about seven HCoVs, focusing on their discovery history as well as their origin and transmission within the organism.
Importantly, we compare and distinguish between HCoVs from viral assay concepts and genetic compositions.
The current CoV 2019 (COVID-19) pandemic is discussed in this context.
In addition, the requirements for successful transformation of the disease and the final decision on viral risk assessment of the disease are also stated.
Coronaviruses (CoVs) belong to the family Coronaviridae, which comprises a hybrid group of single-stranded RNA viruses.
These viruses house the largest genome of 26 to 32 kilobases of RNA viruses that have been named "CoVs" due to the complexity of their structure when viewed under a microscope.
Structurally, CoVs have eight non-shared genes to share a single organism.
Approximately two-thirds of a gene is composed of two major transcription factors (ORF1a and ORF1b), which are translated into pp1a and pp1b replicase polyprotein.
This polyprotein was re-activated to produce 16 non-structural proteins, formulated as nsp1~16.
The remaining portion of the gene pool consists of the ORFs for protein structure, including spikes (s), envelope (E), membrane (M) and nucleoprotein (N).
A number of specific sequence proteins have been inserted into the spores of different CoVs.
Based on the variation in protein sequence, CoVs are classified into four subtypes (alpha-CoV, bet-CoV, gamma-CoV and delta-CoV), with the bet-CoV subtype containing most HCoVs and further divided into four primary subtypes (A, B, C and D).
Evidence from a lineage study has shown that bats and mice are the largest genetic reservoir of alpha-CoVs and beta-CoVs, while birds are the largest reservoir of gamma-CoVs and delta-CoVs.
For thousands of years, CoVs have been crossing the species barrier and emerging as important viruses for humans.
To date, seven human HCoVs have been identified.
These include HCoV-229E and HCoV-NL63 which are alpha-CoVs.
The other five beta-CoVs include HCoV-OC43, HCoV-HKU1, the coronavirus that is a symptom of acute respiratory syndrome (SARS-CoV), the coronavirus that is a symptom of Middle East respiratory syndrome (MERS-CoV) and SARS-CoV-2.
HCoV-229E, HCoV-OC43, HCoV-HKU1 and HCoV-NL63 usually cause mild symptoms, such as a common cold and/or diarrhoea.
Instead, the newly discovered SARS-CoV, MERS-CoV and SARS-CoV-2 are highly infectious, causing severe lower respiratory infections in a large number of patients with a high probability of developing acute respiratory distress syndrome (ARDS) and symptoms of acute lung effects.
The first HCoV-229E virus, B814, was isolated from the nasal secretions of flu patients in the 1960s.
Since then, much knowledge has been gained through extensive studies on HCoV-229E and HCoV-OC43, both of which cause symptoms of psychoinhibition.
In fact, it is widely accepted that infection with HCoVs is generally harmless until the SARS outbreak.
The SARS outbreak occurred in 2003 and is one of the worst in history, with more than 8,000 cases and a mortality rate of nearly 10%.
Ten years later, the Middle East respiratory syndrome outbreak (MERS) caused a sustained outbreak in the Arabian Peninsula and a subsequent outbreak in the rest of the world.
The HCoV-nCOV) 2019 variant, which was subsequently renamed SARS-CoV-2, is the causative agent of the novel coronavirus disease pandemic 2019 (COVID-19), which has killed more than 3,120 people and infected more than 91,000 people as of March 3, 2020.
The dawn has struck and the world must prepare for the coming SARS-CoV-2 pandemic.
All seven HCoVs have zoonotic descendants from mice, rats, or domestic animals.
Several lines of evidence support mutant lineages of all HCoVs from the feces, whereas the viruses are well adapted and do not cause infection but exhibit significant genetic variation.
The COVID-19 outbreak has posed huge health, scientific, social and moral challenges to China and the world.
Investigation of the origin of transgenic HCoVs provides a framework for understanding the natural history, the carrying capacity and the barrier factors of transgenicity.
This can also guide or facilitate the tracing of the reservoir, intermediate and host populations of SARS-CoV-2, with important implications for preventing future spread to other locations.
In this review we present a summary of transgenicity, transmission to other organisms and the pathway of development of HCoVs.
Specifically, we will highlight and discuss the general topic of origin of HCoVs. They are normally sterile against the infected organism in the natural reservoir but become infectious after cross-infection and transmission.
We also review the direction of HCoV in which the upward transmission is most likely to occur when its infectivity is decreased.
The ongoing SARS-CoV-2 outbreak was also discussed at the forum.
Animal CoVs have been known since the late 1930s.
Prior to the initial detection of HCoV-229E B814 in nasal fluid from patients with influenza, several CoVs were isolated from infected animals, including deer, mouse, cattle, pigs, cats and dogs.
In recent decades, seven HCoVs have been identified.
A brief summary of the history of HCoV detection in the sequence (Table 1) will be informative and instructive.
The HCoV-229E virus was first identified in the respiratory tract of patients with upper respiratory infection in 1966, and was subsequently infected to grow in the WI-38 lung tissue.
Patients infected with HCoV-229E showed symptoms of influenza, including headache, dizziness, restlessness and sore throat, with fever and cough seen in 10-20% of cases.
In late 1967, HCoV-OC43 was found in cell culture and sequence transcription in mouse brains.
The diagnostic features of HCoV-OC43 infection appear to be similar to those caused by HCoV-229E, which are not identifiable as symptoms of infection with other respiratory viruses such as influenza A viruses and rhino viruses.
Both HCoV-229E and HCoV-OC43 have spread worldwide, most likely through large-scale transmission during the transition period of the climate.
On average, the incubation period for both viruses is less than a week, followed by approximately two weeks of illness.
According to the human volunteer study, healthy individuals infected with HCoV-229E had a moderate cold.
Only a few patients with low immunity showed severe infection of the lower respiratory tract.
SARS, also known as "common cold", was first well documented as a global disease caused by HCoV in human history and the original cause is SARS-CoV, the third HCoV discovered.
The first SARS case can be traced back to late 2002 in the Guangdong province of China.
The SARS outbreak resulted in 8,096 reported cases and 774 deaths, spreading across many countries and continents.
Apart from the main vectors, it is estimated that each case can cause approximately two additional cases, during the symptom-free period of 4 to 7 days and the peak viral potency manifesting on the 10th day of illness.
Patients with SARS-CoV initially have muscle pain, headache, fever, lethargy and chills, followed by shortness of breath, cough and respiratory distress as a later symptom.
Anaemia, liver function tests, and elevated creatine kinase are common laboratory complications of SARS.
Alveolar drug proliferation, the proliferation of mucous membranes and the increase of macrophages have also been observed in SARS patients.
About 20-30% eventually require emergency care and mechanical ventilation.
In addition to lower respiratory tract, many nerves including the intestinal tract, heart and lungs can also be infected in these severe cases, often accompanied by cytokine release, which can be potentially fatal in immunocompromised patients.
The virus was first isolated from open-air lung samples from nearby patients who had traveled to Hong Kong from Guangzhou.
Since then, a lot of efforts have been made to scientifically test HCoVs.
HCoV-NL63 was isolated from a 7-month-old baby from the Netherlands in late 2004.
It was initially found to be more prevalent in young children, the elderly and patients with immunocompromised and respiratory illnesses.
Symptoms of nasal mucositis, urinary retention, fever, and bronchitis are common in infections caused by HCoV-NL63.
Another independent study described the quarantine of the same disease by studying the nose samples of an 8-month-old boy with bronchitis in the Netherlands.
Although it was discovered in the Netherlands, it has spread around the world.
It is estimated that HCoV-NL63 accounts for approximately 4.7% of common respiratory infections, with its highest incidence occurring in early summer, spring or autumn.
HCoV-NL63 is associated with inflammatory bowel disease, also known as laryngitis.
In the same year, HCoV-HKU1 was detected in a 71-year-old man who was being treated for bronchitis and bronchitis in Hong Kong.
In addition to community-transmitted burnout and respiratory tract inflammation, HCoV-HKU1 is reported to be associated with acute respiratory distress.
Similar to HCoV-NL63, HCoV-229E and HCoV-OC43, HCoV-HKU1 has been found worldwide, as a cause of mild respiratory infections.
All four of the community-detected HCoVs have adapted well to humans and are generally less likely to develop into a highly contagious disease, although cases have occurred for unknown but rare reasons than the more common HCoV-NK63 virus strain, which is now reported to be the cause of the severe infection of the lower respiratory tract in China.
In general, when HCoVs lack effective transmission capabilities and persistently persist in the environment, they become less toxic or more infectious.
MERS-CoV was first identified in 2012 in a 60-year-old heart patient with acute bursitis and renal failure in Saudi Arabia.
While most cases confirmed by laboratory tests originated in the Middle East, imported cases with additional spread among infected people have been reported in various European countries and Tunisia.
Another outbreak occurred in South Korea in 2015 with 186 confirmed cases.
The clinical characteristics of MERS are similar to those of SARS, which is characterized by a highly advanced, acute form of the virus.
Unlike MERS, many patients with MERS have been diagnosed with renal failure, which is very different from MERS caused by HCoV infections.
More than 30% of patients have gastrointestinal symptoms, such as diarrhoea and rashes.
As of February 14, 2020, more than 2500 laboratory confirmed cases have been reported to have a high case fatality rate of 34.4%, making MERS-CoV one of the most destructive viruses known to man.
During mid-to-late December 2019, groups of patients with bronchitis were found to be approximately unaware of SARS-CoV-2 infection in Wuhan, Hubei Province, China.
The World Health Organization has announced the ongoing outbreak of lower respiratory tract infection caused by SARS-CoV-2 as a Public Health Emergency of Global Concern, also known as COVID-19.
As of 3 March 2020, 90,053 cases have been confirmed worldwide, with a fatality rate of 3.4%.
In particular, the death rate in Hubei, China is 4.2%, while the overseas one is 1.2%.
SARS-CoV-2 causes severe respiratory infections such as SARS-CoV and MERS-CoV, which are manifested as fever, cough and oxygen deprivation.
Swallowing is also seen in some patients.
A blister is one of the most severe symptoms and can quickly turn into a severe respiratory illness.
Although SARS-CoV and SARS-CoV-2 share a high nucleotide sequence similarity of 82%, they are classified into different subtypes on the cluster tree of mutations.
SARS-CoV-2 is evidently less virulent but more transmissible than SARS-CoV and MERS-CoV.
Subjects without symptoms of SARS-CoV-2 infection have been reported and may be contributing to its rapid spread worldwide.
Comparing and isolating SARS-CoV-2 from the other six HCoVs produced similarities and differences of major importance.
First of all, the duration of the absence of the disease and the duration of the disease are very different.
Thus, SARS-CoV-2 follows the general mutations of the other six HCoVs.
Secondly, the risk of COVID-19 symptoms is between SARS-CoV and the four community-transmitted HCoVs (e.g., HCoV-2229E, HCoV-OC43, HCoV-HKU1 and HCoV-NL63).
On the other hand, it has been observed during community-transmitted infections of HCoVs, including non-specific, mild or even asymptomatic exposures.
On the other hand, sub-categories of severe COVID-19 cases can also be observed as in the case of SARS-CoV infection, although the proportion is small.
Third, transmission of SARS-CoV-2 also exhibits interesting features common to both HCoVs and SARS-CoVs.
On the other hand, the transmission capacity of SARS-CoV-2 is at least as high as that of HCoV through community transmission.
On the other hand, it still needs to be confirmed that the transmission capacity of SARS-CoV-2 decreases after its transmission to humans as in the cases of SARS-CoV and MERS-CoV.
Finally, other HCoV-like strains, SARS-CoV-2 can be found in fecal samples.
Whether transmission of SARS-CoV-2 by oral mucus has played a role in the transmission of SARS-CoV cases at least under some circumstances should still be confirmed in future studies.
It is also of particular importance to consider that SARS-CoV-2 may exhibit periodic variation as community cases acquire HCoVs.
However, the characteristics of SARS-CoV-2 including its transmissivity, virulence and long-term infectiveness after transmission to humans will be the final factor in the ongoing COVID-19 pandemic.
All four HCoVs found in the community that cause mild symptoms have been well adapted to humans.
On the other hand, it may be true that humans have adapted well to forty HCoVs.
In other words, both could be survivors of the earlier HCoV pandemic.
HCoVs that cause infectious disease in humans and infectious disease in humans have been eliminated.
For this to happen, it must replicate in humans to a sufficient degree to allow for the adaptation of mutants that fight the genetic causes of Alzheimer's.
In this sense, prolonged persistence of SARS-CoV-2 infection and more infected populations are the major possibilities for better adaptation to humans.
If it adapts well, its transmission to humans will be difficult to prevent by quarantine or other infection control measures.
Over the years, the four community-acquired CoVs have been circulating in the human environment, inducing flu-like reactions in healthy people.
And viruses do not need any host.
In comparison, most SARS-CoV and MERS-CoV viruses are not well adapted to humans and their transmission to humans cannot be prevented.
They want to maintain and further spread their stocks of zoonotic diseases to humans and seek opportunities to infiltrate vulnerable human populations into their target populations, using one or two intermediate pathways and increasing the infectivity.
SARS-CoV-2 has similar symptoms to both SARS-CoV/MERS-CoV and the four HCoVs that have infected the community.
It is highly transmissible as the HCoVs have been found in the community, at least for the time being.
However, it is more virulent than community-acquired HCoVs and less virulent than SARS-CoV or MERS-CoV.
It remains to be seen whether it will fully adapt to humans and circulate within humans without any reservoir or animal-mediated pain.
Before we talk about the animal origin of HCoVs, it would be useful to talk about the definitions and characteristics of mutation, biology, storage, pathogenicity and transmission of HCoVs.
The organism acts as a mutated host for HCoV if it hosts an early host closely related to it by sharing high nucleotide sequence ratios.
He had a normal reaction to the virus and was not contagious.
Also, host reservoirs provide HCoVs with a permanent and long-term host.
In both cases, the infection occurred naturally and was caused by the HCoV or the virus.
Conversely, if HCoV is newly transmitted to a moderate host shortly before the virus is transmitted to humans, it is not well-adapted to the new host and is usually infectious.
An intermediate pathogen can be the source of a zoonotic disease that infects humans and can play a role as a pathogen aggravating agent by allowing the virus to multiply in a short period of time and then to infect humans to increase the spread of human infection.
HCoV can become infectious after infection if it cannot survive in the intermediate stage.
In contrast, HCoVs can also adapt to a central nervous system infection and maintain isolation for long periods.
In this case, a migraine becomes a natural pain reliever.
Data from epidemiological studies have shown in a review that the first case of SARS had a historical connection to animal care.
The subsequent tests of the infection rate showed that livestock traders had a higher prevalence of SARS-CoV igG compared to the general population.
The bush cat (Paguma larvata) and the wild dog in live animal markets were first identified as carriers of SARS-CoV-like viruses that are mostly similar to SARS-CoV.
This was indirectly supported by the fact that more SARS was not reported after killing all the wild cats on the market.
However, it has been reported that captive wild cats in the wild or in farms not exposed to live animal markets are largely absent from SARS-CoV, suggesting that captive wild cats may be only a moderate acute vector but not a natural reservoir of SARS-CoV.
Notably, since 80% of the various animals in the Guangzhou markets have antibodies against SARS-CoV, the possibility that several micro-organisms in mammals could also be potentially intermediate vectors for SARS-CoV cannot be ruled out.
All of these appear to be end-stage SARS-CoV infections.
Sequential tracing of the natural animal pathogen SARS-CoV revealed a closely related sensor CoV, known as SARS-related Phinolophus Cov derived from the HKU3 (SARSr-Rh-BatCoV HKU3), which is present in the Chinese horseshoe sensor.
These strains have antibodies to SARS-CoV and the SARSr-Rh-BatCoV genome sequence HKU3.
This and other viral CoVs share 88-92% of the same nucleotide sequence with SARS-CoV.
This study laid the groundwork for the new idea that nighttime is a reservoir for emerging human pathogens.
Several SARS-like CoVs (SL-CoVs) have also been detected in the virus, but none other than one modified WIV1 can be identified as a living virus.
Human angiotensin-converting enzyme 2 (ACE2) has been identified as a SARS-CoV receptor.
WIV1 from testes of the spirochete was found to use the spirochete, the wild cat, and ACE2 in humans as nerve entry into the cell.
Interestingly, the serums of patients recovering from SARS were able to get rid of WIV1.
To a certain extent, WIV1 represents the closely related ancestral strains of SARS-CoV found in the virus, sharing 95% of their nucleotide sequence in their isoform.
Despite the great similarity between the two viruses, it is widely believed that WIV1 is not the immediate origin of the SARS-CoV virus and that the sensors are not the immediate pathogenic reservoir of SARS-CoV.
Analysis of the genome studies group MERS-CoV together with the same group of CoV-HKU4 and CoV-HKU5 receptors.
Both CoV-HKU4 and MERS-CoV use the same pathogen, dipeptidyl peptiase 4 (DPP4), which is specific for viral transmission.
The RNA-dependent RNA polymerase of MERS-CoV is currently clustered close to those of similar beta-CoVs found in Europe and Africa.
As of now, no live MERS-CoV has been found in wild turkeys.
MES-CoV and its closely related cousin CoV-HKU25 share 87% of nucleotides and are basically the same sequence.
Therefore, evening sickness may not be the most immediate indicator of MERS-CoV infection.
On the other hand, a study in the Middle East shows that the single-clawed camel has a unique anatomical molecule mediating MERS-CoV, and that camels native to the Middle East are similar to those in mainly African countries.
MERS-CoV, which directly looks like a virus found in humans, has been found in camels in tests, and camels have shown immunity to MERS-CoV.
It is also worth noting that generally mild symptoms but significant release of the virus have been observed in test camels with MERS-CoV infection.
Interestingly, infected camels not only released the virus through the respiratory tract but also through the fecal tract, which is the main route for virus transmission.
However, questions remain as many confirmed MERS cases had no history of contact with camels before the onset of symptoms, possibly caused by human-to-human transmission or unknown transmission pathways involving an unknown animal that provided MERS-CoV with a home.
SARS-CoV-2 shares 96.2% of the same nucleotide origin from the CoV RaTG13 isolated from the Rhinolophuw affinis virus.
As in the cases of SARS-CoV and MERS-CoV, the sequence variation in SARS-CoV-2 and RaTG13 is also a strongly suspected paternal link.
That is to say, the SARS-CoV-2 virus is not a reservoir of virus (s) until similar SARS-CoV-2 viruses are discovered in the future.
It is possible that the SARS-CoV-2 vector animals are from the wildlife that was smuggled into the Hunan SeaFood Market, which has been overlooked as the first case of COVID-19, indicating the exact case of animal-to-human transmission.
A number of recent studies studying the sequence of genes suggested that a group of critically endangered small mammals known as pangolins (Manis Javanica) may also be the origin of the related SARS-CoV-2 beta-CoV strain.
The newly identified pangolin-derived coV shares 85-92% of the same basic nucleotide sequence with SARS-CoV-2.
However, they are equally and closely related to RatG13 at approximately 90% identification of the nucleotide sequence level.
It divides into two sub-strains of SARS-CoV-2 as viruses in the reproductive system, one shared by the receptor binding defect (RBD) of SARS-CoV-2, with 97.4% amino acid sequence identification.
The morphological similarity of SARS-CoV-2 to RBD and RaTG13 is very different, although there is a high degree of broad genetic similarity in the gene structure.
An earlier study in pangolins also detected a highly contagious virus in a heart sample, which mutated to be related to SARS-CoV-2.
This study used combined methods and manual therapy to produce partial sequences of HIV genes that comprised approximately 86.3% of the full genome of the virus.
We cannot rule out the possibility that he is a carrier of SARS-CoV-2.
However, at present there is no evidence that leads directly to the origin of pangolin SARS-CoV-2 due to sequence variation in SAR-CoV-2 and SARS-CoV-2 in pangolin that are related to beta-CoVs.
Furthermore, the spacing between SARS-CoV-2 and RaTG13 is even much shorter than that between pangolin SARS-CoV-2 and SARS-CoV-2 associated beta-CoVs.
The pathway of SARS-CoV-2 mutation in bats, pangolins, and other mammals is still under investigation.
While a high genetic similarity to RBD yada was found between SARS-CoV-2 and the mutation, SARS-CoV-2-associated beta-CoV yada and RaTG13 share a broad genetic similarity to the original.
It is highly speculated that the similarity found in the RBD of SARS-CoV-2 to pangolin-associated beta-CoV and SARS-CoV-2 is due to intermediate selection of the same assays.
Another proposal favours recombinant SARS-CoV-2 to pangolins infected with beta-CoV and RaTG13 and to third-generation wildlife.
By driving the evaluation force, the recombination will spread rapidly to the beta-CoV.
The decision-making team is still at a loss on the origin of the zoonotic disease SARS-CoV-2.
In addition to the multi-infectious HCoVs, the origin of the zoonotic diseases HCoV-229E, HCoV-OC43, HCoV-NL63 and HCoV-HkU1 were also studied.
Evidence from biosafety studies shows that HCoV-NL63 and HCoV-229E both descended from the late CoV, while the original viruses HCoV-OC43 and HCoV-HKU1 were found in mice.
It was reported that the APCoV.2 (Appalachian Ridge CoV) variant observed in North America in a tri-color APV showed a very close relationship to HCoV-Nl63.
On the other hand, HCoV-229E is genetically related to another viral-causing CoV, known as Hipposideros/GhanaKwam/19/2008, which was detected in Ghana, where a camel strain was suspected to be a medium-to-medium-sized pathogen.
As a reference, current knowledge of the animal origin of the identified HCoVs is summarized in Figure 1 and Table 2.
Analysis of the biochemical studies has provided evidence that the incidence of transmissions between HCoVs is significant.
When HcOV-OC43 was transmitted to humans from wild boar in the 1890s, the international respiratory infection was recorded.
History of transmission of HCoV-229E in the host is well established.
It has been found that our alpha-CoV subtype is closely related to HCoV-229E.
Among them is the alpaca alpha-CoV.
There is evidence that suggests the Y-Virus may have directly infected humans.
First of all, humans, not alpacas, are the closest to interacting with the sea otter in its common habitat.
Instead, humans have a close relationship with alpacas.
Second, HCoV-229E associated with the alpha-CoV in the alpaca is distinct from other alpaca-infected viruses, whereas the alpaca-CoV caused the respiratory disease of infected animals.
Finally, alpaca alpha-CoV has not been found in wildlife.
Therefore, the possibility cannot be excluded that alpacas may have contracted HCoV-229E from the human-associated alpha-CoV.
In fact, the sensor is a direct source of several human pathogenic viruses including rabies virus, Ebola virus, Nipah virus and Hendra virus.
Therefore, it is not surprising that the virus can transmit HCoV-229E directly to humans.
Similarly, while the alpha-CoV is the gene pool for HCoV-229E, alpacas and camels may be a medium-sized vector for transmission of the virus to humans, as is the case with MERS-CoV.
MERS-CoV is an excellent example of the transmission of the organism through the veins to camels and from camels to humans.
The origin of the MERS-CoV mutation from the sensor was known for its early identification and was also confirmed by the sequencing results.
It is common for these vectors to provide a large amount of viral enrichment for interaction between organisms, exchange of genetic material and transmission of the virus.
Longevity, dispersed groups, close social interaction and strong flight capacity are all ideal conditions for the sensor to be a suitable 'virus transmitter'.
On the other hand, MERS-CoV has infected camels and goats in the last few decades.
They adapted well to this patient who went from moderate to severe pain to a natural, chronic pain response.
MERS-CoV causes a very mild disease and maintains very few mutations in these animals.
Its limited transmission to humans is an accident and humans are a terminal disease of MERS-CoV as its transmission cannot survive.
In contrast to the role of camels in the transmission of MERS-CoV, the role of avians, if any, in the transmission of SARS-CoV-2 is different.
Specifically, the beta-CoVs of the genus are more virulent than the mosquitoes.
They may be a non-infectious beta-CoV related to SARS-CoV-2, similar to SARS-CoV wild cats.
The possibility of SARS-CoV-2 transmission from animals to humans via a few parasites is being tested or excluded for future studies.
First, the sensors could be the reservoir of a SARS-CoV-2-related virus that is largely similar to SARS-CoV-2.
People can share their sense of community through cutting meat or grilling coal.
Secondly, pangolins may be one of the mediators of the recently discovered SARS-CoV-2 virus-related disease.
Humans are infected with the virus through exposure to and consumption of predator meat.
It is possible that large herds of mammals, including domestic animals, are more susceptible to SARS-CoV-2.
A general test on domestic and wild animals for antibodies has been validated.
Third, as mentioned above, the recombination and adaptation of SARS-CoV-2 may have been due to a third strain that was associated with both the primates and the nationals.
The investigation into the animal origin of SARS-CoV-2 is still ongoing.
Apart from the variety of pathogenic species, the three main viruses are also important for facilitating CoVs to cross the biotypical barrier.
First of all, in terms of the genetic makeup, there's a huge amount of mutation in the RNA.
Compared to other single-stranded RNA viruses, the estimated mutation margin of CoVs can be identified as "medium" to "high" with an average mutation margin of ~10-4 mutations per year at position 2, depending on the phase of CoV adaptation to an abnormal disease.
CoVs have a confirmed exoribonuclease readout, elimination that results in an extremely high mutation and reduced or no replication.
Interestingly, the nucleotide analogue Remdesivir is known to reduce CoV replication through the inhibition of exoribonuclease and RNA-dependent RNA polymerase.
Remdesivir is one of the most effective SARS-CoV-2 inhibitors to be tested in clinical trials.
However, the mutation threshold for CoV is almost a million times higher than for the carriers.
In addition, the mutation threshold is often higher when the CoV does not respond well to infection.
Compared to SARS-CoV with a high mutation limit, the mutation limit of SARS-CoV-2 is clearly lower, suggesting a high degree of human adaptation.
Perhaps he had already dealt with a pain that was more common to humans.
In addition to SARS-CoV-2, this also applies to MERS-CoV, which has adapted well to camels with a single vertebra.
In theory, it is unlikely that the extinction of the genome will produce vaccines and antivirals against SARS-CoV-2 that are not functional as quickly.
Second, the extended genome RNA in CoVs propagates through additional sequencing of the genome sequences of the mutant and the assembler, thus increasing the chance of heterotypic mutation, which is ideal for emergence of unusual CoVs when the environment becomes suitable.
This is supported by the unique open reading patterns available and the protein functions inserted at end 3 of the genome.
Third, CoVs often change their structure indefinitely during the course of RNA replication through a special "self-replication" process.
In a relapsing form of the disease, the mutation occurs mainly during the replication of the RNA CoV.
The highly homologous full-length and subgenomic RNA can recombine to produce a new CoV.
Evidence of natural recombination in mutation studies has been found in both HCoV-HKU1 and HCoV-OC43, as well as in animal-derived CoVs such as the SL-CoV virus and the CoV-HKU9 virus.
Interaction with other viruses in terms of transmission
In addition to the three factors mentioned above, the interaction of the virus with the sympathetic nervous system is another important factor affecting the transmission of the virus.
Here, the recombination of SARS-CoV is taken as a typical example, which has also shown evidence of good selectivity during the trans-species transmission cycle.
Based on comparative analysis between quarantined human and civet SARS-CoVs, SARS-CoV is thought to undergo rapid adaptation to various vector diseases, especially when accompanied by RBD mutations in the S protein.
In general, RBD in protein S of CoV interacts with the cell's neurons and is strongly stimulated by antibody responses to pain.
SARS-CoV, RBD gu is located at 318th to 510th amino acid sequence in the S1 domain, which binds to human ACE2 and similarly to the surface of the virus's neurons.
SARS-CoV RBD is able to recognize ACE2 receptors in a variety of animals, including bats, civet, mice and wild dogs, allowing the virus to cross organisms.
In fact, only six amino acids have been found to be different from the human and wild cat RBD viral classifications, and four of them are in the neural structure of the ear to interact with ACE2 receptors.
SARS-CoV from feral cats has the K479N and S457T mutations in RBD genes, which may enhance its affinity for the spike protein that it is associated with the human ACE2 receptor.
In other words, the mutation of these two amino acids is a risk factor for the adaptation of the human virus.
It is worth mentioning that SARS-CoV-2 shares the same cell-based sensors as SARS-CoV.
The 30% difference between SARS-CoV-2 and SARS-CoV in the S1 domain of the S protein indicates that the binding of the S protein to the human ACE2 can be modified.
In fact, a cryo-Em study shows that there is 10 to 20 times more adhesion than between human ACE2 and SARS-CoV S protein.
It would also be of interest to know whether other cell surface receptors may be required for transmission of SARS-CoV-2.
Interestingly, HCoV-NL63 is also resistant to ACE2 but is resistant to the other S subtype.
There are other HCoV receptors, such as the aminopeptidase N for HCoV-229E, and 9-O-acetylated sialic acid for HCoV-OC43.
It may be caused by successful adaptation of CoV to humans following intra-biological transmission from infected animals.
In addition to these cellular mechanisms, the outcome of HCoV's intra- and intra-organism transmission is also controlled by pathogenicity and restriction factors.
Variations in these anti-HIV proteins between humans and natural anti-HIV reservoirs of HCoVs such as bats, dromedaries and mice may contribute to the prevention of cross-infection between the same organisms.
HCoVs can spread through antigen-dependent factors and undergo antigen-blocking factors to successfully self-infect with the same organism.
Thus, the molecular markers within this critical area of viral-pathogen interaction must be identified and characterized.
A large-scale, non-invasive genetic investigation of the AIDS-dependent and SARS-CoV-2 inhibitory factors using the state-of-the-art CRISPR technology is likely to bear fruit.
Emergence of a new HCoV: reversing the original.
The evening variants of the CoV provide ample opportunity for the emergence of new HCoVs.
In this sense, the virulent CoVs serve as the carrier genes for all HCoVs.
In addition, rapid growth mutation and gene recombination also provide the basis for HCoV evaluation and serve as two important steps in the process.
For example, the presence or absence of a gene that describes a protein makes it possible to reproduce the genetic identity of a virus.
Among the additional proteins in SARS-CoV, ORF8 is thought to be important for human infection, as SARS-CoV is associated with isolated viruses but has been found to produce a different ORF8 protein.
The 29-nucleotide deletion of SARS-CoV was found in isolated populations at the beginning of the human pandemic.
Loss of ORF8 cells in ORF8a and ORF8b is thought to be due to adaptation to the growth hormone mutation that promotes pathogenic mutation.
However, SARS-CoV has the potential to produce a single gene combination of alpha and beta-CoV, with a number of smaller gene combinations as seen in RNA polymerase-dependent RNA.
Rearrangement sites of this gene have also been reported in nsp9, most commonly nsp10, and in some nsp14.
Similarly, the MERS-CoV pandemic has been observed in cases of gene rearrangement in various herds, which occurred in camels in a brown bear enclosure in Saudi Arabia.
In addition to SARS-CoV and MERS-CoV, recombination events have also been observed in other HCoVs, where HCoVs have combined genes of non-structural carriers of other animal CoVs.
It should also be noted that human selection can contribute to unintended changes in the viral genome, often causing the virus to survive selective suppression, such as the pathogen's immune system.
An example of the effect is the normal long-term loss of the same ORF4 strain of HCoV-229E, which has a two-nucleotude deficiency.
While ORF4 deficiency can be seen in both the evening and camel-associated viruses of HCoV-229E, the alpaca alpha-CoV exhibits nucleotide entry sites, which result in a gene-specific growth spurt.
Last but not least, the evaluation of novel HCoVs was also derived from gene-transference samples from the pathogenic bacillus.
No symptoms or only mild symptoms have been observed when the virus infected with CoV, indicating a two-way interaction between the virus and the virus.
It appeared that the film adapted well to the CoV both in terms of physiology and functional characteristics.
For example, the enzymes that cause the inflammatory response in the virus effectively reduce the infectivity of the CoV.
Furthermore, the natural killer activity of the epithelial cells has been suppressed due to increased stimulation of the natural killer inhibitor of the NKG2/CD94 neuron and the low specificity rate of the class I molecular interaction.
However, the high level of biooxygenic stimulation (ROS) resulting from the chemical metabolism of viruses both suppresses CoV reproduction and the re-reading effect of exoribonuclease, which provides selective suppression of the emergence of highly virulent virus strains when a new pathogen is introduced.
Many strains of the viruses that cause CoV can slowly grow and recombine, leading to the production of new proteins or proteins with the characteristics of disease-like adaptation.
So it's no coincidence that the three new HCs have emerged over the past two decades.
CoVs are either non-viral or cause mild symptoms from pathogens such as measles and mumps.
They reproduce vigorously without suppressing the strong anti-pathogenic immune response.
Here's the secret of why people who are asymptomatic are considered sick and what causes the tragic cases of human infection.
The more severe symptoms are those that are usually due to the activation of the immune response and the cytokine reaction, while the more severe immune response, is more likely to cause a fatal injury and heart attack.
Instead, in asymptomatic patients, the immune response is interrupted by the CoV mutation.
The synthetic strategy of cutting off the immune response may have a beneficial effect in the treatment of SARS-CoV-2.
The interferon response is particularly strong in the retina.
Therefore, taking type I interferon at least in the early stage of SARS-CoV-2 infection in humans is beneficial.
In addition, the NLRP3 inflammasome in the retina is deficient.
For this reason, the NLRP3 inflammasome inhibitor with MCC950 is effective in treating COVID-19.
The emergence of SARS-CoV-2 follows the common theme from which SARS-CoV and MERS-CoV have emerged.
While the beta-CoV with which it shares 95% nucleotide similarity to SARS-CoV has been identified, there is also a CoV with which it shares 96% nucleotide similarity to SARS-CoV-2.
While feral cats and other animals on the market have been found to carry viruses similar to SARS-CoV, the closest intermediate pathogen for SARS-CoV has not been identified.
Beta-CoVs of pangolin that are highly sensitive to SARS-CoV-2 have been identified, suggesting that pangolins may be one of the intermediate carriers or beta-CoVs of pangolin may provide a genetic component for the terminal strain of SARS-CoV-2.
Despite the questions, there is no evidence that SARS-CoV-2 is man-made, either intentionally or accidentally.
CoVs have returned to the spotlight due to the impending SARS-CoV-2 outbreak.
Studies of the CoV in mice and other animals have dramatically changed our perception of the importance of the origin of zoonotic disease transmission to humans and the animal ecology of HCoV transmission to humans.
The large-scale disease showed that SARS-CoV, MERS-CoV and SARS-CoV-2 have a viral origin and are transmitted to humans through a mild to moderate infection.
If SARS-CoV infection had originated from human-animal contact known as civets in the market, the closure of wet markets and the killing of civets would have effectively ended the SARS epidemic.
For the same reason, pangolin yads should be removed from wet markets to prevent transmission of animal diseases to humans, given the detection of several pathogens in pangolin beta-CoVs that are closely related to SARS-CoV-2.
However, whether and how SARS-CoV-2 is transmitted to humans via pangolin and other mammals is to be clarified in future studies.
On the other hand, MERS-CoV has been present in camels for a long time.
Camels provide an important means of transportation as well as the main source of meat, milk, leather and fur products from the local population.
It is widely distributed throughout the Middle East and Africa.
It is therefore possible to vaccinate all camels to control MERS, as has been done in wildlife in China to prevent the spread of SARS-CoV and SARS-CoV-2.
To stop the recurrence of MERS outbreaks, a comprehensive approach must be taken to develop effective vaccines against MERS-CoV in camels, along with other infection control measures.
Since we are unable to eradicate these viruses, new genotypes may emerge to cause outbreaks.
Various zoonotic viruses that infect humans circulate in the environment.
In particular, the CoVs with the potential for zoonotic transmission to humans are highly variable.
There is a high probability that the CoVs that infect animals will evolve and recombine, causing the emergence of new CoVs that are more transmissible and/or more lethal to humans in the future.
The practice of eating wild animals in some parts of China should be abandoned to reduce unnecessary contact between humans and animals.
For the SARS, MERS and COVID-19 crises, a good preparation and response plan should be put in place.
In fact, viruses have been around for a very long time.
They stay in their natural reserves until there is a chance for them to spread elsewhere.
Although termites have many features that help spread viruses, the chance that humans will come into contact with termites and wildlife can be reduced if people are trained to avoid them.
Continued monitoring of mammals is conducive to better understanding of the habitat of CoVs and their natural disease carriers, which demonstrates their effectiveness in preventing transmission from animals to humans and future outbreaks.
In conclusion, the most effective way to prevent zoonotic viruses from passing to humans is for humans to avoid natural habitat reserves of zoonotic viruses that pass to humans.
Several pieces of evidence for the origin of the animal-to-human SARS-CoV-2 virus are still missing.
First, if the bats transmit an earlier SARS-CoV-2 virus to pangolins, it would be interesting to see the circumstances that led to the bats and the bats sharing the same habitat.
Second, if the virus plays a more direct role in transmission to humans, how humans interact with the virus should be studied.
Third, if the third mammal is to be a true intermediate pathogen, how it penetrates various organisms, including humans, bats and pangolins, must be determined.
Finally, since many mammals including washed animals can carry SARS-CoV-2, both surveillance and infection testing should be done.
Whether it is a lizard, pangolin or other mammal, it is expected that SARS-CoV-2 and its progeny viruses will be detected in a natural immunodeficiency.
Continued investigations in this area will identify the evolutionary pathway of SARS-CoV-2 in animals, with important outcomes for the prevention and control of COVID-19 in humans.
The updated COVID-19 diagnostic pattern for "suspected case" and "confirmed case" is critical.
On 6 February 2020, our team published an emergency guideline for the diagnosis and treatment of the 2019 novel cornoavirus (2019-nCoV) infection. This guideline has enhanced our expertise and formed a good reference for combating this global pandemic.
However, the coronavirus 2019 (COVID-19) is a new disease, and our awareness and knowledge is gradually increasing based on the results of ongoing research and clinical screening indications; therefore, diagnostic and treatment strategies are also being updated on a continuous basis.
In this paper, we have responded to one comment in the guideline and provided the final diagnostic pattern of "suspected case" and "confirmed case" with reference to the COVID-19 Diagnostic and Medical Guidelines (version 7) issued by the National People's Health Commission of China.
In December 2019, the novel coronavirus 2019 (2019-nCoV) caused an outbreak, which is now officially known as the 2019 coronavirus disease (COVID-19) and the virus is named as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
On 11 March 2020, the World Health Organization has identified COVID-19 as a global disease.
To combat the SARS-CoV-2 infection, our team developed an emergency protocol and published it online in the Military Medical Review on 6 February 2020.
It has attracted great attention since the day it was published.
Note that although COVID-19 is a new disease, our awareness and knowledge is gradually increasing based on research findings and clinical testing experience; therefore, diagnostic and treatment strategies are also being updated continuously.
Diagnostic and therapeutic measures for COVID-19 issued by the National Committee for Public Health of China (http://www.nhc.gov.cn/), from 16 January 2020 to 3 March 2020, have produced a total of seven revisions that have substantially changed their content.
Now our rules were inspired by Zhou et al., they came up with a simple proposal based on medical expertise.
Their work has added clarity to the norm and has also provided a valuable reference for the global reach of the disease.
We recognize their important work and express our gratitude to them.
However, their work also needs updating with reference to the latest COVID-19 Diagnostic and Treatment Guidelines (Weekly Test Type) and current studies.
Referring to the one-week revision (3 March 2020), to confirm suspected cases it is necessary to combine one item of the historical manifestos of the epidemiological study with two items of the clinical manifestos to make a complete diagnosis, or the need to obtain three items of the clinical manifestos if there is no clear epidemiological history.
History of epidemiological studies: (1) history of travel or residence in Wuhan and surrounding areas, or other communities where cases of COVID-19 were reported within the last 14 days prior to the onset of symptoms; (2) history of associated SARS_CoV-2 infection (detected by nucleic acid testing); (3) history of contact with patients with fever or respiratory symptoms from Wuhan and surrounding areas, or other communities where COVID-19 was reported within the last 14 days prior to the onset of symptoms; (4) contact history of confirmed cases (>= 2 cases with fever/respiratory symptoms within two weeks in other areas, such as home, classroom, school, etc.)
Health symptoms: (1) fever and/or respiratory symptoms; (2) with the photographic symptoms of COVID-19 infection; (3) total white blood cell count indicating normal, decreased, or low white blood count in the early onset stage.
a confirmed case should be based on a suspect case with only viral material or evidence of blood leakage as follows: (1) real-time testing with PCR for SARS-CoV-2; (2) whole genome sequence virus showing a high-level of coronavirus or unusual known; (3) detected specific IgM antibody and IgG antibody for SARS-CoV-2 in the test serum; or replacement of specific SARS-CoV-2 IgG antibody that has been missing, or >4 times higher than the measured face-to-face ratio in a negative test.
We can see that real-time PCR testing for nucleic acid from respiratory or blood samples has been included in the second (18 January 2020) and third (22 January 2020) editions.
The germ detection from blood samples was added in the fourth edition (27 January 2020) and the fifth (February 8, 2020), and the subsequent germ detection was added in the seventh edition.
This modification builds on the ongoing work of researchers to find a better and faster nucleic acid detection tool for testing, as well as samples from respiratory patients for blood testing, which has increased the availability of more tests, and supported the delivery of specific antibodies to the resulting test as a validated method.
Besides, there is plenty of evidence to remind us to be alert to both abnormal and symptomatic symptoms in patients.
Therefore, the Zhou et al. map should be revised, as it classifies the person with no symptoms as "low risk".
The credit system also requires confirmation of additional medical procedures and studies.
To conclude, we hope to see more direct evidence and to invite readers to contribute their comments.
In the investigation of "suspected case" and "confirmed case", we suggest that they be traced and follow the latest guidelines of their home countries.
Our team will update our guidelines from time to time to provide assistance.
Bangladesh reports five new deaths from COVID-19, the highest daily number.
Yesterday, Bangladesh confirmed five new deaths caused by COVID-19 on the same day.
This is the highest number of deaths in a single day caused by the virus.
As of yesterday, the Bangladesh Institute for Disease Research and Control (IEDCR) reported the number of cases it had recorded, including 114 active cases and 33 recovered cases who were at home.
A total of 17 deaths were reported.
In an online summary, IEDCR director, DR Meerjady Sabrina Flora, said the deaths were a combination of four men and one woman.
According to DR Meerjady, two cases were over 60 years old, two were between 51 and 60, and one was 41-50 years old.
She also said that two of the victims were from Dhaka.
The World Health Organization (WHO) declared COVID-19 a global pandemic on the 11th of March.
A hospital official told Anadolu Agency, a local newspaper, that among the dead was Jalal Saifur Rahman, director of the Bengal Anti-Corruption Commission, who was being treated at Kuwait Maitree Hospital.
On Saturday, in an online video announcement, Bangladesh Minister of Road Transport and Bridges Obaidul Quader said that public transport will be halted for longer than previously planned, until next Saturday.
The public transport strike began early on March 26 and was scheduled to end on Saturday, April 4.
Transportation of basic goods -- healthcare, fuel and food -- is still allowed.
The first recorded case of COVID-19 infection in Bangladesh was on March 8, two people who returned from Italy and also the spouse of one of them.
As of March 19, all three have already recovered.
SARS-CoV-2 has surpassed one million cases worldwide.
On Thursday, the total number of cases of SARS-CoV-2 coronavirus infection exceeded one million worldwide, data from Johns Hopkins University showed.
At least 52 thousand deaths have been linked to COVID-19, the disease caused by the coronavirus.
The incident came on the same day that Malawi confirmed its first coronavirus infection and Zambia had its first coronavirus-related death.
South Korea has said that, as of Thursday, it is one of the few countries that has survived the coronavirus infection.
Yesterday, the World Health Organization reported 1,051,635 confirmed cases, including 79,332 cases in the twenty-four hours prior to 10 a.m. Central European Time (0800 UTC) on April 4.
In the United States, more than 244 thousand cases of coronavirus have been recorded, with at least 5,900 deaths associated with it.
CBC News reported, citing data from Johns Hopkins University, that there were more than 1,000 deaths in the US on Wednesday from coronavirus infection.
Globally, countries have announced drastic measures to stop the spread of the disease.
On Thursday, Moscow mayor Serei Sobyanin extended the curfew in the capital until May 1.
Nationally, President Vladimir Putin announced that Russians will continue to receive unemployment benefits until April 30.
The Portuguese parliament voted to extend the national state of emergency for 15 days, with 215 voting in favor, ten against, and one against.
Saudi Arabia extended the curfews on the holy cities of Mecca and Medina throughout the day; previously, the curfew was only in effect from 3 p.m. to 6 a.m.
Thailand plans to implement a curfew from 10 p.m. to 4 a.m.
Ohio Governor Mike DeWine announced that the state has extended the stay-at-home order until May 1.
Shops in Australia have lowered the toilet paper limit per purchase.
On Sunday and Saturday, the Australian supermarket chains Woolworths and Coles reduced restrictions on the purchase of toilet paper to two and one pack per purchase in all national supermarkets, respectively.
ALDI only had one issue, Monday.
The restrictions were posted as messages on the exit platform and a series of Facebook pages.
Buyers reportedly purchased in fear of COVID-19 in case people needed to self-isolate.
On Wednesday, Woolworths also limited the purchase of toilet paper to one package per order for home delivery.
These changes follow the previous four-pack-per-purchase restriction issued by Woolworths and Coles on March 4 and 5, respectively.
Coles, in her March news release, criticized the four-block ban as "too much money to buy a watch", calling the move "unprecedented", while ALDI, in a Facebook post, called it unexpected.
The purchase increased with a "surprise increase" last week, according to a Woolworths spokesperson.
Cost Store in Canberra also limited the amount allowed for two packs last week.
To further reduce shortages, Coles ordered large quantities from suppliers by speeding up deliveries, Woolworths ordered more product, while ALDI made the scheduled product Wednesday earlier.
Russell Zimmerman, executive director of the Australian Retailers Association, said that retailers are increasing their products, but local council restrictions on shipping times have put pressure on them.
He expects the cost of production to rise, and the distribution of private goods to try to meet the demand, among other things.
On Tuesday, Aldi announced that the next round of product deliveries, in some stores will not continue on Wednesday in particular,
News.com.au reports that Dr Gary Mortimer, retail expert at the Queensland University of Technology, said that the warehouses will be filled with goods every night.
He said toilet paper is a heavy material, which leads to low product count, and, when sold, leaves the shelves empty, reinforcing the feeling of shortage.
Colos and Woolworths have the idea that if they can fill the shelves with their products, if things like toilet paper and hand sanitizer are full, then it will reduce the fear", Russell Zimmerman said according to ABC News.
The recycled toilet paper manufacturers who produce our high-quality toilet paper said last Wednesday that they were going to run out.
Kimberly-Clark, which makes Kleenex toilet paper, and Solaris Paper, which makes Sorbent, stressed that they are working 24/7 to maintain the supply of products, according to News.com.au.
Domain.com, a real estate site, reports that some property buyers are giving away free toilet paper to the first bidder at the Melbourne auction, when a small number of auctions were held because buyers were away for the long International Labour Day weekend.
The NT News edition, on Thursday, published Darwin's eight-page article, which was meant to be cut and used as toilet paper.
The bakery was initially reluctant to lift the restrictions, according to a March 3 ABC Australia report, saying it had no plans to impose purchase restrictions.
Rusell Zimmerman added that other products are in high demand, including mouthwashes, disinfectants, dry products, hand washing powder and flour.
Similarly, outside Australia, online retail giant British Ocado on Sunday evening was reported to have limited the sale of Andress toilet paper to two 12-packets.
The World Health Organization has declared COVID-19 a global disease.
On Wednesday, the World Health Organization declared the ongoing COVID-19 outbreak caused by the SARS-CoV-2 coronavirus to be a global disease.
Although the term "global disease" refers to a disease that is spread globally but is not as deadly as in some cases, the World Health Organization has stressed the need for governments to take action.
All countries can still change the course of this pandemic. Wikinews_6:1159 https://en.wikinews.org/wiki/World_Health_Organization_declares_COVID-19_pandemic CC_BY-SA_2.5 en if countries can detect, detect, treat, follow up and mobilize their populations for the response, said Tedros Adhanom Ghebreyesus, WHO's director general.
I am deeply concerned by both the alarming levels of risk and the alarming levels of inaction.
According to Dr. Tom Frieden, former director of the US Centers for Disease Control and Prevention, the global epidemic is "unprecedented".
He said, in comments published by CNN in February, "Apart from influenza, no other respiratory virus has been tracked from the point of emergence to its sustained spread around the world.
Ghebreyesu also expressed a similar view, saying "we have not seen a global pandemic of coronavirus before".
He continued, "We've never seen a global pandemic that could be contained at the same time".
In the new situation as the global pandemic continues, the World Health Organization (WHO) has announced in January the declaration of a public health emergency of global concern.
Director of the US National Institute of Allergy and Infectious Diseases, Dr. Anthony Fauci, said the rupture, "basically, will be the worst".
As of Thursday, the Associated Press reported that there were at least 126,000 COVID-19 cases worldwide, resulting in more than 4,600 deaths.
The global coronavirus pandemic 2019-20 is the ongoing global coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
The outbreak was first identified in Wuhan, China, in December 2019, and was declared a Public Health Emergency of Global Concern on 30 January 2020, and was recognized as a global disease on 11 March 2020.
As of 10 April 2020, an estimated 1.6 million COVID-9 cases have been reported in 210 countries and territories, resulting in an estimated 97,000 deaths.
Nearly 364,000 people have recovered.
The case fatality rate is estimated to be 4% in China, while globally the rate ranges from 13.04% in Algeria to .08% in New Zealand,
The most common symptoms include fever, cough and shortness of breath.
Severe cases include bruising and symptoms of severe respiratory problems.
The time from the time of susceptibility to the onset of symptoms is about five days, but it can range from two to fourteen days.
There is no known vaccine or specific treatment against the virus.
Primary care is symptomatic treatment in support of the disease. Suggested precautions include hand washing, covering the mouth when coughing, maintaining social distancing, and personal monitoring and quarantine of people suspected of being infected.
World leaders responded by implementing travel restrictions, quarantines, quarantines, risk controls in workplaces and closures.
The global pandemic has caused severe socioeconomic disruption around the world, postponement or cancellation of sporting, religious, political and cultural events and widespread supply shortages exacerbated by consumer panic.
Schools and universities have been closed nationally or locally in 193 countries, affecting an estimated 99.4 percent of the world's student population.
Misinformation about the virus has spread online, and there are incidents of xenophobia and discrimination against Chinese, other people of East Asian and Southeast Asian descent, and others from areas with high virus cases.
Due to the reduction in travel and the closure of large industries, there is a reduction in air pollution and carbon emissions.
Health authorities in Wuhan, Shinaha (capital of Hubei Province) reported cases of a cluster of unknown bursitis on 31 December 2029, and an investigation was launched in early January 2020.
Most of the cases are linked to the Huanan Seafood Wholesale Market, so the virus has a source in animal-to-human transmission.
The virus that caused the outbreak is known as SARS-CoV-2, a newly discovered virus that is related to the influenza coronavirus, the coronavirus, and SARS-CoV. The first person to have symptoms was later diagnosed with the disease on 1 December 2019, and the person has no apparent connection to the later marketed group.
Of the first group of cases reported in December 2019, two-thirds were found to be linked to the market.
On 13 March 2020, an unconfirmed report by the South China Morning Post suggested that the case was traced back to 17 November 2019, with a 55-year-old man from Hubei Province as the first case. On 26 February 2020, the World Health Organization reported that new cases reported in China had decreased but had increased in Italy, Iran, South Korea, and the number of new cases in China exceeded the number of new cases in China for the first time.
Serious cases, especially those with mild symptoms, may not be reported.
As of 26 February, the proportion of cases reported was small among young people, with those aged 19 and under accounting for 2.4% of cases worldwide. The UK's Chief Scientific Adviser, Patrick Vallance, estimated that 60% of the British public would be infected before a robust and effective immune system could be achieved.
Cases refers to the number of people tested positive for COVID-19 who tested positive for the disease according to official protocols.
As of 23 March, a country that has screened more than 3% of its total population had many countries have official rules to screen people with mild symptoms, such as Italy, the Netherlands, Spain, and Switzerland, where the most commonly diagnosed disease is HIV.
A study published on 16 March found that in China, as of 23 January, an estimated 86% of COVID-19 infections were undetected, with unregistered infections accounting for 76% of the documented cases.
Taxilin statistically published on 30 March that the estimated number of infections in Italy may be significantly higher than the reported cases.
The previous estimate of the baseline reproductive index (R0) for COVID-19 was 1.4 to 2.4.
A study published by the US Centers for Disease Control and Prevention concluded that the risk is 5.7.
Most people with COVID-19 recover.
For those who have not, the period from the onset of symptoms to death is between 6 and 41 days, with a maximum of 14 days.
As of 10 April 2020, an estimated 97,000 deaths were due to COVID-19.
In China, as of 5 February, nearly 80% of deaths were in people over 60 years old, and 75% of these had pre-existing medical conditions including heart disease and diabetes. The official total death toll from the global COVID-19 pandemic is generally referred to as people who have been diagnosed with COVID and die according to official protocols.
The actual death toll from COVID-19 is likely to be much higher, not including those who die without being tested - for example, those who die at home, in home care, etc.
A subset of the data from Italy is the additional number of deaths during the global pandemic that exceeded the official total number of COVID-19 by 4-5x.
A spokesperson for the US Centers for Disease Control and Prevention (CDC) acknowledged "We know that [the reported death toll] is relatively low", a quote confirmed by an unofficial report of a lowered toll in the US. Similarly, a decrease in the number of deaths often occurs during epidemics, such as the 2009 N1N1 swine flu pandemic. The first confirmed death occurred in Wuhan on 9 January 2020.
The first death outside mainland China occurred in the Philippines on 1 February, and the first death outside Asia occurred in France on 1 February.
As of the end of February 28, outside mainland China, more than a dozen deaths were being recorded in each of Iran, South Korea, and Italy.
By the end of 13 March, deaths had been reported from more than four countries and territories, on every continent except Antarctica. Several measures have been commonly used to reduce mortality.
This number varies from region to region and is facilitated by the number of diagnoses, quality of care, treatment options, time since the outbreak began, and demographic characteristics such as age, gender, and overall health. The case-to-case ratio shows the number of deaths divided by the number of cases detected for a given virus.
Based on Johns Hopkins University statistics, the global case-by-case mortality rate is 6.0% (97,039/1,617,204) as of 1 April 2020.
The numbers vary from region to region.
In China, the mortality to case ratio has been estimated to have decreased from 17.3% (for those with onset of symptoms 1-10 January 2020) to 0.7% (for those without onset of symptoms after 1 February 2020). Other measures include the mortality rate (CFR), which reflects the percentage of people tested who died from the disease, and the infectious mortality rate (IFR), which reflects the percentage of people who were infected (both tested and untested) and died from the disease.
The statistics are not time-bound and follow the specific community from infection to case resolution.
A number of academics have tried to account for this number for a specific number of people.
The University of Exford's Cluster of Health-Based Diseases Centre estimates the global infection mortality rate to be between 0.1% and 0.39%.
The upper part of this figure is consistent with the results of the first randomized COVID-19 test in Germany, and the analysis of the study statistically as a result of the CFR test.
The World Health Organization says the global epidemic is under control.
The maximum duration of the outbreak is uncertain and varies by region.
Macieji Boni of Penn State University says, "It was left unchecked, our contagion was mostly in the highlands".
But it's impossible to make any realistic predictions now about when it will be".
Chinese government's top health adviser Zhong Nanshan argued that "it will end by the end of June" if all governments are organized to follow World Health Organization's steps to stop the spread of the virus.
On 17 March, Adam Kucharski of the London School of Hygiene & Tropical Medicine said that SARSCoV-2 "will be in a circular state, probably within a year or two".
According to the Imperial College study led by Neil Fergusin, physical distancing and other measures are required "until vaccination is achieved (possibly 18 months and beyond)".
William Schaffner of Vanderbilt University said, "I think it is unlikely that it is a coronavirus-because it is so transmissible-it is gradually becoming extinct" and it is "likely that it is a seasonal disease, which can reappear every year".
The risk of relapse is related to a strong immune system and mutation boundaries.
Symptoms of COVID-19 are generally unknown and may not be symptomatic.
The two most common symptoms are fever (88%) and cough (68%).
Less common symptoms include fatigue, production of shortness of breath (hypoxia), loss of sense of smell, shortness of breath, muscle and joint pain, joint pain, headache, seizures, dizziness, coughing, blood clotting, dizziness or blue coloration. The World Health Organization states that approximately one person with six symptoms may be very ill and have difficulty breathing.
The US Centers for Disease Control and Prevention (CDC) lists immediate symptoms such as difficulty breathing, chronic abdominal pain, no pressure, sudden vomiting, difficulty arousing, and facial or facial flushing; immediate medical attention is recommended for anyone experiencing symptoms. Further progression of the disease can lead to severe bronchitis, severe respiratory symptoms, acute respiratory distress, hypotension, and death.
Those infected may be asymptomatic, meaning they have no clinical symptoms but test results confirm infection, so researchers have issued a recommendation that anyone who has had close contact with someone who has confirmed infection should be closely quarantined and tested to rule out infection.
China estimates the proportion of asymptomatic people at around 44%.
The incubation period (the time between infection and onset of symptoms) ranges from one to 14 days; most commonly five days. For example, for uncertainty, the dose-disruption in people with COVID-19 who have lost their sense of smell was initially 30% and then fell to 15%.
Some information on how the disease spreads is still unknown.
The disease is believed to be most spread by close contact and cough droplets that appear when a person coughs, sneezes, or talks; that is, from a person within 1 to 2 meters (3 to 6 feet) of them.
A study found that uncovered coughing can cause coughing spots that fly from 4.5 meters (15 feet) to 8.2 meters (27 feet) high.
Some have suggested that the virus can also be transmitted through small droplets that remain in the air for a long time, which may appear when speaking. Respiratory droplets may also appear through the respiratory tract, including when speaking, although the virus is not normally transmitted through the air.
The droplets may be on the nose and mouth of people who are close to the area or it may be in the airways.
Medical procedures such as deep breathing and cardiopulmonary resuscitation (CPR) may cause a pulmonary embolism that can be transmitted through the air.
It can also be spread by touching a sensitive area, such as the skin, and then touching the eyes, nose, or mouth.
With concerns that it could spread through feces, the risk is believed to be decreasing.
The Chinese government denied the possibility of oral transmission of SARS-CoV-2. The virus is most likely to spread during the first three days of onset of symptoms, although spread may be possible before symptoms appear and in the later stages of the disease.
The people were diagnosed with the disease three days before they showed symptoms, suggesting that transmission was possible before they developed symptoms.
There are only a few reports of symptomatic cases confirmed in the laboratory, but symptomatic transmission has been detected in some countries during testing of people who have been exposed.
The European Centre for Disease Control and Prevention (ECDC) says that because it is not universally clear how easily the disease spreads, one person can usually infect two to three others, and the virus can live on surfaces for hours to days.
Specifically, the virus was found to be detectable on polypropylene surfaces for up to three days and 304 stainless steel, for one day on wood, and for up to four days on copper surfaces.
This, however, varies depending on the humidity and temperature at which cats and other animals have been tested for COVID-19.
There is no evidence that animals can transmit the virus to humans, although British authorities are urging people to wash their hands after touching animals, as well as after touching other surfaces that people may have been exposed to.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an uncommon virus, first identified in three people with bronchitis in connection with a cluster of cases of acute respiratory syndrome in Wuhan.
All features of the novel SARS-CoV-2 virus occur in the same naturally related coronavirus. Outside the human body, the virus is killed by domestic soapworms, which break down its hard shell. SARS-CoV-2 is closely related to the original SARS-CoV.
It is thought to have an animal origin and is transmitted to humans.
Genetic analysis revealed that the coronavirus is genetically related to the subgenus Betacoronavirus, the subgenus Sarbecovirus (Gen B) with two derived strains.
96% is the same overall genome sequence as other coronavirus strain samples (BatCov RaTG13).
In February 2020, Chinese researchers discovered that there is only one amino acid difference in specific parts of the genome sequence between the human and the human virus.
Comparison of whole genome to date has detected up to 92% of the genetic patterns shared by the novel coronavirus and SARS-CoV-2, which is not enough to prove that the mutants are intermediate disease.
Viral infection can be professionally diagnosed based on symptoms, although confirmation ultimately requires a reverse transcription polymerase reaction (rRT-PCR) sequencing of the outcome or CT scan.
A comparative study of PCR and CT in Wuhan suggested that CT is much more sensitive than PCR, although it is particularly weak, with many of its symptoms obscured by other proteases and pathways.
In March 2020, the American College of Radiology advised that "CT should not be used as a primary test for COVID-19".
WHO published several RNA testing methods for SARS-CoV-2 with the first one being announced on 17 January.
The test uses real time replication of the polymerase reaction sequence (rRT-PCR).
The test can be performed by a breathalyser or a blood sample.
The results are usually available within a few hours to a few days.
The test is generally done through a nasal swab, although a throat swab may be used.A number of laboratories and companies perform a blood swab test, which detects antibodies against the virus.
As of 6 April 2020, none have been confirmed to be suitable for approval for widespread use.
In the United States, the Cellex-made blood plasma test was approved for emergency use only in authorized laboratories.
Characteristics of radiographic and computed tomography (CT) images of people with symptoms include a floor-to-ceiling glass and the absence of a fluid gap between the lungs and the chest.
The Italian Radiology Association is collecting online a global database of the results of radiography of confirmed cases.
Due to the co-infection of other infections such as adenovirus, imaging without PCR confirmation has limited validity for identification of COVID-19.
A large study in China compared the results of CT and PCR to the chest and showed that although imaging is not specific to infection, it is faster and more sensitive, suggesting its consideration as a tool for testing infection sites.
Artificial intelligence-based neural network mapping was developed to detect viral imaging patterns on both X-ray and CT scans.
Strategies to prevent transmission of the disease include maintaining good general personal hygiene, hand washing, avoiding contact with the eyes or mouth with unwashed hands, and coughing or sneezing in the toilet and taking a toilet seat.
Those who have previously had infection are advised to wear surgical masks in public.
Discernible social distancing measures are also recommended to prevent transmission.Many governments have restricted or warned against all non-essential travel to and from countries and areas affected by the outbreak.
However, the virus has reached community spread in many parts of the world.
This means that the virus is spreading within communities, and some parts of the community do not know where or how it has been infected.Healthcare providers who are caring for someone who may have been infected are advised to use advanced precautions, touch precautions, and eye protection.Following contacts is an important way for health authorities to identify the source of the infection and prevent further transmission.
The use of location data from mobile phones by the government for this purpose has raised privacy concerns, with Amnesty International and over 100 other organizations publishing articles calling for such restrictions.
Applications on several mobile phones have been activated or suggested for optional use, and as of April 7, 2020, more than a dozen expert groups have been working on encryption solutions, such as using Bluetooth to see the proximity of other mobile phone users.
Users will then receive a message if they have been in close contact with someone who has tested positive for COVID-19. Myths circulate about how to prevent infection; for example, washing the nose and cleaning the throat with mouthwash does not work.
There is no vaccine for COVID-19, although many agencies are working to develop one.
Hand washing is recommended to prevent the spread of the disease.
The CDC recommends that people wash their hands frequently with soap and water for at least twenty seconds, especially after going to the bathroom or after hands are dirty, before eating; and after blowing a nose, coughing, or sneezing.
This is because outside the human body, the virus is killed by household soap, which preserves its virulence.
The CDC further recommended the use of alcohol-based hand sanitizers with at least 60% alcohol by volume when soap and water are not readily available.
The WHO advises people to avoid touching their eyes, nose, or mouth with unwashed hands.
The surface can be sterilized with a number of solutions (one minute application of a disinfectant to stainless steel surfaces), including 62-71% ethanol, 50-100% isoproponal, 0.1% sodium hypochlorite, 0.5% hydrogen peroxide, and 0.2-7.5% povidone-iodine.
Other solutions, such as benzalkonium chloride and chrohexidine gluconate, are less reactive.
The CDC recommends that if a suspected or confirmed case of COVID-19 is found in a healthcare setting such as an office or day care facility, all areas such as offices, restrooms, public areas, shared electronic devices such as tablets, touch screens, keyboards, remote controls, and ATM machines used by infected individuals, should be disinfected.
Health authorities recommend that people cover their mouth and nose when coughing or sneezing on the sides of their throat or breath, and that they cover any excrement immediately.
Surgical masks are recommended for those who are exposed, as wearing a mask can limit the range and distance the exposed person can travel when speaking, coughing, or sneezing.
WHO has issued recommendations on when and how to use masks.
According to Stephen Griffin, a virologist at the University of Leeds, "Wearing a mask can reduce the urge [of] people to touch their face, which is a major risk factor if proper hand hygiene is not followed".Masks are also recommended for use by those who are caring for someone who is infected.
The WHO has recommended the wearing of masks for healthy people in high-risk situations, such as those caring for someone with COVID-19, though it also acknowledges that wearing masks can help people avoid touching their faces.
Several countries have begun to encourage the use of face masks by members of the public.
In the United States, the CDC recommends wearing non-sanitary cloth face masks. China has specifically recommended the use of disposable medical masks for public health members, especially when they are within 1 meter (3 feet) or less of others.
Hong Kong recommends wearing surgical masks when travelling in public transport or in crowded areas.
Health authorities in Thailand encourage people to make cloth face masks at home and wash daily.
The Czech Republic and Slovakia have stopped going out in public without wearing a face mask.
On March 16, Vietnam requested everyone to wear a face mask when going to public places to protect themselves and others.
The Austrian government mandates that anyone entering a department store must wear a face mask.
Israel has asked all residents to wear face masks in public.
Taiwan, which had been producing ten million masks a day as of mid-March, required passengers on trains and buses in the cities to wear masks from 1 April.
Panama mandates the wearing of face masks when going outside, while also recommending the production of home-made face masks for use by those who cannot afford to buy face masks.
Face masks are also widely used in Japan, South Korea, Malaysia, and Singapore.
Social distancing (also known as visual distancing) is an infection control action aimed at reducing the spread of disease by reducing close contact between people.
These measures include curfews, travel restrictions, and closures of schools, workplaces, playgrounds, concerts, or shopping centers.
People can implement social distancing policies such as staying at home, restricting movement, avoiding crowded areas, using non-contact greetings, and keeping a physical distance from others.
Many states are now mandating or recommending social distancing in areas affected by the outbreak.
The maximum maximum gathering size recommended by US government officials and health authorities has been reduced from 2,500 people (if no known COVID-19 outbreak exists in the region) to 50 people, and to a maximum of 10 people.
On 22 March 2020, Germany banned social gatherings of more than two people.Adults and those with low-level health conditions such as diabetes, heart disease, respiratory illness, blood pressure and a low immune system face a high risk of chronic illness and disability.The CDC advised people to stay at home as much as possible in the communities where the outbreak has occurred.At the end of March 2020, the WHO and other health agencies began to replace the term "social distancing" with "visible distance", to clarify whether the goal is to reduce the visibility of social distancing by maintaining social contact, whether directly or indirectly from one place to another.
The use of the term "social distancing" has led to people engaging in complete social isolation, rather than being encouraged to contact others in the same way.Some authorities have provided sexual health advice for use during the global pandemic.
These include the recommendation that you only have sex with a partner who is not infected or has no symptoms of the virus.
Home quarantine is recommended for people who have tested positive for COVID-19 and those who suspect they may have it.
Health authorities have issued clear guidelines for proper quarantine.Many governments have mandated or recommended quarantine for all communities in affected areas.
The strongest quarantine recommendations were given to groups at high risk.
Those who may have been in contact with someone with COVID-19 and who have recently traveled to a country or region with widespread transmission are advised to self-quarantine for 14 days from the last possible contact.
Strategies to control the outbreak are stop, slow, and minimize.
Stops are taken in the early stages of the outbreak and seek to locate and quarantine those infected and similarly introduce other infection control and vaccination measures to stop the disease from spreading to the rest of the community.
When it is not possible to stop the spread of the disease, efforts are then directed towards mitigation, taking steps to slow the spread and minimize its impact on health and social systems.
Both the termination and the reduction can be taken at the same time.
Reducing requires more drastic measures to curb the global pandemic by reducing the baseline infection rate to less than 1. The infectious disease control unit tries to reduce the rise in the epidemic, known as the expanding saphenoid curve.
This reduces the risk of healthcare services running out and gives more time to make vaccines and medicines.
The most common interventions to address discrimination include personal protection measures, such as hygiene, wearing face masks, and self-quarantine; social distancing measures such as closing schools and stopping mass gatherings; community engagement to discourage and discourage such interference; and similarly strong environmental measures such as surface disinfection. Many stronger measures to stop discrimination have been taken in China as the extent of discrimination has become apparent, such as urban quarantining and stronger measures to stop violence.
Other countries have also implemented several measures aimed at limiting the spread of the virus.
South Korea has instituted widespread search and local quarantine, and issued warnings about the movement of infected people.
Singapore provided financial support to those who were affected and who isolated themselves and imposed heavy fines on those who did not do so.
Taiwan has increased the production of face masks and has sanctioned the price increase for medical supplies. British and American designs show that mitigation (reducing but not stopping the spread of the epidemic) and suppression (reversing the growth of the epidemic) have many challenges.
The best mitigation techniques can reduce the need for healthcare at the top by 2/3 of these deaths, but still results in hundreds of thousands of deaths and that health systems are destroyed.
The strain is optional but needs to be maintained while the virus is circulating in the human community (or until a vaccine is available, if that is desired), otherwise transmission will double quickly when the measures are relaxed.
The long-term intervention of the global pandemic has a social and economic cost.
There is no approved specific antiviral treatment for COVID-19, but efforts to develop it are ongoing, including testing of existing drugs.
Taking available anti-inflammatory medication, drinking juice, and rest can help to relieve symptoms.
Depending on the severity, oxygen therapy, hydration, and respiratory support may be required.
The use of steroids can worsen the outcome.
Several previously approved vaccines for the treatment of other viral diseases are being investigated for use in the treatment of COVID-19.
WHO also states that some "traditional and home remedies" can alleviate the symptoms caused by SARS-CoV-2.
Increasing the scope and adaptation of health care to the needs of COVID-19 patients was identified by WHO as a fundamental response to the pandemic.
ECDC and WHO's European regional office issued guidance for hospitals and primary health care services on multi-level resource transfer, including focusing laboratory services on COVID-19 testing, stopping screening procedures whenever possible, isolating and quarantining COVID-19 patients, and emergency care capacity through staff training and increasing the number of available ventilators and beds.
There are several claims about where the first case (the so-called Hebrew patient) was found.
The first known case of the novel coronavirus could be in December 2019 in Wuhan, Hubei, China.
Within a month, the number of coronavirus cases in Hubai increased steadily.
These were later linked to the Huanan Seafood Wholesale Market, which also sold live animals, and one theory is that the virus originated from one of these animal species; or, in other words, it has an animal origin and is transmitted to humans.The so-called burukiitis cluster was detected on 26 December and treated at Hubei Provincial Hospital by Dr. Zhang Jixian, who notified the Wuhan Jianghan CDC on 27 December.
On December 30, a team of economists at Wuhan Central Hospital warned colleagues of "SARS-like coronavirus".
Eight of the doctors, including Li Wenliang, warned the police about the spread of fake news, and among other things, Ai Fen was reprimanded by her supervisor for promoting fear.
The Wuhan Municipal Health Commission finally issued a public notice on March 31 and informed the World Health Organization.
An unknown amount of mumps was reported to Wuhan health authorities who initiated an investigation in early January. During the early stages of the outbreak, the number of cases doubled by an average of seven cases a day.
In early and mid-January 2020, the virus spread to other provinces in China, sparking the Chinese New Year traffic as Wuhan is the transport hub and the largest railway interchange.
On 20 January, China reported nearly 140 new cases in one day, including two cases in Beijing and one in Shenzhen.
Official data showed that 6,174 people had already shown symptoms by the end of January 20, 2020, and on March 26, the United States surpassed China and Italy as the country with the highest number of confirmed cases worldwide.As of April 9, 2022, more than 1.61 million cases have been reported worldwide; more than 97,000 people have died and more than 364 have recovered.
Nearly 200 countries and territories have had at least one case.
Due to the global pandemic in Europe, many countries in the Schengen Area have restricted free movement and imposed border controls.
The quarantine response includes restrictive measures such as quarantine (known as stay-at-home orders, stay-at-home orders, or general lockdowns) and curfews.As of 2 April, nearly 300 million people, or nearly 90% of the population, are under some form of lockdown in the United States, more than 50 million people are under lockdown in the Philippines, nearly 59 million people are under lockdown in South Africa, and 130 billion people are under lockdown in India.
On 26 March, 1.7 billion people worldwide were under some form of restrictions, which rose to 2.6 billion people two days later - nearly one-third of the world's population.
The first confirmed case of COVID-19 transmission was traced to 1 December 2019 in Wuhan; unconfirmed reports suggest the first case was on 17 November.
Dr. Zhang Jixian noticed a group of cases of bruxism of unknown cause on December 26, where her hospital reported Wuhan Jianghan to the CDC on December 27.
Genetic testing of the first patient samples on 27 December 2019 found a SARS-like strain of the coronavirus.
A medical advisory was issued by the Wuhan Municipal Health Commission on 31 December.
The World Health Organization was notified on the same day.
When the alerts were issued, the Wuhan economist warned the police to "spread false reports" about the outbreak.
The National Health Commission of China said earlier that there is no "clear evidence" of human-to-human transmission.
In late January, the Chinese government launched a revolutionary campaign that was later described by Chinese Communist Party General Secretary Xi Jinping as a "people's war" to stop the spread of the virus.
In what has been described as "the greatest quarantine in human history", the lockdown announced on 23 January stopped travel to and from Wuhan, expanded to 15 capitals in Hubei, and affected a total population of about 57 million.
The use of private cars is prohibited in the capital.
Chinese New Year celebrations (25 January) are cancelled in many places.
The chief also announced the construction of a temporary hospital, Houshenshan Hospital, which was completed in 10 days.
Another hospital was built later, Leishenshan Hospital, to handle new patients.
In addition to the newly built hospital, China has converted 14 other locations in Wuhan into temporary hospitals, such as convention centers and stadiums. On 26 January the government introduced additional measures to curb the spread of COVID-19, including the provision of medical certificates for travelers and the extension of the Spring Festival holiday.
Schools and communities were closed across the country.
Hong Kong and Macau have introduced several measures, especially concerning schools and universities.
Measures for working outside the workplace have been introduced in nearby provinces in China.
Travel restrictions have been implemented in and out of Hubei.
Public transportation has been modified, and all theaters in China have been temporarily closed.
Controls on social movement have been implemented in many capitals, with an estimated 760 million people (more than half the population) subjected to some form of temporary restrictions.After the outbreak entered its global stage in mid-March, Chinese authorities took drastic measures to prevent "export" from other countries.
For example, Beijing imposed a 14-day mandatory quarantine for all international travelers entering the capital.On 23 March, mainland China reported only one domestic case five days earlier, a case through a traveler returning from Guanzhou from Istanbul.
On 24 March 2020, Chinese Premier Li Keqiang said that the domestic spread of the highly transmitted measles had been controlled and that the outbreak would be contained within China.
On the same day that travel restrictions were eased in Hubei, except Wuhan, two months after the imposition of the lockdown, the Chinese Ministry of Foreign Affairs announced on 26 March 2020 that visa-entry and residency permit holders will be suspended from 28 March onwards, with no specific information specifying when the restriction will end.
Those who wish to enter China must apply for a visa at a Chinese embassy or consulate.
The Chinese government encourages businesses and industries to reopen on 30 March, and provides incentives to businesses.The provincial council has declared a day of mourning beginning with a three-minute national mourning at 10:00 on 4 April, coinciding with the Qinming Festival, although the central government has asked families to express their condolences online by maintaining physical distancing to avoid the outbreak of COVID-19 and to renew.
COVID-19 is confirmed to have spread to South Korea from China.
The National Health Agency reported a significant increase in confirmed cases on February 20, largely due to the Daegu gathering of the Shincheonji Church of Jesus movement.
Shincheonji worshippers visiting Daegu from Wuhan were suspected of being behind the outbreak.
As of 22 February, 9,336 church followers, 1,261 or nearly 13% reported symptoms. South Korea declared a state of high alert on 23 February 2020.
On 28 February, more than 2,000 confirmed cases were reported in Korea, which rose to 3,150 on 29 February.
All military installations in South Korea have been quarantined after three of the soldiers tested positive for the virus.
Flight schedules were also affected and therefore changed.South Korea launched what is considered the largest and best-organized program in the world to screen the population for the virus, quarantine any infected person and track and quarantine those who have been in contact with them.
Methods of testing include mandatory eyewitness reporting of symptoms from people from around the world using a phone app, going for viral testing with results available the next day, and increasing the testing capacity to be able to test 20,000 people per day.
The South Korean program was considered successful in containing the outbreak despite the absence of quarantine in all capitals. The South Korean community had previously been blocked in response to President Moon Jae's crisis.
Many Koreans have signed a lawsuit claiming that Moon's removal was a misrepresentation of the government's disclosure, or a praise of his response.
On 23 March, it was reported that South Korea had its lowest daily case total in four weeks.
On 29 March it was announced that from 1 April all travellers from abroad would be quarantined for two weeks.
According to media reports on April 1, South Korea received requests from 121 different countries to facilitate testing for the virus.
Iran reported its first confirmed case of SARS-CoV-2 infection on 19 February in Qom, while, according to the Ministry of Health and Medical Education, two people died later that day.
The government announced drastic measures including the cancellation of concerts and other cultural events, sporting events, and Friday prayers, and the closure of universities, colleges, and schools.
Iran has allocated five trillion riyals to fight the virus.
President Hassan Rouhani said on 26 February 2020 that there is no plan for quarantine zones affected by the outbreak, only people will be quarantined.
Plans to restrict travel between capitals were announced in March, although large traffic jams were still in place between capitals before the Persian New Year.
Shiite holy sites remain open for worship as of 16 March 2020, with Iran becoming the epicentre of the virus spread after China in February.
Despite the moderate claim of concealing the border crossing inside Iran, more than ten countries had followed up with Iran by the end of February 28, indicating that the border crossing was more severe than the 388 cases reported by the Iranian government that day.
Iran's parliament has been shut down, with 23 of the 290 members of parliament reportedly infected with the virus on 3 March.
On 12 March, the Human Rights Watch urged Iranian prison authorities to unconditionally release human rights defenders imprisoned for ideological differences, as well as to release all deserving prisoners temporarily.
She said there is a greater risk of the virus spreading in closed facilities such as prisons, which lack adequate health care.
On 5 March, the Iranian government reported 100 deaths in a single day, the highest number the country has recorded since the start of the genocide.
At least 12 Iranian current or former politicians and government leaders have died from the disease since late March 17.
By the end of 23 March, Iran was experiencing 50 cases per hour and one death per ten minutes due to the coronavirus.
According to the World Health Organization officials, there may be five times more cases in Iran than reported.
It has also been suggested that US sanctions on Iran may affect the country's economic ability to respond to the outbreak of the virus.
The UN High Commissioner for Human Rights has called for the easing of economic sanctions on countries most affected by the global pandemic, including Iran.
The outbreak was confirmed to have spread in Italy on 31 January, when two Chinese tourists tested positive for SARS-CoV-2 in Rome.
Cases began to rise rapidly, prompting the Iranian government to suspend all flights to and from China and declare a state of emergency.
A cluster of COVID-19-related cases was finally detected, starting with 16 confirmed cases in Lombardy on 21 February. On 22 February, the Council of Ministers announced a new round of regulations to stop the outbreak, including quarantining more than 50,000 people from 11 communes in northern Italy.
"There will be no entry or exit in areas affected by the outbreak", said Vice President Giuseppe Conte.
A moratorium on work and sports activities was ordered in those areas. On 4 March, the Italian government ordered the complete closure of all schools and churches across the country, bringing the total in Italy to 100.
All sporting events, including Serie A football matches, must be held in closed venues, but on 9 March, all sporting events were cancelled completely for at least one month.
On 11 March, Prime Minister Conte ordered the suspension of almost all business activities except supermarkets and pharmacies. On 6 March, the College of Anaesthesia, Trauma, Delayed Resuscitation and Emergency Care (SIAARTI) published a health recommendation with reference to the isolation protocols that may be implemented.
On 19 March, Italy surpassed China to become the country with the highest number of coronavirus-related deaths in the world when it reported 3,405 deaths from the global pandemic.
On 22 March, it was reported that Russia had sent nine military aircraft to Italy as medical supplies.
As of 5 April, there were 128,98 confirmed cases, 15,887 deaths, and 21,815 recoveries in Italy, most of these cases occurred in the Lombardy region.
A report released by CNN shows that the combination of the large number of elderly people in the Italian population and the inability to test people for the virus could contribute to the high mortality rate.
The UK's response to the virus initially appeared to be the most lenient, and in the affected countries, as of 18 March 2020, the UK government had not implemented any social distancing or mass quarantine measures.
As a result, the government has been criticized for its lack of action and its slowness in responding to the concerns faced by the public.On 16 March, Prime Minister Boris Johnson issued a public notice advising people to avoid non-essential travel and social interaction, suggesting that people work from home whenever possible and avoid places such as bars, hotels, and theatres.
On 20 March, the government announced that all leisure venues such as bars and gyms would be closed as soon as possible, and pledged to pay up to 80% of workers' wages with a ceiling of £2,500 per month to prevent unemployment during the crisis. On 23 March, Raisul Wasdiaraha made announcements of social distancing, bans on gatherings of more than two people and strict controls on movement and stay at home that were deemed essential.
Unlike previous measures, these restrictions were enforced by the police through suspension and dismissal of meetings.
Most businesses were ordered to close, except for those deemed "essential", including supermarkets, pharmacies, banks, construction equipment stores, battery plants, and garages.
On January 20, the first known case of COVID-19 was confirmed in the Pacific Northwest in Washington State in a man who returned from Wuhan on January 15.
The White House Coronavirus Task Force was established on 29 January.
On 31 January, the Trump administration declared a public health emergency and imposed restrictions on the entry of travelers from China.
On 28 January 2020, the Center for Disease Control - the primary public health agency of the US government - announced that it had developed its own test kit.
Despite this, the U.S. government's investigation is a low-key one, which obscures the true scale of the time-lapse.
The survey was affected by faulty testing materials issued by the federal government in mid-February, lack of federal government approval of testing materials for non-governmental (academic, corporate and hospital) testing until late February, and limited patterns of people eligible for testing until early March (after a final recommendation was required).
On February 27, The Washington Post reported that fewer than 4,000 tests were conducted in the United States.
As of March 13, the Atlantic reported that fewer than 14,00 tests had been conducted.
On 22 March, the Associated Press reported: "Many people with symptoms and doctor's orders waited hours and days to be tested".Following the first American death reported in Washington state on 29 February, Governor Jay Inslee declared a state of emergency, an action that was later followed by other states.
Schools in the Seattle area canceled classes on March 3, and by mid-March schools across the country were closed. On March 6, 2020, the US advised a team of epidemiologists from Imperial College London to predict the impact of the novel coronavirus on the country.
The same day President Trump signed the Emergency Preparedness and Response Act, which provided $8.3 billion in immediate funding to federal agencies to respond to the crisis.
Companies have targeted their employees with travel restrictions, cancellation of meetings, and encouraging employees to work from home.
Events and sporting events were cancelled. On 11 March, Trump announced travel bans for most of Europe, except the UK, for 30 days, effective 13 March.3
The next day, he expanded the restrictions to include the United Kingdom and Ireland.
On March 3, he declared a national emergency, making federal funding available for disaster response.
Beginning on March 15, many businesses across the United States have closed or reduced their hours of operation in an attempt to slow the spread of the virus.
On 17 March, the infection was confirmed in all 50 states and the District of Columbia. On 23 March, it was reported that New York City had detected 10,700 cases of the coronavirus, more than the total number of cases in South Korea.
On 25 March, the activist said that social distancing seemed to be working, as the doubling rate of cases dropped from 2.0 days to 4.7 days.
As of 28 March, there were 32,308 confirmed cases in New York City, and 672 deaths from the virus.On 26 March, the United States reported more confirmed cases of coronavirus infection than any other country in the world, including China and Italy.On 8 April, 400,335 cases were confirmed in the United States, and 12,841 people died.
According to media reports on March 30, US President Trump decided to extend social distancing recommendations until April 30.
On the same day, the USNS Comfort, a hospital ship with nearly 1000 beds, docked in New York.
On 3 April, the United States recorded 884 deaths from coronavirus in 24 hours.
New York State cases surpassed 100,000 on April 3.The White House has been criticized for underestimating the risk and controlling messages by ordering health officials and scientists to comb through articles and publications related to the virus in the office of Vice President Mike Pence.
Trump's overall handling of the disaster is being challenged in partisan ranks.
Some US officials and commentators have criticized the US's reliance on importing critical goods, including basic medical supplies, from China.
Taxilin air travel chart was used to map and predict the pattern of spread and was published in The Journal of Travel Medicine in mid-January 2021.
According to the 2018 data of the International Civil Aviation Association, Bangkok, Hong Kong, Tokyo, and Taipei had the highest number of travelers from Wuhan.
Dubai, Sydney, and Melbourne were also reported as the most popular destinations for travel from Wuhan.
Bali is reported to be among the least prepared of the 20 most popular travel destinations, while Australian capital cities are identified as the most prepared. Australia released the New Coronavirus (COVID-19) Emergency Response Plan on 7 February.
It was reported that while much is still unknown about COVID-19, Australia will be tightening border controls and communications in response to the global pandemic.
On 21 March, measures to protect humans from dangerous and invasive species were announced in Australia.
With the effective quarantine of public transport in Wuhan and Hubei, several countries have planned to evacuate their citizens and businesses from the area, primarily using chartered state-owned flights, with the Chinese authorities providing official approval.
Canada, the United States, Japan, India, Sri Lanka, Australia, France, Argentina, Jamaica, and Thailand were among the first to condemn the evacuation of their citizens.
Pakistan says it will not evacuate any of its citizens from China.
On February 7, Brazil evacuated 34 Brazilian nationals or family members in addition to four Polish nationals, a Chinese national, and an Indian national.
Citizens from Poland, China, and India were flown back to Poland, when a Brazilian plane stalled before it could continue to Brazil.
Brazilian citizens who traveled to Wuhan were quarantined at a military base near Brasília.
On the same day, 215 Canadians (176 on the first flight, and 39 on the second flight chartered by the US government) were evacuated from Wuhan and taken to CFB Trenton for two weeks of quarantine.
On February 11, another Canadian Air Canada Flight 185 from Wuhan landed at CFB Trenton.
Australian authorities released 277 citizens on February 3 and 4 to the Christmas Island Prison, which was set up as a quarantine facility, where they were held for 14 days.
A New Zealand flight arrived in Auckland on 5 February, and its passengers (including those from Australia and the Pacific) were quarantined at the naval base at Whanaparoa, north of Auckland.
On 15 February, the American announced that it would be bringing American sailors aboard the cruise ship Diamond Princess.
On February 21, a flight carrying 129 passengers from Diamond Princess Canada landed in Trenton, Ontario.
Earlier in March, the Indian government started repatriating its citizens from Iran. On 14 March, the South African Airways, owned by the South African government, brought back 112 South African nationals.
Medical tests were performed prior to quarantine, and 4 South Africans who showed symptoms of coronavirus were left untreated to reduce risk.
Only the missing South Africans were repatriated.
The results of the investigation identified all South Africans, including flight attendants, pilots, hotel staff, police and military involved in the humanitarian operation who, as a precautionary measure, were all kept in quarantine for 14 days at the Ranch Resort.
On March 20, the Americans began to withdraw their troops from Iraq due to the invasion.
On 5 February, the Chinese Foreign Ministry said that 21 countries (including Belarus, Pakistan, Trinidad and Tobago, Egypt, and Iran) had sent aid to China.
Some Chinese students from US universities came together to help deliver relief to the virus-affected areas of China, with a joint team in the greater Chicago area reportedly managing to ship 50,000 N95 masks to hospitals in the Hubei province on January 30. Humanitarian Aid Direct Aid, working with FEDEX, sent 200,000 face masks along with other personal protective equipment, including gloves and gloves, by air, to the Wuhan Union Hospital on January 30.
On 5 February, Bill and Melinda Gates announced a donation of $100 million to WHO to fund vaccine research and treatment efforts while protecting "the most at-risk populations in Africa and Asia".
Interaktion reports that the Chinese government donated 200,000 masks to the Philippines on February 6, after Senator Richard Gordon donated 3.16 million masks to Wuhan.
On 9 February, the Singapore Red Crescent announced that it would send $2.26 million in aid to China.
Japan donated one million face masks to Wuhan, Turkey delivered medical equipment, Russia sent more than 13 tons of medical supplies to Wuhan, Malaysia announced a donation of 18 million Chinese medical gloves, Germany donated medical supplies to 10,000 patients in the Hazmat suits, and the United States donated 17.8 tons of medical supplies to China and pledged an additional $100 million in economic support to the affected countries.After cases in China appeared to be declining, the country sent aid to various countries hit by the global pandemic.
In mid-March, China, Cuba and Russia sent medical supplies and experts to help Italy deal with the coronavirus outbreak.
Prime Minister Jack Ma has sent 1.1 million test kits, 6 million face masks, and 60,000 protective suits to Addis Ababa, Ethiopia for distribution to the African Union.
He then sent 5,000 screening kits, 100,000 face masks and 5 respirators to Panama.
Ma also donated medical supplies to Canada. The Netherlands, Spain, Turkey, Georgia, and the Czech Republic expressed concern about Chinese-made masks and testing kits.
For example, Spain has shipped 58,000 Chinese-made coronavirus test kits with an accuracy rate of 30%, while at the same time, the Netherlands returned 600,000 Chinese face masks that were faulty.
Belgium recalled 100,000 disposable masks, thought to be from China, but actually from Colombia.
On the other hand, Chinese assistance has been well received in parts of Latin America and Africa.On April 2, the World Bank launched an emergency operational support for developing countries.
WHO has praised the efforts of Chinese authorities in managing and controlling the epidemic.
WHO reported a contrast between the 2002-2004 SARS outbreak, where Chinese authorities were accused of covering up the delay in prevention and control efforts, and the current crisis where the central government is "providing new monitoring to prevent stress during the Lunar New Year holidays".
On 23 January, reacting to the decision of central authorities to implement the travel ban in Wuhan, WHO Representative Gauden Galea noted that it was not "a recommendation by WHO", it was also "a very important step in the commitment to restrict travel where it is most prevalent" and was called "a lack of understanding in the history of public health". On 30 January, following confirmation of human transmission outside China and an increase in the number of cases in other countries, WHO declared the epidemic as a Public Health Emergency Emergency of International Concern (PHEIC), until vaccination was introduced during the 2009 swine flu pandemic.
WHO Director-General Tedros Adhanom said PHEIC is "close to a global pandemic, especially in low- and middle-income countries without robust health systems".
Reacting to the implementation of the travel restrictions, Tedros said that "there is no reason to take measures that do not adequately address international travel and trade" and that "WHO does not recommend restrictions on travel and trade".
On 5 February, WHO appealed to the global community for $675 million to fund strategic preparedness for low-income countries, expressing the urgency to support those countries "which do not have systems in place to detect people infected with the virus, even if it emerges".
Tedros further quoted an article that "we are only as strong as our weakest link" and called on the international community to "invest today or give more tomorrow". On 11 February, WHO held a press conference and named the disease COVID-1.
On the same day, Tedros said that UN Secretary General Antonio Guterres had agreed to give "the UN system's overall authority to react".
The UN Disaster Management Team was activated as a result, allowing for a coordinated overall response by the UN, which WHO says will allow "we to focus on medical response while other agencies can contribute expertise to address the broader social, economic and developmental impacts of the outbreak".
On 14 February, a WHO-led Joint Task Force with China was activated to ensure that international experts and WHO in China assist in local management and assessment of the "severity and transmission of the disease" by holding seminars and meetings with key stakeholders at the national level and to conduct site visits to assess the "impact of regional and autonomous level response activities, including in urban and rural areas". On 25 February, the WHO announced that "the international community is doing more to prepare for a possible global outbreak of the coronavirus", stating that despite the early stage of the pandemic, countries are always "on alert".
In response to the ongoing killings in Iran, WHO sent a Joint Task Force to assess the situation.On 28 February, WHO officials said that the global coronavirus risk assessment had been upgraded from "high" to "very high", the highest level of warning and risk assessment.
Mike Ryan, executive director of the WHO's emergency health program, warned in an article that "This is a fact check for every government on the planet:
The virus could be on its way and you need to be ready", saying that the right reaction steps could help the world avoid "the worst".
Ryan went on to say that the current data does not guarantee that public health officials would declare it a global disease, saying that such a declaration would mean "that we fundamentally accept that every human being on the planet is susceptible to the virus".
On 11 March, WHO declared the coronavirus to be a global pandemic.
The Director-General said that WHO was "deeply concerned about both the alarming rates of infection and mortality, and the alarming rates of inaction". WHO faced heavy criticism for what appeared to be its inadequate response to the global epidemic, including the late declaration of a public health emergency and the recognition of the virus as a global pandemic.
The criticism included a petition to WHO Director-General Tedros Adhanom to submit his resignation, which was signed by 733,000 people on 6 April.
On 26 March 2020, the United Nations Human Rights Expert Panel reiterated the need to respect the rights of all individuals during the COVID-19 pandemic.
The expert group stated that everyone has the right to life-saving services and that the state is responsible for them.
Some groups stressed that lack of income or health insurance should never be an excuse for discrimination against a particular group.
The experts emphasized that everyone has the right to health, including people with disabilities, from minority groups, the elderly, internally displaced persons, the homeless, those living in extreme poverty, people in prisons, as well as refugees and other unnamed groups who need government support.
International government agencies report the economic and social impact of the COVID-19 pandemic.
The Organization for Economic Cooperation and Development has launched a platform to provide comprehensive and timely information on the reaction of countries around the world, as well as insights and advice.
From ways to strengthen global health systems and economies to addressing the impact of lockdown and travel restrictions, the state-of-the-art hub, part of the National Compliance Framework, aims to help countries learn from each other and facilitate collaborative global responses to the coronavirus challenge.
The Chinese government was criticized by the United States, British Cabinet Secretary Michael Gove, and Brazilian President Jair Bolsonaro's son, for its handling of the global epidemic that started in China's Hubei province.
A number of provincial-level administrations of the Communist Party of China (CPC) have been fired for their handling of quarantine efforts in Central China, a sign of dissatisfaction with the reactions that the policies have created to the decline in those regions.
Analysts believe the move was aimed at protecting Chinese Communist Party General Secretary Xi Jinping from the social unrest caused by the coronavirus outbreak.
Some Chinese officials, such as Zhao Lijian, have denied previous claims that the coronavirus outbreak began in Wuhan, citing conspiracy theories about whether COVID-19 originated in the United States or Italy.
US administration Donald Trump described the coronavirus as "the Chinese virus" or "the Wuhan virus" saying that Chinese tests have brought a virus that has now become a global pandemic", which critics have condemned as "hateful and distracting" for its management's failure to contain the outbreak.
The Daily Beast found a US government cable showing communications fraud with clear origins from the National Security Council, with a strategy that says "It's all about China.
We were told to try and get these messages out in any way possible, including press conferences and television appearances".Publications such as Politico, Foreign Policy, and Bloomberg reported that China's efforts to send aid to countries hit by the virus is part of a global push to contain the virus.
EU foreign policy co-chair Josep Borrell warned of "a geopolitical dilemma that includes the challenge of influencing through the lens of diplomacy and 'political opportunism'.
Borrell also said, "China is aggressively pushing the message, in addition to the United States, that it is a responsible and reliable partner".
China also called on the US to lift sanctions on Syria, Venezuela and Iran, sending aid to the latter two countries.
Jack Ma's delivery of 100,000 masks to Cuba was blocked by U.S. sanctions on April 3.
US officials have also been accused of diverting aid intended for other countries to their own country.
There have been reported problems with masks between other countries, such as Germany, Austria, and Switzerland; and the Czech Republic and Italy.
In addition, Turkey seized hundreds of ventilators that were being delivered to Spain.
In early March, the Italian government condemned the European Union for its lack of attention to Italy affected by the coronavirus.
Maurizio Massari, the Italian ambassador to the EU, said "only China has responded in a two-way manner.
This is certainly not a good symbol of European solidarity".
On 22 March, after a telephone call with Italian Prime Minister Giuseppe Conte, Russian President Vladimir Putin arranged for the Russian Army to send military doctors, special vehicles for infectious disease, and other medical equipment to Italy.
Italian newspaper Stampa quotes an unknown "high-profile political source" as saying that 80 percent of Russian aid was "ineffective or of little benefit to Italians".
Sources accused Russia of using "geopolitical and diplomatic" campaigns to seek support.
Lombardy President Attilio Fontana and Italian Foreign Minister Luigi Di Maio rejected the media reports and expressed their gratitude.
Russia also sent a cargo plane carrying medical aid to the US.
Kremlin spokesman Dmitry Peskov said that "in providing friendly assistance to the United States, [Putin] assumes that as the manufacturers of medical equipment and other supplies in the United States gain power, they are also able to retaliate if necessary".
The planned NATO military exercise "Defense 2020" in Germany, Poland, and the Baltic states, the largest NATO military exercise since the end of the Cold War, will be conducted on a smaller scale.
Secretary-General of the Nuclear Weapons Disarmament Organization Kate Hudsan criticized the Defence 2020 campaign: "The current public health crisis, endangers the lives not only of the US and many European countries' troops who are responding but also of the people in the countries where they are operating". The Iranian government has been severely affected by the virus, with nearly two dozen members of parliament infected as well as fifteen other current and former political officials.
Iran's Hassan Rouhani wrote a general letter to world leaders asking for help on 14 March 2020, saying that his country was struggling to combat the gap caused by lack of access to international markets as a result of the US sanctions on Iran. The pandemic crisis led to calls for the US to implement social policies on par with other rich countries, including universal health care, universal child care, paid family leave, high rates of social and health spending.
Political analysts predict it will negatively affect Donald Trump's chances of re-election in the 2020 presidential election.Japanese-South Korean diplomatic relations have deteriorated due to the global pandemic.
South Korea has criticized the "ongoing quarantine measures" after Japan announced that anyone arriving from South Korea would be quarantined for two weeks at a government-designated facility.
South Korean society has already been divided over President Moon Jae-in's reaction to the disaster.
Many Koreans signed a petition declaring Moon's removal from office for his comments on the government's handling of the outbreak, or praising his response.The global pandemic allowed countries to pass emergency response legislation.
Some analysts have expressed concern that it will allow governments to strengthen their grip on power.
In Hungary, its parliament voted to allow Prime Minister Viktor Orban to enact laws without discrimination, suspend parliament as well as elections and punish those deemed to have spread misinformation about the virus and the government's handling of the crisis.
The coronavirus pandemic has been blamed for several supply shortages, caused by increased consumption of materials to combat shortages, panic buying, and a crisis in factory and logistics operations.
The US Food and Drug Administration has issued a warning about shortages of medicines and medical supplies due to increased consumer demand and supply shortages.
Several areas also witnessed panic buying which caused the end of retail stores such as food, toilet paper, and bottled water, leading to a shortage of supplies.
The technology industry has been especially warned about the delay in the launch of electronic products.
According to Tedros Adhanom, Director-General of the World Health Organization, the demand for personal protective equipment has increased by 100 times.
This demand caused a price increase of twenty times the normal price which also caused delays in medical supplies of four to six weeks.
It has also caused shortages of personal protective equipment worldwide, with the World Health Organization issuing a warning that this would put healthcare workers at risk.
In Australia, the pandemic has provided a new opportunity for the proxy stores to sell Australian products to China.
The move caused a shortage of baby milk in some supermarkets which was later banned by the Australian government.Despite the spread of COVID-19 cases in Northern Italy and the Wuhan region, and the high demand for food supplies, both areas survived the severe food shortage.
The measures taken by China and Italy to combat the promotion and illegal trade of dangerous goods have been successful, avoiding the dire food shortages expected in Europe as well as North America.
Northern Italy, with a large agricultural production, has not seen any significant decline, but prices may increase according to industry representatives.
Empty food trays were found temporarily, even in the inner city of Wuhan, as the Chinese government officially released pigs' food to ensure public nutrition.
A similar rule exists in Italy, which requires the production of food to be stored and consumed in a similar emergency situation.
The global economic shock is being felt in China: according to media reports on 16 March, China's economy has been hit hard in the first two months of 2020 due to government measures to stop the spread of the virus, with retail purchases down by 20.5%.
As mainland China is a major economic and manufacturing hub, the virus outbreak has been seen as a major disruptive threat to the global economy.
Agathe Demaris of Financial Analysts predicts that the market will remain resilient until a clear picture of viable outcomes emerges.
In mid-January 2020, some analysts predicted that the economic recovery from the pandemic would surpass the 2002-2004 SARS epidemic.
One estimate by an expert at Washington University in St. Louis put the impact on global supply chains at $300+ billion that could last for up to two years.
The Organization of Petroleum Exporting Countries (OPEC) is reportedly "in turmoil" after a sharp drop in oil prices caused by lower demand from China.
The stock market of tokens declined on 24 February due to a surge in the number of COVID-19 cases outside mainland China.
On 27 February, amid growing concerns over the coronavirus outbreak, stock indices including the NASDAQ-100, S&P 500 index, and the Dow Jones Industrial Average posted their lowest decline since 2008, while the Dow fell 1,191 points, the largest one-day drop since the 2007-08 financial crisis.
All three commodity stock indices ended the week with declines of over 10%.
As of 28 February, the rating company SCope Ratings GmbH confirmed the independent risk assessment of Chinese investment, but it remained a negative view.
In the stock market, again based on the coronavirus scare, the biggest drop was on March 16.
Many people see the possibility of a recession.
Economist Mohamed El-Erian thanked the Central Bank and the state for the swift action.
Central banks are reacting faster than in the 2008 financial crisis.
Tourism is the worst affected due to travel restrictions, closure of public places including tourist attractions, and government warnings against traveling anywhere in the world.
As a result, a number of airlines have canceled flights due to falling demand including British Airways, China Eastern Airlines, and Qantas, while the British regional airline Flybe has collapsed.
The impact on the cruise line industry is at a level never seen before.
Several train stations and ferry terminals were also closed.
The pandemic has been on the rise in Chunyun, a major travel season associated with the Chinese New Year holidays.
A number of events involving mass gatherings have been canceled by local and national governments, including the annual New Sand Festival, with private companies closing their stores and tourist attractions such as Hong Kong Disneyland and Shanghai Disneyland.
Most Lunar New Year events and tourist attractions were closed to prevent crowds, including Forbbiden City in Beijing and the traditional temple complexes.
In 24 of China's 31 provinces, municipalities and prefectures, officials extended the New Year holiday to February 10, ordering most workplaces not to reopen until that date.
These regions represented 80% of the country's gross domestic product and 90% of exports.
Hong Kong has raised its response to the pandemic to the highest level with a declaration of a state of emergency, school closures until March and cancellation of New Year's celebrations.
Retail visits to Europe and Latin America fell by as much as 40%.
Retailers in North America and the Middle East saw a 50-60% drop.
This was also due to a 33-43% decline in the number of shopping malls in March compared to February.
People operating shopping malls around the world have been subjected to additional measures, such as improved hygiene, the installation of thermometers to monitor the temperature of shoppers, and the cancellation of event platforms.According to estimates by the United Nations Economic Commission for Latin America, the global pandemic has caused an economic downturn that has left between 14 and 22 million people in extreme poverty in Latin America compared to the global pandemic's lack of resources.
In mid-January and February, during the rise of the Wuhan pandemic, nearly 5 million workers in China lost their jobs.
Most of the nearly 300 rural Chinese migrant workers are stuck in the interior or stuck in Hubei. By mid-March 2020, more than 10 million Americans had lost their jobs and applied for government assistance.
The coronavirus outbreak could cost 47 million US jobs and the unemployment rate could reach 32%, according to estimates from the Federal Reserve Bank of St. Louis. India's restrictions have left tens of millions of migrant workers (who are paid a day's wages) without a job. A comprehensive survey by the Angus Reid Institute found that 44% of Canadian households have experienced some form of unemployment.About 900,000 workers have lost their jobs in Spain since the lockdown ended in mid-March 2020.
During the second half of March, 4 million French workers applied for temporary unemployment benefits and 1 million British workers applied for the popular old-age benefit scheme. Nearly half a million workers in Germany sent their workers to the government-backed short-term work plan known as Kurzarbeit.
The German scheme for compensation for part-time work has been adopted by France and the United Kingdom.
The art and cultural heritage sector has been greatly affected by the global pandemic, affecting the activities of organizations as well as individuals - both employed and self-employed - across the globe.
Organizations in the voluntary arts and cultural sector have attempted to support their mission (usually with community funding) to provide access to a tangible legacy for the bush, sustain the safety of its workers and community, and support artists where possible.
At the end of March 2020, all the world's museums, libraries, concert halls, and institutions have indefinitely cancelled or postponed their exhibitions, events, and festivals.
In response, there has been a major effort to provide alternative service through digital platforms.Other factors that are now accelerating the spread of the epidemic are the cancellation of religious services, major sporting events, and other cultural events, such as music festivals and concerts, technology conferences, and fashion shows.
The record company also suffered, and the Vatican announced that Holy Week celebrations in Rome, which took place last week during the Christian Lent, were canceled.
Many church leaders have suggested that elderly Christians stay at home while attending Sunday services; in some churches services can be found on the trail, online or on television while others will offer services in the vehicle.
As the leader of the Roman Catholic Church closes its churches and temples and the Christians vacate St. Peter's Square, the citizens of other faiths have also canceled services and restricted public gatherings in churches, mosques, synagogues, temples and places of worship in Gurdwara.
Iran's Health Ministry announced the cancellation of Friday prayers in the outbreak-affected areas and the holy sites were closed again, while Saudi Arabia banned entry of foreign pilgrims as well as its own to the holy sites of Mecca and Medina.
The pandemic has caused the biggest disruption to the sport since World War II.
Major sporting events have been cancelled or postponed, including Euro 2020, the 2019-20 NBA season, and the 2019-20 NHL season. including the 2019-20 UEFA Champions League, the 2019-20 Premier League, UEFA Euro.
The pandemic disrupted the 2020 Summer Olympics, which were originally scheduled to begin in late July; the International Campaign Committee announced on 24 March that the event would be held "after 2020 but not later than summer 2021". The casino and other international platforms were closed for good and the International Poker Tournament was postponed or closed.
This has led to many gambling enthusiasts moving online, which many gambling websites have reported as a significant increase in revenue for new users. The entertainment industry has also been affected, with various bands cancelling or cancelling their shows.
Major theaters such as Broadway also canceled all performances.
Some artists are looking for a way to drive production and how to put their work online, which is another way to present it live, such as live streaming of their exhibitions or making "quick change" art online, distributing and then publishing their work.
Online, many coronavirus apps have been circulating on the Internet that are jokes about the unknown.
Since the start of the COVID-19 pandemic, much hatred, racism and racial discrimination has been directed against Jains and people of East Asian origin, as well as people from Europe, the United States and other countries.
Incidents of fear, suspicion, and violence have been observed in many countries, including Europe, Western Asia, North America and the Asia Pacific region.
The reports in February (when most cases were confirmed in Jains) mentioned the hysteria that various groups around the world were doing something against Jains that they said was deserved.
In some countries in Africa, there has been a Jaina hatred.
Many people in Wuhan and Hubei said they were discriminated against because of where they came from.
There has been a lot of support for the pandemic, both online and offline, in the areas where the virus has been spreading.
After new countries were reached by the outbreak, the people of Italy, the first European country to be found with a severe COVID-19 outbreak, are also suspected to be a source of suspicion and distance. Nationals from Malaysia, New Zealand, Singapore, and South Korea have signed a campaign to ban Chinese from entering their country in order to stop the spread of the disease.
In Japan, the hashtag #ChineseDontComeToJapan is going viral on Twitter.
Jainis as well as other Asians in the UK and US also reported an increase in racism, as well as abuse.
US President Donald Trump has been criticized for calling the coronavirus a "Gay virus", a term that some see as racist and a slur against the Gays.
Protesters in Ukraine attack buses carrying Ukrainians and foreigners from Wuhan to Novi Sanzhary.
A student from North India, which is located in the Jaina valley, and people studying in major Indian cities are said to have been subjected to harassment related to the coronavirus pandemic.
Bharatiya Janata Party Chief in West Bengal Dilip Ghosh said that the Jains had destroyed the wildlife and "that is why God is taking revenge on them".
The statement was later criticised by the Jain Consulate in Kolkata, which called it "wrong".[4] In Jainism, the campaign had brought hatred and discrimination against non-Jain people, and described foreigners as "trash" and should be "dumped" on the target.[5]
News articles purchased by the public have removed some or all of the coronavirus articles.
Some scientists have published scientific reports related to open access.
Some scientists have chosen to share their rapid findings in the first published graphs on bioRxiv.
Emergent disease - An infectious disease that develops in the course of an infection, usually in the form of a new infection or a new form of transmission.
Gastroenteritis and pain - Summary of Gastroenteritis and the transmission of pain
Epidemiology and disease list - List of deaths due to epidemics
Wildlife poisoning and dengue fever - health risks associated with the trade in untreated wildlife
Test for respiratory coronavirus syndrome 2019 (COVID-19) and its relationship with the SARS-CoV-2 virus including the detection of the person's infection and the detection of the presence of antibodies which then respond to the infection.
Detection of virus samples confirmed by RT-PCR, which then tracks the coronavirus RNA.
The test is specifically designed to detect viral RNA from SARS-CoV-2.
It is used to confirm a recent or existing infection.
Antibody (serogly) testing can be used for laboratory sampling and surveillance.
Antibody tests show the number of people who have the disease, including people with very few or no symptoms or those who have symptoms.
The exact extent of the disease and the degree of the reaction of the civil immunity can be determined by this test.
Due to limited sampling, as of March 2020, no country had reliable data to prevent the virus from affecting their population.
As of March 23, no country had tested 3% of its population, and there is a large gap between the number of tests done by countries.
This variance is likely to be reflected in the increasing case fatality rate, which is likely to be much higher than the predicted number in some countries.
Using the rRT-PCR (reverse transcription polymerase) assay in the laboratory to make a respiratory sample obtained from various sources, including a sputum sample or a fluid sample.
The results usually take from a few hours to 2 days.
The RT-PCR test is performed on food samples that can only be detected during the first week of the disease.
When the virus is active, it can escape through the throat and spread to the lungs.
In the second week of the infection, other samples may be taken from the airway that absorbs the urine or the fluid that is coughed (the urine) can be used.
One of the first PCR tests performed by Charite in Berlin in January 2020 using the reverse transcription polymerase chain reaction (rRT-PCP), which was sampled from 250,000 doses distributed to the World Health Organization (WHO).
The UK also conducted a test on 23 January 2020. The South Korean company Kogenebiotech developed a clinical, oral-based PCR (PowerCheck Coronavirus) based on SARS-CoV-2 on 28 January 2020.
Based on the "E" gene that is common to all coronaviruses, and the SARS-CoV-2-specific RdRp gene. In June, BGI Group was among the first companies to receive approval from the National Health Laboratories Administration for emergency response to the US-based PCR-based SARS-CoV-2 mouth-to-mouth tracking. In the US, the Center for Disease Control and Prevention (CDC) distributed clinical samples for the Novel Coronavirus (2019-nCoV) RT-PCR laboratory in 2019 as part of its Global Response.
One of the laboratory samples of the early lip replication kits produced an incomplete and therefore incorrect result, and the national lip sample from the CDC in Atlanta produced an average of less than 100 samples per day to be tested positively throughout February 2020.
The test using two units was found to be unreliable until 28 February 2020, when it was allowed for state and local laboratories to begin testing.
The laboratory was authorized by the Food and Drug Administration using its Emergency Powers.In the United States, commercial laboratories began testing in early March 2020.
As of 5 March 2020 LabCorp announced that RT-PCR-based COVID-19 testing will be conducted nationwide.
The nationwide COVID-19 testing drive was launched on 9 March 2020.
No quantity is specified; the sample is taken and must be processed according to the CDC guidelines.
In Russia, the COVID-19 test was developed by the State Research Center for Virology and Biotechnology VECTOR.
On 11 February 2020, the lab was incorporated into the Federal Health Care Oversight Service. On 12 March 2020, Mayo Clinic said they had developed a lab to detect COVID-19 infection. On 13 March 2020, Roche Diagnostic approved a lab that can perform multiple tests in 3.5 hours, so one machine can perform an average of 4,128 tests in 24 hours.
On March 19, 2020, the FDA issued an emergency approval (EUA) to Abbott Laboratories to test Abbott's m2000 system; the FDA had previously granted similar approval to Halogic, LabCorp, and Thermo Fisher Scientific.
On 21 March 2020, Cepheid also received approval from the US FDA to perform a 45-minute lab test.
The FDA has approved the isothermal nucleic acid test, a technique that amplifies the DNA instead of PCR.
Since this requires no more than a large temperature change, this method can predict the outcome of a person from a few minutes to 13 minutes.
There are currently about 18,000 of these machines in the US and Abbott is expected to produce up to 50,000 samples per day.The samples will use only antibodies that are specific to the novel coronavirus nucleocapsid protein (N-antibody) that is being developed in Taiwan, with the expectation that results will be available within 15 to 20 minutes as with most flu samples.
In March 2020, the existing data was reviewed for "thorax radiography in the low-cost laboratory in the past, where CT [microcomputer image] results may show more severe symptoms".
A typical CT scan consists of a series of longitudinal lenses with their relationships, patterns and patterns.
Sexual dysfunction, manic behavior and clashes when the disease is severe.
A study comparing PCR and CT done in Wuhan, the source of the current pandemic, showed that CT is more sensitive than PCR, although less so, with many of the imaging patterns overlapping, such as pneumonia and the course of the disease.
As of March 2020, the American College of Diabetes recommends that "CT should not be used for laboratory or primary testing for COVID-19".As of March 2020, the CDC recommends that primary testing be PCR.
Part of the immune response to infection is the formation of antibodies including IgM and IgG.
It can be used to diagnose infection in individuals from the first 7 days or when symptoms appear, to check immunity, and then to monitor the population.The test can be done either by CLT or by PoCT.
The high-throughput systems of many medical laboratories can therefore be combined, but the availability depends on the output of each system.
A single-stage CLT is usually used for blood infection, although a complex sample may be used for follow-up.
PoCT is detected by drilling a blood droplete through the skin.
Unlike the PCR method, the test does not require a collection site.On 26 March 2020, the FDA designated 29 companies to notify the agency as needed so that they could distribute the antibody samples.
As of April 7, 2020, only three laboratories have been approved by the FDA for emergency use authorization. In late March 2020, Euroimmum Health Laboratories and Epitope Laboratories approved for Europe their oral laboratory vaccines, which can be tracked against IgG and IgA antibodies against the virus in blood samples.
The lab's capacity is to produce hundreds of samples in a few hours, which is much faster than the traditional PCR method for viral RNA.
Antibodies are usually monitored for 14 days after the first infection.Earlier in April, the UK introduced a non-antibody vaccine that was sold and used for good.
The UK's NHS has announced a clinical trial to screen people at home to eliminate the risk of other patients becoming infected if they are in hospital or if ambulances are not used. Secondly, by using a portable vehicle to screen people for COVID-19, healthcare professionals will be required to screen using the sample.
Mobile transportation facilities help South Koreans get through emergency testing, which is not much higher than in other countries.In Germany, the National Association of Health Insurance Status and Doctors said on 2 March, they have the ability to perform up to 12,000 tests a day in ambulances and 10,700 were tested a week ago.
The cost is paid by the health insurance if the doctor has prescribed the test.
According to the president of the institute Robert Koch, Germany has the capacity to produce 160,000 samples per week in total.
From 19 March, the mobile lab will be offered in several major cities.
As of 26 March 2020, the total number of tests performed in Germany is unknown, as only the number of those who are found is reported.
The first lab sample collection then took place in the week of 12/2020 with a total of 483,295 samples tested including in the week of 12/2020 and 33,491 samples (6.9%) from a lab found to be SARS-CoV-2.In Israel, researchers from the Technion and Rambam Hospital developed and tested a method to test samples from 64 similar patients, then combining the samples to perform further tests if the results are available.Wuhan's 2,000 square meter lab lab known as "Huo-Yan" (Red: XX, or "Isha" in English) was opened on 5 February 2020 by BGI, which can quickly test more than 10,000 samples per day.
The construction, which was supervised by BGI Founder Wang Jian and carried out in a 5-day layout, found that more than 47% of the cost of removing the quarantine would be doubled if the samples were not compliant.
The Wuhan lab was followed immediately by the Huo-Yan lab in Shenzhen, Beijing's Taizhou, and Shanghai, and a total of 12 cities in China.
On 4 March 2020, the daily printing capacity was 50,000 samples per day.An open source, robotic design developed with Origami Assays was released that can now test up to 1122 COVID19 patient samples using only 93 samples.This balancing design can be handled with small samples without the need for robotic hands to operate.
In March, the scarcity and insufficient quantity of chemical compounds became the backbone of many laboratories in the EU and the UK and the US.
This has led some authors to monitor the sample preparation process which then heats the sample at 98 C (208 C) for 5 minutes to remove the extra RNA genomes from the laboratory. On 31 March, the FDA announced that it would make more samples of the human coronavirus than any other country, and monitor the weight of the sample to reach a larger population.
This was the combination of the vehicle's capacity for loading, the purchase of the small Group 42 and BGI laboratories (which are in their Huo-Yan emergency monitoring laboratory in China).
Built in 14 days, the laboratory has the capacity to process ten thousand RT-PCR tests per day and is the first of its kind in the world to operate outside of Jaipur.
The combination of different laboratories to target different skin components for the coronavirus has been done in China, France, Germany, Hong Kong, Japan and the United States.
The World Health Organization has taken German-made compounds to send to low-income countries that do not have the resources to own and consume them.
The German content was released on 17 January 2020; the system developed by the US Centers for Disease Control and Prevention did not appear until 28 January, which delayed the availability of the samples in the US. Japan and the United States had problems with the lab-based content before the pandemic, and these countries and Austria lacked sufficient samples for the applications and the samples recommended by health experts.
In fact, experts said that South Korea's wide access to testing has helped reduce the spread of the novel coronavirus.
The power of the laboratories, mostly private laboratories, has been built up over the years by the South Korean government.
On 16 March, the World Health Organization called for a unified testing program as the best way to reduce the spread of COVID-19. The high demand for testing due to the high prevalence of the disease has resulted in hundreds of thousands of tests being confined to private labs in the US, and there is a shortage of sample materials and chemicals.
In March 2020, Jayna stated that she has a problem with the reliability of her lab's data.
In the United States, the CDC's test kits were "defective"; the government later removed the blockade on private labs. Ispawn purchased test kits from the Chinese company Shenzhen Bioesy Biotechnology Co. Ltd. whose results were found to be false.
The company explained that the incorrect result was due to incorrectly taken samples or incorrect use of the lab.
The minister of health said that they would withdraw the claim for the erroneous results and replace the various laboratory kits they made at Shenzhen Bioeasy. 80% of the laboratory kits that the Republic of China bought from Jayna had false results. Islofahiya bought 1.2 million laboratory kits from Jayna that had given false results.
Prime Minister Matovic said that these were poured into the Danube.Kara the Turkish Health Minister said that the lab kits they bought from Jayne were "highly faulty" and therefore "not used".The British bought 3.5 million lab kits from Jayne but had earlier in April 2020 announced that they could not be used.
The laboratory, followed by quarantine of the human and those traces of the SARS-CoV-2 infected were found close to each other, leading to the subsequent detection.
Researchers working in the Italian city of Vaud, where the first COVID-19 death in Italy was detected, conducted a second round of community-wide testing of approximately 3,400 people, over a period of ten days.
Half of the people found were asymptomatic, and all of the people found were quarantined.
By removing the constrictor, this eliminates the pain entirely.
With the lifting of travel restrictions, testing and quarantine, the 2020 coronavirus outbreak in Singapore saw a much slower spread than in other developed countries, but without the drastic tightening of restaurant and store closures.
Many events were cancelled, and Singapore first told people to stay at home on 28 March, but schools reopened after the holiday on 23 March.
Several other countries are restricting travel with strict entry points, travel restrictions at the point of origin, testing and quarantine, but the stay-at-home order is not as strict as in Iceland and South Korea.
The statistics suggest that these countries developed a high incidence of HIV, so the number of adults who died was lower, which may have been due to their ability to detect when there were few or no symptoms.
WHO recommends that countries without national testing capacity and therefore limited experience with COVID-19 send the first 10 samples of COVID-19 positive samples to one of the 16 WHO laboratories to confirm the tests.
Of the 16 sites, 7 are in Asia, 5 are in Europe, 2 are in Africa, 1 is in North America and 1 is in Australia.
In the following table, the section "Results in % of laboratories" is defined by the national laboratory code.
In the country alone, the number of people hospitalized is higher than the percentage of people who have been tested by laboratories in the country, whether they have symptoms or not, rather than whether they are infected.
Handwashing (or handwashing), also known as hand hygiene, is the practice of cleaning one's hands to remove dirt, oil, insects, and other debris.
Handwashing (or handwash), also known as hand sanitization, is the practice of cleaning one's hands to remove dust, dirt, insects, or other unwanted substances.
Washing hands with soap regularly at these "critical times" of the day prevents the spread of many diseases, such as typhoid and cholera, which are spread through saliva.
People can also get respiratory diseases such as colds or dysentery, for example, if they do not wash their hands and then touch their eyes, nose or mouth (e.g. with their own excrement).
Five times a day when hand washing with soap is important: before and after cleaning, after changing the baby's diaper, before feeding, before eating and before preparing food or handling raw meat, fish or poultry.
If you do not have soap and water, you can clean your hands with ash. The World Health Organization recommends hand washing:
Before, during, and after preparing food
Before and after caring for a sick person.
After changing bed sheets or washing the baby with a washcloth.
After blowing your nose, coughing or sneezing.
After touching an animal, feeding an animal, or using animal waste.
Medical hand hygiene refers to hygienic practices related to health care systems.
Handwashing before medical treatment prevents or slows down the spread of infection.
The main health purpose of hand washing is to remove infections (bacteria, viruses, or other pests that can cause illness) and chemicals that can cause harm or disease.
This is especially important for those working in the food or health sector, but also for the general public.
Hand washing has many health benefits, including reducing the spread of influenza, coronavirus, and other illnesses; reversing infections caused by diarrhea; respiratory infections; and preventing heart attacks.
It reduces the mortality rate of babies born at home.
A study conducted in 2013 shows that improvements in handwashing procedures can lead to improvements in the development of children under five years old.
In developing countries, the infant mortality rate associated with respiratory problems and diarrheal diseases can be reduced by changing habits, such as hand washing with soap.
This simple step can reduce the mortality rate from these diseases by up to 50%.
Campaigns that promote handwashing can reduce the need for hand washing by up to a third, which is equivalent to providing clean water to people in low-income areas.
The 48% reduction in diarrhoea is associated with hand washing with soap. Hand washing with soap may be the most effective and inexpensive alternative to diarrhoea and acute respiratory infection (ARIs), which can be done directly at home, in schools, and in the community.
Pneumonia, a major A.R.I., is the leading cause of death in children under five, which kills approximately 1.8 million children a year.
Diarrhea and pneumonia combined cause about 3.5 million child deaths per year.
According to UNICEF, hand washing with soap before eating and after taking a mouthful can save more lives than any vaccine or treatment, and can reduce the risk of diarrhea by half and deaths from respiratory diseases by half every three months.
Handwashing is usually combined with other hygiene awareness programs, such as the Water, Sanitation and Hygiene (WASH) program.
Handwashing also protects against skin infections that can be passed through contact.
A small negative effect of frequent hand washing is that frequent hand washing can cause the skin to dry out.
A 2012 study in Denmark found that too much hand washing can cause itching, skin irritation such as eczema or itching and acne, which is commonly known to healthcare workers.
Frequent hand washing is a symptom of what is known as obsessive-compulsive disorder (OCD).
There are five times a day when hand washing with soap is important to reduce pain in the mouth: after using the toilet (after urination, after feeding), after washing the baby's bottom (instead of a diaper), before feeding the baby, before eating and before/after preparing food or handling meat, fish or poultry.
Other instances where proper hand washing should be used are when preventing the spread of infection, including before and after treating a wound or injury; after coughing, coughing, or sneezing; after touching animal feces or working with animals; and after touching litter.
In many countries, there are few people with soap on their hands.
A study shows that in 54 countries in 2015 it was found that on average, 38.7% of households practice handwashing with soap. A study conducted in 2014 showed that Saudi Arabia has the highest share at 97 percent; the United States near the middle with 77 percent; and China with the lowest rate at 23 percent. Several innovative and adaptive methods now exist to increase the adoption of handwashing practices during sensitive times. Group handwashing of children in schools at certain times of the day is an option for countries to contribute to the development of handwashing practices.
The "Cloud Health Care Program" implemented by the Department of Education in the Philippines is an example of an action plan to improve children's health and education.
Providing twice a year, in addition to the pleasure of soap, tooth brushing and flossing, is the origin of a national program.
It is also well-established in Indonesia.
The skin is cleaned with soap or water.
The main step of the method is to reduce the barriers to solutions, and increase their availability.
Water alone is not enough to cleanse the skin, as the fats and proteins, which are part of the natural solvent, are not water soluble.
Cleaning is, however, aided by a reasonable water flow.
Solid soap, as it is reusable, can contain bacteria left over from previous use.
A few studies on the transmission of bacteria from contaminated soap have shown that bacteria have difficulty passing through water.
The CDC recommends "that a liquid soap that is not hand-washed and then flushed out of the container is preferable".
The use of soap for the treatment of diseases is heavily advertised so that healthcare professionals are aware of it.
To date, there is no evidence that the use of pesticides or recommended disinfectants for selected insecticides is biologically safe.
However, antibacterial soaps contain a commonly used bactericide such as triclosan, which in turn contains a pesticide that kills the insects.
So, even if antibiotic-resistant strains are not selected for antibacterial soaps, they may not be as effective as marketed.
In addition to being applied on the surface and skin, advanced formulations may include acids (acetic acid, ascorbic acid, lactic acid) as pH-regulating agents, active benzoic acid and additional skin conditioners (aloe vera, vitamins, menthol, herbal extracts). A comparative evaluation by the University of Oregon Department of Public Health shows that pure soap is effective as a consumer soap for the pre-trichosis bacterial disruption and removal of bacteria from hands.
The hot water that you can hold in your hand is not the hot water that kills bacteria.
The concentration of bacteria increases when the body temperature is 37°C.
However, boiled soapy water is more effective than regular soapy water in terms of natural oil baths that capture dirt and bacteria.
Contrary to popular belief, a study by scientists shows that using warm water has no effect on reducing handworms.
A hand sanitizer or hand disinfectant is a hand sanitizer that does not use water.
In the late 1990s and early 21st century, alcohol-free hand sanitizers (also known as alcohol hand washers, hand sanitizers, or hand sanitizers) became popular.
Most are made from isopropyl alcohol or ethanol, which is then mixed with the soluble carbomer (the polymer of acrylic acid) and then made into a gel, or a humectant such as glycerin in a solution, or foam so that it can be easily used to reduce the toxic effects of alcohol.
The addition of a dilute hydrogen-peroxide deodorant increases the disinfectant's effectiveness. A hand sanitizer with at least 60 to 95% alcohol content is sufficient to disinfect.
Hand sanitizer is effective at killing bacteria, resistant bacteria (MRSA and VRE), tuberculosis, and some viruses (including HIV, herpes, RVS, rhinovirus, vaccinai, influenza, and gonorrhea) and viruses.
Alcohol hand sanitizer containing 70% alcohol kills 99.97% (3.5 percent reduction, also 35 percent reduction in number) of bacteria on the hand after 30 seconds of application and 99.99% to 99.999% (4 to 5 percent reduction) of bacteria on the hand after 1 minute of application.Hand sanitizer is more effective against bacteria and less effective against viruses.
Alcoholic hand sanitizers are usually immune to norovirus (or Norwalk) viruses, which are the most common causes of gestroentertis. Hands should be sterilized with a hand sanitizer or good alcohol while wet or with good exposure to both hands.
The front and back of both hands and between and the ends of all the fingers are rubbed together for an average of 30 seconds until the liquid, blister or gel dries.
The US Centers for Disease Control and Prevention recommends washing hands above the surface by using hand sanitizer, especially when the hands are very wet.
The widespread use of these products is due to their ease of use and their effective killing of pests; however, they should not be a substitute for traditional hand sanitizer except with soap and water.
Regular use of alcohol-based hand sanitizers can cause dry skin with dry skin and/or acne emollients.
The dry effect of alcohol can be reduced or eliminated by removing glycerin and/or adding other emollients to the drink.
In clinical trials, hand sanitizers containing alcohol emollients cause less skin irritation and dryness than soaps or detergents.
Allergic reactions to touch, urticaria or alcohol-induced nausea or alcohol-induced hand-shake are uncommon.
The lower level of reduction of contact dematitis is then achieved with soap and water.
However effective, non-water-based hand washes do not naturally kill germs.
That's why hand sanitizers are not as effective as soap and water in preventing the spread of insects, as the insects will remain on the hands.
Non-alcoholic hand sanitizers are highly versatile in their ingredients and formula, and have always been more effective when used with alcohol-based hand sanitizers.
Recently, the emergence of benzalkonium chloride has been observed in the maintenance and organization of insecticide activity after application, unlike alcohol, which has been observed to be less active when used regularly, as it is more likely to be skin irritating.
Many people in low-income communities cannot afford to buy coffee and instead use it for lunch or dinner.
Soap and sand are both water-soluble, but less effective than soap.
One concern is that the mosquitoes may be associated with the plague, which in turn increases the spread of the disease instead of reducing it.
Like soap, detergent is also a cleanser because when it interacts with water, it forms an alkaline mixture.
WHO recommends that the soap should be replaced by a washing machine when soap is not available.
Proper handwashing techniques recommended by the US Centers for Disease Control and Prevention for the prevention of contagious disease include the following steps:
Wash your hands with warm or running water.
Running water is recommended, as standing water can be polluted and the temperature of the water does not make a difference.
Scrub the skin of your hands thoroughly with soap, including the back of your hands, the tips of your fingers, and under your nails.
Soap removes germs from the skin, and studies show that people wash their hands better after using soap than after using only water.
You rub your hands together for at least 20 seconds.
The scratching creates a rash, which then helps to pass germs through the skin, and then further scratching removes a whole bunch of germs from the skin.
The water flow is reduced.
Adding those who are standing can also help to relieve the hands.
Drying in the towel or in the air.
Wet or slightly damp hands can easily become contaminated. The most commonly contaminated areas are the thumbs, wrists, the area between the fingers, and under the nails.
Insects can hide under the painted nail and the painted nail.
Hand washing is often recommended to prevent dry hands; dry skin can lead to skin damage and thus increase the risk of infection.
Various inexpensive things can be done to facilitate washing hands when tap water and/or sanitation are not available, such as, pouring water from a drain or a well and/or using a faucet if you are in a developing country. In situations of water scarcity (such as in schools or rural areas in developing countries), there are ways to store water, such as "small-scale disposable disposable" and other inexpensive options.
A small plastic hand sanitizer is a simple technology that uses plastic that has been wrapped in a wrapper, then twisted so that a small amount of water can be used to wash hands with soap and water.
Proper hand drying is an important part of the sanitization process, but the effectiveness of hand drying in public spaces is controversial.
Many studies show that towels are much more hygienic than the hand dryers with flashlights in many toilets.
In 2008, a study was conducted by the University of Westminster, London, sponsored by the paper towel industry European Tissue Symposium, to compare the hygiene standards provided by paper towels, air-dryers and modern air-dryers.
After washing hands and drying them in the warm air, the number of bacteria found on fingers increased by 194% and on palms by 254%.
Airborne drying increased the total bacterial count by 42% and the total bacterial count by 15%.
After washing and drying with hand dryer, bacteria decreased from fingers by 76% and from handprints by 77%.Scientists also developed tests to detect possible cross-infection from other areas of the hand wash and wash environment that could result from the drying process.
The air dryer, which then expels air at a speed of 180 m/s (650 km/h; 400mph), was able to spray the insect on the hands and contaminated the area and the people using the area and the bathing area up to 2 meters away.
Using a warm air dryer spreads insects within 0.25 meters of the dryer.
No major spread of the pest was observed in the toilets.In 2005, a study by TUV Produkt and Umwelt, which evaluated different methods of hand drying.
The following changes in the number of bacteria after drying hands were observed:
There are many different companies that manufacture hand dryers, and the drying equipment has been compared to paper drying.
Hand washing with a hand sanitizer is another option for walking when soap and water are not available.
alcohol-based hand sanitizers with a alcohol content of 60%.
The medical pill became mandatory after the Hungarian physician Ignaz Semmelweis discovered its usefulness (1846) in preventing illness in the hospital environment.
There is an electronic device that reminds hospital staff to wash their hands when they forget.
One study found a decrease in infection rates with their use.
Hand hygiene is a wash of hands for at least 15 seconds, using a large amount of soap and water or a gel to wipe and scrape each part of the hands.
The hands should be shaken with a clenched fist.
If there is debris under the nails, a brush can be used to remove it.
Since disinfectants remain in the water, it is important to irradiate it well and then dry it in a clean towel.
After drying, the water can be used to shut off the water (and to open the exit door if necessary).
It is very safe to keep your hands off the handle.
The reason for hand washing in the health care system is to remove the presence of germs and prevent transmission.
The New England Journal of Medicine reports that sterilization is not allowed in most healthcare settings, where many doctors and healthcare assistants forget to wash their hands regularly before touching patients, thus transmitting the germs.
A study shows that hand washing and other simple procedures reduce the rate of blood infection in the urine by 66 percent. The World Health Organization has published a document that lists the level of hand washing and hand-shaking in the health care sector.
The guidelines for hand hygiene are available for public comment on the website.
The most prominent critic was Whitby et al.
Devices sold can be tested for hand hygiene, if necessary to demonstrate compliance with the requirements.
The World Health Organization has defined "Five times" to wash hands:
after contact with blood or body fluids
before you perform any dirty work, and
after serving the patient. Also chemical disinfectant soaps ("medicated soap" or "sanitizer") act to kill insects when washing hands.
Such a disinfection may be required before an operation or where the infection is likely to be killed. The hand should be rubbed with a 'drying' pad, if necessary a tube can be opened and closed without contact, some chlorinated or iodine is washed, a clean towel is used to dry the hands after washing, and a clean towel brush and other cleaning materials are used to clean under the fingers.
All makeup should be removed.
This procedure requires washing hands and wrists from the forearm to the wrist, usually for 2-6 minutes.
Long periods of time (10 minutes) are not required.
When carrying water, water that has been spilled into the hands must be prevented from falling back into the hands.
After finishing hand washing, the hands should be cleaned with a hand sanitizer and the surgical cloth should be worn.
To reduce the spread of infection, it is advisable to wash hands or use a hand sanitizer before and after serving a sick person.
For the control of staphylococcal infections in hospitals, the greatest benefit of hand washing was found to be from early washing of up to 20%, and to a lesser extent when frequent washing exceeds 35%.
Regular hand washing with soap is three times more likely to spread foodborne bacterial infections than washing with disinfectant. Compared with hand-washing with alcohol and hand-washing with antibacterial soap for a period of about 30 seconds each, hand-washing with alcohol has a 26% lower rate of bacterial infection than with disinfectant soap.
However, soap and water are more effective than alcohol-based hand sanitizers in reducing the spread of H1N1 influenza A virus and Clostridium infection in the hands. Hand hygiene interventions in healthcare settings can include teaching employees about hand washing, increasing access to hand sanitizer, and writing and speaking reminders to employees.
Further research is needed to determine which of these is best suited for different health care settings.
In developing countries, handwashing with soap is known as the cheapest, and most necessary, way to achieve good health, and even good nutrition.
However, with the lack of water, soap and other facilities in people's homes, schools and workplaces, it is difficult to emulate the universal happiness culture.
For example, in many rural areas of Africa, there are few private toilets or public toilets nearby, even though it is the cheapest option to build a spa.
But, the paradox is an inherited behavior from the lack of soap and water.
Promoting and campaigning for happiness through the use of soap can influence policy decisions, create awareness of the benefits of happiness and lead to long-term behavioral change in the public.
To achieve this effectively, monitoring and evaluation are required.
An evaluation of 70 studies found that community-based approaches are effective in increasing happiness in LMICs, while social engagement campaigns are less effective.One example of school-based happiness awareness is UNICEF's "Three-Straw Model" which encourages schools to take simple, inexpensive steps to ensure students are happy with soap, as well as other hygiene requirements.
When the minimum level is reached, the school removes the top three stars.
Creating a happy environment can be part of the campaign to reduce child morbidity and mortality.
The International Day of Happiness is another example of awareness raising to change behaviour. Due to the 2019-20 coronavirus pandemic, UNICEF is running a campaign to embrace happiness.
Several studies have looked at the patterns of happiness in developing countries associated with the DALYs epidemic.
However, one of the recommended incentives for handwashing with soap is more valuable as an effective alternative to other water and sanitation activities.
The importance of charity to human health - especially for people in vulnerable situations such as a mother who is giving birth or wounded soldiers in hospitals - was first recognized in the mid-19th century by two leaders in hand hygiene: the Hungarian physician Ignaz Semmelweis who practiced in Vienna, Austria and Florence Nightingale, who is known in English as "the founder of modern medicine".
At the time, most people believed that the infection was caused by a smell called miasmas.
In the 1980s, food-borne infection and related health care led the US Centers for Disease Control and Prevention to actively begin promoting hand hygiene as an important method of preventing the spread of infection.
The 2009 swine flu pandemic and the 2020 COVID-19 pandemic increased awareness in many countries of the importance of drinking water to prevent disease.
For example, leaflets about "the right techniques for happiness" have been posted near happiness in public toilets and in the halls of office buildings and airports in Germany.
The term "sharing" comes from the notion that someone is not responsible for promoting or sharing something.
It comes from the biblical passage in Matthew in which Pontius Pilate washed his hands of the sentence of death of Jesus Christ, but it has become a broader term that is widely used in some English communities.
In Shakespeare's Macbeth, Lady Macbeth begins to forcibly wash her hands in an attempt to cleanse herself of the imaginary dirt, symbolizing her guilty conscience about the crimes she committed and led her husband to commit.
It has also been found that people, after remembering or performing a conscious act, wash their hands more often than before, and try to value the pleasure item more than before.
Furthermore, those who are allowed to wash their hands after being so regarded are also less likely to engage in other "clean" acts, such as voluntarism.
Religions define fasting and hygiene in an exemplary manner.The symbols of fasting, by using unsaponified water to fast, include fasting in many religions, including the Baha'i Faith, the Hinduism, the Tevilah and the Netilah Yadayim in Judaism, the Lavabo in Christianity, and the Wudhu in Islam.
Hinduism, Judaism, and Islam require that we celebrate the departure of the soul.
And, for Hindus, Buddhism, Sikhism, Judaism and Islam, they require happiness before food.
Workplace risk management for COVID-19 is the application of workplace safety and health protocols to control harm to prevent coronavirus disease 2019 (COVID-19).
The exact method for controlling workplace risk depends on the workplace and the job, on the risk assessment based on where the person is exposed, the extent of the infection in the community, and the risk situations of individual employees who are susceptible to contracting COVID-19.
According to the US Occupational Safety and Health Administration (OSHA), reducing the risk of infection from people at work reduces the transmission from the public to the workplace, requiring basic prevention measures, including hand washing, encouraging employees to stay home if they are sick, have a respiratory illness, and to regularly maintain hygiene and disinfect at work.
The minimum risk category includes those who are required to be in close contact with unknown or suspected COVID-19 but may have contracted the infection from the community while traveling abroad.
These include workers who have access to the general public, such as schools, crowded workplaces, and public shops.
Risk prevention for this group, as well as basic infection prevention measures, including respirators that use highly effective air purifiers, protection against the infection of others, and access to personal protective equipment available if a person has come into contact with a person with COVID-19.
OSHA considers health care and senior staff exposed to unknown or suspected COVID-19 individuals to be at high risk, which increases the risk if the employee has a general screening, or collecting or processing samples, of a known or suspected COVID-19 patient.
The control of harm to the workers, including the control of the negative pressure air-conditioning system, and personal protective equipment for the workplace.
The spread of COVID-19 can have negative effects on the workplace.
An employee may be absent from work because of illness, because he or she may need to take care of another person, or because of fear of being ill.
The business model can change, which goods are needed, and how these goods are obtained (e.g. buying the wrong timepiece or buying a house or car).
Finally, products from areas that are highly susceptible to COVID-19 can be compromised.The infectious disease preparedness and response plan can be used to guide you through the necessary precautions.
Plans for responding to risks related to different workplaces and occupations, including evacuation, hazardous situations at home and in the community, and personal workplace hazardous situations such as old age or chronic health problems.
It also describes how clouds respond to emergencies, and plans for escape in the event of an emergency.
Preparedness and response plans for infectious diseases may require or modify recommendations.
Effective responses to the outbreak include reducing transmission among employees, protecting those at greatest risk of adverse health effects, maintaining business operations, and reducing negative feedback from other suppliers.
The severity of the social problem in which the business is located affects the response.
According to the hierarchy of risk management, a system of work is a broad application of occupational safety and health to the effective risk management of a group.
Where the harmfulness of COVID-19 cannot be limited, the most effective way to control it is to establish containment, followed by administrative containment, and finally personal protective equipment.
The control of the risk of harm to the employee without relying on the employee's behaviour is the most cost-effective solution.
Administrative control is a change in the system or regulation that requires the employee to take action.
Personal protective equipment (PPE) is considered less effective than the development and implementation of containment, but can prevent certain infections.
Each type of PPE must be selected for worker hazards, properly accessible and suitable (e.g., respirator), be worn regularly and occasionally, inspected regularly, repaired, replaced, and properly disposed of, cleaned, stored or disposed of to prevent the risk of infection.
According to the U.S. Occupational Safety and Health Administration (OSHA), low-risk jobs are those in which there is little or no contact with co-workers.
Basic prevention measures recommended for all workplaces include regular and thorough hand washing, encouraging employees to stay home if they are sick, have respiratory infections including mouth and nose infections if they cough and sneeze, providing sanitary towels and trash can, arranging for them to work in another workplace or to adjust the arrival times if necessary, calling on employees to use tools and equipment together, and regularly cleaning and disinfecting the workplace.
Removing the person from the workplace immediately may cause infection, which is an important step to protect employees, customers, visitors, and others in the workplace.
The U.S. Centers for Disease Control and Prevention (CDC) recommends that employees with symptoms of severe respiratory illness stay home until the fever, symptoms, and other symptoms have disappeared for at least 24 hours without using pain-relieving or analgesic medications, and that they have flexible sick leave policies, which allow employees to stay home and care for a sick family member, and that employees are aware of these policies.
According to OSHA, low-risk jobs include those where people are in frequent contact with each other or with customers less than six feet (1.8 m) away from people who are unknown or suspected COVID-19 patients, but may have SARS-CoV-2 as it is a communicable disease in the business area, as well as travel to another area where COVID-19 is suspected.
These include workers in public areas such as schools, high-risk workplaces, and crowded areas in shopping malls. Implementing controls for high-risk groups includes providing high-quality air purifiers, increasing ventilation, introducing products such as anti-fouling pads, and providing a safety watch for employees. The management of these practices and the enforcement of the safety measures include requiring workers who are ill or at risk to stay at home, replacing the mask with a mask and protective clothing, maintaining a workplace safety plan, providing COVID-19-related safety measures, employing a workplace safety plan, providing health and hygiene, and providing employees with proper clothing, hand-wear, and protective clothing.
Workers in this high-risk group do not often use ventilation.
If a person becomes ill on an aircraft, the appropriate controls for staff and other passengers to be accommodated include removing the person from the other passengers and then moving them to a distance of 6 feet, assigning one person to the seriously ill person, and placing a mask on the person who is ill or requiring the person to cover his or her nose and mouth and remove a mask when coughing or sneezing.
Airline personnel shall wear a medical mask only when servicing a sick passenger or handling waste or areas where infection may occur, and additional personal protective equipment if a sick passenger has a fever, persistent cough, or respiratory distress.
For commercial shipping, including cruise ships and other passenger ships, precautions include delaying the voyage, isolating the person, and providing immediate medical care if the person has an injury or other illness while on board.
In schools and child care centers, the CDC recommends that a person who is infected come to school with a temporary lockdown for cleaning or disinfection, regardless of whether they have spread the infection to the community.
In the case of a moderate or severe community outbreak, social distancing measures are implemented such as stopping educational travel, gatherings, and other large gatherings such as studying or art classes or dining out, increasing the distance between tables, adjusting arrival and departure times, limiting unnecessary visits, and using a separate medical office in another location for children with symptoms such as flu.
When there is a widespread infection in the local community, in addition to social distancing measures, school closures may be considered.For police forces on day duty, the CDC considers their health risks to be low.
Police officers who come in contact with people with confirmed or suspected COVID-19 are advised to follow the same guidelines as emergency medical technicians, including personal protective equipment.
If contact occurs when touching the person, the worker must clean and disinfect the work belt and equipment before reusing it using household cleaning spray or towel, and follow the standard workplace procedure for waste disposal and disposal of used PPE in the washing of dirty clothes.
OSHA considers that some occupational health care and deaths are too high or have a high risk of infection.
Jobs with a high risk of being terminated include the provision of health care, support, laboratory, and medical transportation personnel who have tested positive for or are suspected of having COVID-19.
This can be especially dangerous if the employee is working on the job, or is involved in the collection or testing of samples, of suspected or known COVID-19 patients.
The general procedures include, for example, a cough, bronchoscopy, some dental treatment and laboratory tests, or a hard sample.
High-risk, lethal jobs include workers preparing for the funeral of known or suspected COVID-19 patients at the time of death; these are at high risk if they are performing surgery on the corpse. Additional technical controls for the risk group include the locker room for known or suspected COVID-19 patients, as well as general work performed at the time.
Special negative pressure can be set up in health care systems and in funeral homes.
The sample must be reported to the Biosafety Level 3 inspector.
The World Health Organization (WHO) recommends that patients undergoing quarantine be placed in a special quarantine depending on whether COVID-19 is suspected. Similarly to PPE, OSHA recommends that respiratory personnel be kept within 6 miles of patients known to, or suspected to, have SARS-CoV-2, and for general medical care.
In the United States, the NIOSH-approved N95 respirator is used for positive, documented respiration in the surveillance program including attachment testing, decimation, and clinical laboratory testing.
Other forms of respiratory protection can provide greater protection and enhance comfort for the staff. WHO does not recommend full face coverings, as COVID-19 is a respiratory disease that does not transmit fluids.
The WHO recommends the use of surgical face masks only for personnel in the lab entrance.
For people who are collecting respiratory samples, caring for, or transporting patients with COVID-19 and for whom there is no standard treatment, WHO recommends wearing surgical masks, face coverings, or face wrap, bandages, and masks.
If a treatment is performed that may cause infection, the surgical mask may be replaced with a N95 or FFP2 mask.
Since availability of PPE is low, WHO recommends reducing the need for PPE audio and video interventions, providing a clean window, which facilitates all persons involved in direct care from entering a room where COVID-19 patients are present, to use only necessary PPE for specific functions, to continue to use the same mask without removing it while going to the clinic for patients with the same illness, to coordinate and coordinate the sale of PPE, and to encourage people to use masks for people who are ill.
On March 4, 2020, I declared a California State of Emergency due to the threat of COVID-19;
ABOUT: All Wikimedia staff members
COVID-19: A declaration of responsibility and preparation for the future
The following pages link to "DATE/HOUR of death: 14 March 2020, 00:24 UTC"
CC0: No number given
We've been in a very difficult situation this month.
The COVID-19 pandemic is a testament to the global interconnectedness and responsibility of humanity towards one another.
We can't stop the spread of this disease, but we know the most reliable way to respond is through awareness, action and building global communities that are therefore engaged in this institution.
This reflects the dedication and commitment that we have seen in all of our staff in emails, conversations and chats, which greatly confirms the incredible humanity that we are so lucky to work with.
I'm not proud of the fact that we're all working together.
Last week, someone posted a thank you for our work.
And it reminded me of how effective it is in the world that at this point you can access Wikipedia, and what a powerful sign it is that the source of all important information is online and available to everyone.
Your work only makes sense if the website is maintained or if our employees receive a salary or social security.
The world needs the information that Wikipedia provides, now more than ever.
At this moment, not only what we do, but how we do it, has a huge impact on the world.
Given the importance of this work and your contribution, we will make a significant improvement to the way we work together, starting this week.
We need to organize our work and schedules.
As Robyn had previously said, the C-team met early in the evening to discuss the format and timetable for the coming days and months.
In this conversation, we looked at what we see as the rational answer to what we face and the best way for the institution to move forward in this moment.
We want to expand our news space and support our work in the long term.
If you need to recall, that's fine.
All employees, contractors and contract workers:
She will work either 4 hours a day, or 20 hours a week until further notice.
We do not guarantee a leave of absence - if you can work at the normal hours, you can be employed.
But, in the world, there's no predictable timing, and whether you need to take care of a family member, buy food, or make a doctor's appointment, your safety is your priority.
We're not running out of time.
If you are sick, do not work.
I'm a freak, but I'm not.
It is not necessary to request sick leave or PTO - just tell your supervisor and help your team to organize their schedule so that they can make time for important tasks.
(If you are advised about COVID-19, please tell Bryan that T&C Ops can help support you and ensure that your condition is properly managed.)
The hourly wage will be paid in full.
We have said before, and we are committed to adhering to our contractual and working hours.
Everyone will be paid the normal hourly wage for normal working conditions.
This includes if you are sick and cannot work.
If you want to work, we will help you.
Many people use work as a way to reduce the noise in the world around them.
It's a fantastic reward, especially in a situation like this.
Again, this is self-care.
All we ask is that you contact your supervisor, so that we can know what to expect and then we can make adjustments.
Some jobs are considered to be compulsory.
There are things we have to continue to do.
SRE, HR Ops, Reliability & Security, and Group Fundraising (and other) are the essential tasks that require additional support.
We're going to start the process across all departments so that we can have the current objectives and then we can focus on supporting our core work.
There's so much that we can do, so we're just going to focus on the projects that are necessary.
Reducing the current does not cause any problems.
We do not plan to "go to work twice" when he is through with the pain.
You are not required to work overtime so that you can complete work that is not possible in the current working hours.
We have accepted that the situation has changed, and we will do this in a targeted and timely manner.
What happened to APP?
In order to adapt to the new regulations and the expected daily work hours, we plan to adapt the time of payment in the 2020-2021 Annual Plan.
We would like to propose an extension of the 2019-2020 plan to allow time for the budget to allow staff to prioritize essential work, personal care, and family care during the reception of people who need or want to work part-time during the first few weeks.
This extension reduces the workload of the current plan and the pressure on the entire organization.
We will be reviewing our plan for the Board next week and will update the agency and teams on the next steps as soon as we confirm them.
And thank you to the APP team for leading this.
Office, reception and cleaning services
Last week, we learned that a SF employee may have contracted COVID-19.
But, in return, we hired a team of disinfectants from the entire San Francisco office.
Use disinfectant products in the hospital for disinfection of the reception area, the reception area and the floor area.
The building has a care system so that the tenants can benefit from the security support.
I was confident that the office would be ready for us when we wanted to return.
Our DC office is located in WeWork, which has shared its COVID-19 protocol with us and all DC staff.
Last weekend, our DC office was moved to work entirely from home in accordance with the guidelines shared with San Francisco.
As some of our NYC colleagues will know, we've also been talking about renting a space in Brooklyn.
The conversation was going on, but it was delayed.
Some of our employees are working elsewhere for the first time.
Our long-time home workers know that we can fix this, so we want to give you some advice:
You can limit the time of the meeting to one or two hours at most.
If a longer platform is needed, you can arrange to delay it for a few days.
For a clearly defined meeting, you must have an agenda, and send a report that is read out in advance.
You create live videos, and use tools like Google Docs and Zoom to facilitate and share them.
You lead the facilitation of each meeting, someone will be accompanied by a conversation about any questions and then a list of speakers, who will help take notes (or combine notes).
Send an e-mail to the technical support department if you need to make a special request.
You use your good half.
Participate in the #remoties Slack discussion about work sharing
The Working Group of the Department of Human Resources is looking at webinar guidelines for increasing the work distribution support of the Foundation.
Last week we urged the community to find a way to suspend Wikimedia fundraising events, such as the editing, until the WHO declares the pandemic over.
We told him that we understood that our application had been suspended and that other restrictions could be imposed on the grant to be granted for the project and that no one deserved to be punished for delaying or altering the grant.
In the coming weeks we will follow more guidelines for Wikimenia and other friendly communities and community gatherings.
The whole structure of the global community seems to have some sadly broken elements but we believe in the power of transparency and community-focused, Wikimedia and others.
In addition, CRT is working to develop a Meta-Wiki page to provide a community platform for tracking impact and tracking our connections.
Follow up on COVID-19
We will be sending out invitations for a special staff meeting next Thursday, 14:00 UTC/07:00 PT.
We will use this time to provide additional information, answer questions and spend extra time in contacting others.
We are all in this together and we will help in any way.
At this time, you will only be able to access this email address, and other essential information related to COVID-19, from the Wikibooks.
The CRT will work to put this website and all the information in one place.
We are also working to stay in touch with the local community in countries where the current situation has a significant impact.
If you have any questions about travel, events, live broadcasts of work, or online meetings, or anything else you need, please do not hesitate to contact CRT.
We are here to help you and work with you as needed.
If you have a confidential or sensitive matter, please send an e-mail to Bryan Judan - Human Resources Manager at the Finnish Labour Department.
None of these changes should be seen as a burden on our work or our obligations.
But it is the identity of this time, and the roles and responsibilities are likely to be as familiar to them as they have been to us in the past.
There are steps that we consider to be essential to support our heritage so that we can continue the work, so that our movement can provide the support that they need, and the services that they depend on.
Our planned work will be there when the time comes.
At this point, it's time to support each other and build a roadmap of the important work for the weeks and months ahead.
We need all of you to make this happen, and we want all of you to take care of yourselves and your families so that we can help when the need arises.
Imra, please -- wash your hands and don't touch your face!
The team was composed of three members: Katherine, CRT (Amanda K, Amy V, Bryan J, Doreen D, Gregory V, Jaime V, Joel L, Lynette L, Ryan M, and Tony S), and the rest of the Leadership Team (Grant I, Heather W, Jaime V, Janeen U, Lisa S, Robyn A, Ryan M, and Toby N).
SARS-CoV-2 virus caused by COVID-19 (coronavirus disease 2019), which is an infectious respiratory disease that was first detected in December 2019, in Wigan, Hubei, China.
ACE2 counteracts the activity associated with angiotensin-converting enzyme (ACE) by reducing the concentration of angiotensin-II and increasing Ang (1-7), making it an effective target for targeting heart disease. ACE2 also acts as a port of entry for some coronavirus cells.
The non-human copy of the enzyme is often referred to as hACE2.
Angiostensin-converting enzyme 2 is a zinc-containing metalloenzyme found on the endothelial surface and in other tissues.
The ACE2 protein contains an N-terminal peptide M2 domain and a C-terminal amino rental receptor domain.
ACE2 is the only type I receptor protein, which has an enzymatically active site that reaches the cell surface of the lung and other tissues.
The ACE2 extracellular region is encoded in the cell region that receives an enzyme called sheddase, which produces a protein that is secreted into the bloodstream and destroys the urine.
ACE2 is present in most cells: ACE2 attacks the normal cell membrane of the pulmonary alveolar type II cells, enterocytes of the small intestine, various vascular and endothelial cells and the mostly vascular muscle cells.
The term ACE2mRNA is also found in cerebral cortex, striatum, hypothalamus, and brain cells.
The first function of ACE2 is to be an ACE regulator.
ACE cleaves the angiotensin I muscle membrane into the angiotensin II.
ACE2 is produced by the carboxyl-terminal amino acid phenylalanine angiotensin II (Asp-Arg-Val-Tyr-lle-His-Pro-Phe) and hydrolysed by the vasodalitor angiotensin (1-7), (H-Asp-Arg-Val-Tyr-lle-His-Pro-OH).
ACE2 also binds to a number of other peptides including [des-arg9] - bradykinin, apelin, neurotensin, dynorphin A and ghrelin.
ACE2 also regulates the flow of neutral amino acid chains from SLC6A19 which is then reported in Hartnup syndrome.
The capture transporter protein, ACE2, is the main cell entry point for some coronaviruses, including HCoV-NL63; SARS-CoV (the virus that causes SARS); and SARS-CoV-2 (the virus that causes COVID-19).
Specifically, the combination of upregulation of S1 proteins of SARS-CoV and SARS-CoV2 in the enzymatic region ACE2 on the cell surface from endocytosis and transmission by viral and enzyme endosomes within the cell.
This entire process requires the inhibition of the S-protease of the serine-like protein TMPRSS2, which is currently being investigated as a naturally occurring protein, which could lead to the hypothesis that it lowers intracellular ACE2 levels, which could help fight the disease.
However, many professional societies and regulatory organizations have recommended the continued standard of care for ACE and ARB therapy.
A series of assessments and metallic evaluations published on July 11, 2012, found that "use of ACE respirator was associated with a significant 34% reduction in risk of pneumonia compared to controls".
Also, "the risk of pneumonia may also be reduced in patients treated with ACE inhibitors who are at higher risk of causing pain, especially in people with epilepsy and heart disease.
Use of ACE inhibitors associated with fatal lung disease reduces the risk, although the effect of the drug is much less than the overall risk of lung disease".
The human ACE2 (rhACE2) complex is a novel treatment for acute lung injury, and a precursor to hemodynamics and dense oxygenation in pigs with symptoms of acute respiratory failure with lipopolysaccharide.
The half-life of the rhACE2 drug is about 10 hours and is based on an additional 30 minutes of action in the 24-hour effective period.
Several studies suggest that rhACE2 is an effective drug for people who are unable to take renin-angiotensin-type respiratory therapy (RAS therapy) or have increased angiotensin II cycle pain. rhACE2 injection was evaluated in a clinical trial for the treatment of severe respiratory illness.
The SARS-like coronavirus WIV1 (Bat SL_CoV-WIV1), also known as SARS-like coronavirus WIV1, is a severe respiratory coronavirus (SARSr-CoV) that was originated from a yellow-bellied parrot (Rhinolophus sinicus).
Various governments have issued or recommended it, and government officials have supported it locally and in some areas.
Several systems have been developed to monitor the app.
Privacy concerns have been raised, particularly with systems based on tracking the location of the app's user.
The smaller version is a Bluetooth-based device that can be used with a different phone.
On April 10, 2020, Google and Apple jointly announced that they will be implementing a way to power the Bluetooth app directly on their Android and iOS operating systems.
Jayna, the government of Jayna, in conjunction with Alipay, developed an app that allows citizens to check if someone has been exposed to COVID-19.
It's used in over 200 cities in China.In Singapore, an app called TraceTogether is used.
The app was developed by the local IT community, released as open source and is being handed over to the government.North Macedonia developed "StopKorona!", a Bluetooth-powered app that monitors the self-discovery of people with the disease and thus provides immediate response for healthcare management.
The app was developed by the Ministry of Communications and Technology and the Ministry of Health.
On April 14, 2020, the app is awaiting approval by the Google Play Store and the Apple App Store.
On 12 April, the government said that a proximity tracking app is in good shape, which will be released later this week.A similar app ("StopCovid") is being planned in Ayr, France.
Both Australia and New Zealand are considering implementing Singapore's TraceTogether app and BlueTrace system.Russia is rolling out a COVID-19 tracking app for Moscow residents, designed to ensure that they do not leave the house.
Ross Anderson, a professor of biomedical engineering at the University of Cambridge, has put together a list of potential problems with the app-based system, including false claims about who is in charge and that the software will be poor if the app is limited to a small number of users.
In response to concerns about the spread of fake or harmful apps for the coronavirus, Apple introduced a restriction on which brands can add coronavirus-related apps to the App Store, which is restricted to "officers" or large organizations.
Google and Amazon have also implemented similar restrictions.
Activists have expressed concern about the potential disruption of mass tracking using coronavirus apps, especially if they are designed to track the building population to combat the coronavirus pandemic and are distributed once the threat is over.
Amnesty International and more than 100 other organizations issued a statement calling for the limitation of such surveillance.
The agency has developed eight criteria for public projects:
surveillance is "legal, illegal and corrupt";
The elimination of monitoring and surveillance was the glowing phrase;
the use of the information is limited to COVID-19 purposes only;
data security and confidentiality could be safeguarded to show that the safeguarding is evidence-based;
digital surveillance can prevent discrimination and harassment;
Sharing of information with others must be regulated by law.
there must be protection against persecution and the right of citizens to respond to persecution;
The effective involvement of all "interested parties" is required, including public health experts and informed groups.The German Chaos Computer Club (CCC) and Reporters Without Borders (RSF) have also produced a watch list.
The Google/Apple-recommended plan is designed to address the problem of constant monitoring by removing the tracking of devices from the system when not needed.
Some countries use local networks to monitor apps, eliminating the need for app downloads and the ability to track.
In Israel, the Internet surveillance system was approved.
Network solutions from common sources have a future encryption problem.
However, not all systems with a central server require information about a person's location; many encrypted systems have been developed that use a central server to link their data (see below).
In South Korea, there is a system without app that monitors proximity.
Instead of using its own app, the system collects tracking information from various sources including mobile device tracking information and card purchase information, and adds this to the text messages created for people who may be infected.
As well as using the proximity alert information, the government also makes location information available to everyone, sometimes with permission as it is difficult to change the privacy laws after the MERS outbreak hit the country.
This information is available everywhere in the app and on the website.
As of April 6, 2020, no details have been released.
The concept of secure password monitoring is broad, which has been improved by extensive data analysis since 2013. On 7 April 2020, a group of ten experts were working on solutions that could protect the privacy, such as using the Low Energy Bluetooth (BLE) to access the area of other people's phones.
However, PEPP-PT combines efforts in a single and decentralized format, not a single format. The single format includes Protected and Encrypted Area Tracking (DP-PPT/DP-3T), Transmission Network Number (TCN, f-Code Time Number, CEN), Sensitive Encryption and Mobile Communications Tracking (PACT) among others.
In these systems, the processing of personal data does not pass through the device, and all processing occurs through the device.
The MIT Media Lab intelligence team developed SafePaths, a platform for using encryption techniques in the collection and retrieval of aggregated data to monitor the spread of COVID-19.
Based on the study found in the white paper "Apps Gone Rogue: Protecting Privacy in the Cloud" published in March 2020. Another similar effort on the SafeTrace platform by Enigma MPC, a technology company that was originally developed at the MIT Media Lab.
SafeTrace leverages encryption technology that enables users to share sensitive location and health information with other users and authorities, without compromising data privacy.
On April 5, 2020, the TCN Global Partnership, founded by a group of collaborators that share the same platform and systems as the Big Data, aims to reduce the backlog, facilitate global connectivity, and monitor and alert the app, a key way to achieve widespread adoption.
On 9 April 2020, the Singapore government announced the launch of the BlueTrace system through the official government app.
On April 10, 2020, Google and Apple, the Android and iOS mobile operating system makers, announced a proximity tracking app, which is said to protect privacy, and incorporates a combination of low-power Cloud technology and overriding privacy protection.
They also shared the content of the technologies the system uses.
According to Apple and Google, the system is designed to be three-dimensional:
The toolkit that enables governments to create a coronavirus tracking app that permanently protects privacy.
Google and Apple have plans to respond to the threat by first distributing surveillance updates to the system, and then removing them when the threat is gone.
The COVID-19 vaccine is still being studied for a vaccine or treatment that eliminates the 2019-20 coronavirus (COVID-19) virus.
This is one line of scientific research that is currently being used to develop safe and effective treatments for COVID-19.
Other studies on the pathogenicity include the development of vaccines and the development of a blood cell pathogen for COVID-19. SARS-CoV-2 has about 66 protein pathogens, each of which has multiple n ligand sites.
The combined domain evaluation provides a reasonable prediction for the development of an effective protein for the COVID-19 virus.
The main target proteins of SARS-CoV-2 include the papain-like protease, RNA-dependent RNA polymersare, helicase, S protein, and ADP ribophosphatase.
Hussein A, et al. studied several compounds which were then used and evaluated in a similar way to the approved advanced drug to accelerate the composition of the anti-SARS-CoV-2 drug in pre-clinical studies for production in the clinical trial model.
Chloroquine is an anti-malarial drug that has also been used in some autoimmune diseases.
On March 18, WHO announced that chloroquine and related hydroxychloroquine will be among the four drugs that will be part of the Union's clinical trial study.
New York Governor Andrew Cuomo announced that trials of chloroquine and hydroxychloroquine in New York State will begin on March 24. On March 28, the FDA approved the use of hydroxychloroquie sulfate and chloroquine phosphate in conjunction with the Emergency Use Authorization (EUA).
The drug has not been approved by the FDA for clinical trials and has been approved under the USA only as an experimental treatment for emergency use in patients who are hospitalized but not kept for clinical trial treatment.
The CDC states that "the use, dose, or duration of hydroxychloroquine for prophylaxis or treatment of SARS-CoV-2 infection" is not yet known.
Doctors said they would use the drug when there was "no other option".
A Turkish research team conducted a small study in Istanbul using chloroquine combined with zinc, vitamin A, vitamin C and vitamin D.
Large studies are being conducted at Duke University and Oxford University.
NYU Langone School of Medicine is conducting a safety and efficacy trial of hydroxychloroquine.
Jayna's clinical trials in Wuhan and Shenzhen reportedly found favipiravir to be "clearly effective".
35 patients in Shenzhen were absent from the unit for 4 days, while the duration of the illness was 11 days for 45 patients who were not given the vaccine.
In a study of 240 patients with pulmonary disease, half were given favipiravir and half were given umifenovir.
The Italian Medicines Agency told the public that there is evidence that the drug is still being tested and is still in the early stages.
On April 2, Germany announced that it would purchase a drug from its Japanese stockpile, which the military would use to deliver the drug to university hospitals, where the drug would be used to treat COVID-19 patients.
In a South China Morning Post article, Shinzo Abe responded to the Trump administration's purchase of the drug, saying it may not be helpful for the virus that first caused the illness.
It may not be safe for use by pregnant women or those trying to conceive.
However, a study with lopinavir/ritonavir (Kaletra), a combination of the antiviral medication lopinavir and ritonavir, "showed no benefit".
The drug is designed for people living with HIV so that the protease synthesis is not altered.
A team of researchers from the University of Colorado is trying to modify the drugs to find agents that synthesize the protease of SARS-CoV-2. There is criticism from the scientific community over the direction of resources to reuse what has been developed specifically for HIV/Aids.
WHO has added lopinavir/ritonavir to the global cohesion trial.
Remdesivir was developed and developed by Gilead Sciences to treat Ebola virus and Marburg virus. Gilead Sciences later developed Remdesivir which had in vitro therapeutic activity against several filo-, pneumo-, paramyxovirus, and coronaviruses.
One problem is that the treatment is designed to treat resistance to replacement which can lead to several diseases and infections.
Some studies on remdesivir have shown that it has a high inhibitory response.There are several ongoing clinical trials, including two being conducted at Cleveland University Hospitals; one in patients with mild to severe allergies.
There is a clinical trial underway to take vitamin C in people hospitalized and those with severe COVID-19 pain; two placebo-controlled (Jena, Canada) and one uncontrolled (Italy).
The state of New York began testing the antibiotic azithromycin on 24 March 2020.
The Japanese National Center for Global Health and Medicine (NCGM) is planning a clinical trial of Teijin Alvesco (ciclesonide), an oral corticosteroid for acute coronary syndrome, to treat patients before they develop novel coronavirus.
It is an angiotensin-converting enzyme 2 phase II trial in 200 patients with severe pain in hospitals in Denmark, Germany, and Austria to determine the effectiveness of the treatment.
Researchers at the Montreal Heart Institute in Canada are currently investigating the role colchicine may play in reducing inflammation and hypertension in patients with mild to moderate COVID-19 disease.
The study, named COLCORONA, included 6,000 adults aged 40 and older who had been diagnosed with COVID-19 and therefore had chronic pain and needed to be hospitalized.
Pregnant women or women who are breastfeeding or who do not take a good birth control are not eligible.
Several anticoagulants are in the process of being tested in Italy.
Heparin low molecular weight is widely used in the treatment of patients, which led the Italian Medicines Agency to issue guidelines for its use.
A multi-clinical study with 300 patients using enoxaparin sodium for prophylaxis and treatment was announced in Italy on April 14.
Since SARS-CoV-2 is a virus, many scientists are focusing on reusing previously approved vaccines for the virus that were developed before the outbreak of MERS, SARS and West Nile virus.
Ribavirin: Ribavirin is recommended for the treatment of COVID-19 according to the 7th edition of the JNA guidelines.
Umifenovir: Umifenovir is recommended for the treatment of COVID-19 according to the 7th edition of the Jayna guidelines.
Some antibiotics have been found to be unsuccessful for reuse in treatment of COVID-19.
Tocilizumab (anti-IL-6 receptor): It was a drug that was approved.
The Italian and Japanese test also tested positive for COVID-19.
It is not yet clear what conditions may occur during pregnancy, including diabetes, heart failure, hypercoagulability or constipation, which may pose an additional risk to pregnant women as it is intended for non-pregnant women.
While there is no complete vaccine in clinical trials, there are several ongoing trials that are being considered for vaccination.
In late February 2020, the World Health Organization (WHO) stated that it does not expect a vaccine for SARS-CoV-2, a deadly virus, to be available in the next 18 months.
Five vaccines were selected for Phase I of the April safety study.
COVID-19 was detected in December 2019.
A global pandemic in 2020 led to a lot of investment and research to find a vaccine.
Many agencies are using insects to produce SARS-CoV-2 vaccines.
As reported in April, the CEPI program is developing vaccines that are then accelerated, have the capacity to produce, scale, and be available globally.
In April, CEPI scientists said 10 technology platforms were under study for testing in early 2020 for an effective COVID-19 vaccine.
The main objectives are to develop Phase I safety in studies, including:
nucleic acids (DNA and RNA) (Phase I - development and release of the vaccine of choice: Moderna, mRNA-1273)
Viral form (Introduction and emergence phase of the vaccine: CanSino Biologics, adenovirus type 5 factor)
According to CEPI scientists in April, 115 vaccine combinations have been developed from the early development of the vaccine, 78 ongoing projects have been confirmed (79, according to the Milken Institute), 37 others reported, but little information is available (which is said to have been planned or designed).
Phase II planned trials of safety and immunogenicity laboratory, usually randomized, placebo control, in many settings, while detecting obvious, effective theft.
Phase III trials typically involve multiple participants, including the control group, and the efficacy of the anti-anxiety drug trial, along with the adverse effects of the drug.
Of the 79 ongoing vaccines (confirmed as early as April 2020), 74 have not yet been evaluated in humans (still in "pre-trial" study).
As of 24 January 2020, in Australia, the University of Queensland announced the development of a potential molecular vaccine that would alter the structure of the viral protein to produce immune response.
As of 24 January 2020 in Canada, the International Vaccine Center (VIDO-InterVac) at the University of Saskatchewan announced the start of vaccine work, which is intended to begin human trials in 2021.
The projects to develop the vaccine were announced by the Center for Disease Control and Prevention on 26 January 2020, and the University of Hong Kong on 28 January.
As of 29 January 2020, Janssen Pharmaceutical Company, led by Hanneke Schuitemaker, announced that it had begun developing a vaccine.
Janssen is collaborating to develop an oral biotechnology vaccine, Vaxart.
On March 18, 2020, Emergent BioSolutions announced that they were co-developing the Vaxart vaccine.
On 8 February 2020, OncoGen Laboratory in Romania published a report that it had developed a vaccine similar to the vaccine neoantigen for cancer treatment.
On 25 March, the agency's chief researcher announced that they had completed development of the vaccine and were beginning trials.
On 27 February 2020, Generex's subsidiary, NuGenerex Ummo-Ancology, announced the launch of a vaccine project based on the li-Key peptide for a COVID-19 vaccine.
They want to develop a vaccine that can be tested on humans "in 90 days".
On 5 March 2020, Washington University in St. Louis announced the project to develop a vaccine.
On 5 March 2020, the US Army Research and Training Command at Fort Detrick and the Walter Reed Army Research Institute at Silver Springs, both in western Maryland, announced that they were working on a vaccine.
As of 10 March 2020, Emergent Biosolution announced that it is working with Novavax Inc.
the development and manufacture of vaccines.
People also announced that they are planning a pre-clinical trial and a Phase I clinical trial by the end of July 2020.
On 12 March 2020, the Health Minister of India announced that they are working with 11 people in isolation, and are accelerating the process so that it takes at least a year and a half to two years to develop the vaccine.
On 12 March 2020, Medicago, a biotechnology company based in Quebec City, Quebec, said it was developing coronavirus-like products with part of its funding from the Canadian Foundation for Medical Research.
The laboratory-selected vaccine, human trials planned for July or August 2020.
Earlier this week, The Guardian published that US President Donald Trump had given CureVac "a lot of money to independently evaluate the Covid-19 vaccine", despite the opposition of the German government.
On 17 March 2020, the US pharmaceutical company Pfizer announced that it is working with the German company BioNTech to develop an mRNA vaccine.
The mRNA vaccine is designated BNT162, which is currently undergoing clinical trials and is expected to begin clinical trials in April 2020.
Italy On 17 March 2020, Takis Biotech, an Italian biotech company, announced that they would receive the results of the clinical trial before April 2020, and that the vaccine they choose would begin testing in the autumn.
France 19 March 2020, the Prep for the Influenza Program Partnership (CEPI) announced US$4.9 million in funding for COVID-19 vaccine research from the collaborative vaccine research from the Institut Pasteur, Themis Bioscience (Fuyeena, Astariya), University of Pittsburgh, bringing the total CEPI funding for the COVID-19 vaccine to US$29 million.
Other CEPI partners that are funding the development of COVID-19 vaccines are Moderna, Curevac, Inovio, Novavax, the University of Hong Kong, Oxford University, and the University of Queensland.
On 20 March 2020, Russian health officials announced that scientists have begun testing a selection of different vaccines on animals.
Researchers at Imperial College London announced that on 20 March 2020 they will develop a self-sustaining RNA vaccine for COVID-19.
The vaccine was selected 14 days after the pandemic was discovered.
In late March, the Canadian government announced that it would invest C$275 million in 96 research projects to combat COVID-19, including several imported vaccines run by Canadian companies and universities, such as the Medicago and University of Saskatchewan programs.
Until then, the Canadian government has announced C$192 million specifically for the COVID-19 vaccine, and plans to create a national "vaccine reserve" for several new vaccines that can be used for the next coronavirus pandemic when it arrives.
On 2 April 2020, researchers from the University of Pittsburgh Department of Medicine reported testing PittCoVacc, a COVID-19 vaccine being tested on mice, stating that "MNA provides SARS-CoV-2 S1 vaccine and specific antigen-antibody response [in mice] that starts within 2 weeks of being injected".
On 16 April 2020, the Canadian Waterloo University Department of Pharmacy announced the development of a DNA vaccine that can be administered through the nose.
Using bacteriophages, DNA is designed to convert bacteria from non-human to harmless viruses, which can make the immune system produce antibodies to the SARS-CoV-2 virus.
In March 2020, the US government, industry, and three universities joined forces to acquire a dedicated IB computer, which could store data on the resources of Hewlett Packard Enterprise, Amazon, Microsoft, and Google.
Some statues have a common function, also known as an unspecified function.
This means that it can be useful for more than just preventing pain.
The additional randomized trial in Austria is required to control the enrollment of 4,170 health care workers.
It is possible that the vaccine is unsafe or ineffective.
Preliminary studies evaluating the vaccine's effectiveness using specific COVID-19 animals, such as mice injected with ACE2, other animal laboratories, and non-human subjects, show that the level 3 safety of the vaccine measures against live virus, and the global collaboration to ensure systemic safety standards, are achievable.
The SARS and MERS vaccines have been tested on non-human models.
As of 2020, there is no cure or vaccine for SARS that has been found to be safe and harmless in humans.
According to the reports of the study published in 2005 and 2006, the identification and development of novel vaccines and drugs to treat SARS has been a priority for governments and health agencies around the world.
With the emergence of MERS, it was seen that existing research on SARS could provide an effective model for vaccination and treatment of MERS-CoV infection.
As of March 2020, there was a (DNA) MERS vaccine that completed phase I of human trials, and three others are underway, all viral vaccines, two adenoviral viral (ChAdOx1-MERS, BVRS-GamVac), and one MVA viral (MVA-MERS-S).
Posters were posted on social media stating that the virus that causes COVID-19 is known and vaccinations have already been done.
The companies posted on various social media platforms the company's first HIV vaccine and vaccines for other coronavirus diseases such as the SARS coronavirus.
Coronavirus b' is a group of related viruses that are transmitted by rodents and birds.
Common symptoms include pain, cough, and shortness of breath.
Other symptoms include fatigue, muscle pain, diarrhoea, throat tightness, foul odor, and stomach pain.
The time from infection to symptom formation is usually about five days, but can be between two and fourteen days.
Although it usually causes mild pain, it can also be caused by viral pneumonia and the failure of many cells.
As of 17 April 2020, more than 2.24 million cases have been reported in 210 countries and territories, resulting in more than 153,000 deaths.
More than 568,000 people have recovered from the virus, which is spread primarily by close contact, and even through saliva droplets from an infected person when they cough, sneeze, or speak.
Although these spots are caused by respiration, they usually occur on the ground or in touching areas where a distance would be necessary to separate them.
Many people can get it by touching a surface on which it is found and then touching their eyes, nose, or mouth.
The virus can survive on surfaces for up to 72 hours.
It is most common in the first three days after the onset of symptoms, although it can be transmitted earlier than the onset of symptoms. The standard method of detection is the instantaneous transcript of the polymerase response (rRT-PCR) of the tumor sample.
The use of masks is recommended for people suspected of having the virus and for caregivers.
The recommendations for the general public vary, with some authorities advising against, some recommending, and others making it mandatory.
At present, there is no specific vaccine or specific drug for the treatment of COVID-19 virus.
Chronic transmission of the disease has been reported predominantly in all six WHO regional areas.
These infections are viruses that cause symptoms similar to the flu, such as nausea, fatigue, and shortness of breath.
Symptoms include difficulty breathing, persistent chest pain or pressure, dizziness, stiffness, and bruising of the face or back; immediate medical attention is recommended if these symptoms are present.
Less widespread, severe respiratory symptoms such as wheezing, runny nose or throat tightness may occur.
Stomach symptoms such as nausea, dizziness, and diarrhea were observed in a variety of cases.
In some cases, Jayna was initially diagnosed with chest pain and a heartbeat.
In some cases, the cause may be lung disease, cell mutation failure, and death.
This is called the symptom-free period.
The symptom-free period of COVID-19 is usually short, ranging from five to six days, with most being two to 14 days.
97.5% of people who develop symptoms will develop the infection within 11.5 days, and reports indicate that not all infected people will develop symptoms.
The role of these symptoms in infection is not yet known; however, preliminary evidence suggests that they may be contributing to the spread of the disease.
The number of people who develop symptoms is unknown at this time, according to a study by the Korea Center for Disease Control and Prevention (KCDC) that 20% of all confirmed cases develop symptoms while in hospital.
The Jayna National Health Authority began adding symptomatic cases to the daily cases from 1 April; of the 166 people infected that day, 130 (78%) had symptoms during the period being tested.
Some bites and stings can carry a large number of viruses.
A large number of such leaves gives a higher score than a small number of leaves.
A study conducted in Singapore found that a cough that is not put into the mouth can cause the throat to fly up to 4.5 meters (15 feet).
Although the virus is not airborne, the Royal Institute of Science has stated that bioserol transmission is possible and that air collectors on the balconies outside the common rooms have been found to contain the RNA virus.
Some medical procedures, such as cardiopulmonary resuscitation (CPR), may involve the removal of breath from the person, which may then lead to respiratory infection.
Although the patient is concerned about the possibility of infection via feces, the risk is considered to be low. The virus is most likely to be transmitted to people with symptoms; although it is possible to transmit to asymptomatic people, the risk is low.
The European Union's Centre for Disease Control and Prevention (ECDC) says that while it is unclear how easily the disease can spread, it typically infects two to three people per person. The virus can survive on a surface for hours to days.
Specifically, the virus can survive on cardboard surfaces for one day, three days on plastic (polypropylene) and metal (AISI, 304) for four hours at 99% survival.
This varies, however, depending on the humidity and temperature of the air.
Soap and detergent are also affected if used correctly; soap destroys the protective viral coating on the surface, as well as removes skin and skin lesions.
Alternatives, such as benzalkonium chloride and chlorhexidine gluconate (an insecticide), which is of little efficacy.In a study in Hong Kong, saliva samples were taken with medication for two days after hospitalization.
In five to six patients, the first sample had a high viral load, and the sixth patient had a higher viral load on the second day of testing.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel novel respiratory syndrome coronavirus, the first three people to be hospitalized had a combination of severe acute respiratory syndrome in Wuhan.
All novel SARS-CoV-2 forms of the virus are related to the natural coronavirus.
In the human body, the virus is killed by household soap, which breaks through the protective layer. SARS-CoV-2 is closely related to SARS-CoV.
The lung is the cell most affected by COVID-19 as the virus can enter angiotensin-converting enzyme 2 (ACE2) cells, which is common in type II alveolar cells of the lung.
The virus uses glycoprotein superstructures called peplomers to bind to ACE2 and all receptors.
Severe cardiac injury occurs in 12% of the patients hospitalized in Wuhan, China, and is most common in acute pain.
The heart rate is high, which causes inflammation response and disrupts the immune system during the course, but severe myocardial injury can also be associated with ACE2 receptors in the heart.
ACE2 receptors are found in the heart and are involved in the heart's failure.
Increased incidence of thrombosis (31%) and venous thromboembolis (25%) was observed in ICU patients with COVID-19 and may be associated with their poor health. In a positive laboratory test on people who died of COVID-19 was found to have alveolar damage (DAD), and with lymphocyte burns in the lung filter.
While SARS-COV-2 has ACE2-like tropism in epithelial cells associated with the respiratory tract, patients with COVID-19 have more severe symptoms of inflammatory system.
Specifically, GM-CSF-induced T-cell pain has been associated with increased IL-6 inflammation and exacerbation of pulmonary pain in COVID-19 patients.
Lymphocytic inflammation is also detected in the urine test.
WHO has published several laboratory tests of the pain.
The official method of sampling is to replace the polymerase response (rRT-PCR) script.
The test is only done on the tissue sample taken with a nasal swab; however, tissue or skin samples can also be used.
The result is usually available within a few hours to two days.
Blood can also be used, but it will require blood samples taken every two weeks, and the result will be slightly different.
Chinese scientists have isolated the coronavirus cell and released it as a sample so that global laboratories can spontaneously produce a PCR sample to detect the virus.
On 4 April 2020, an antibody test (which detects active infection and whether a person has previously had the infection) was developed, but has not yet been widely used.
A laboratory test of Jain showed that it was 60 to 70 percent accurate.
The US FDA approved the laboratory for primary care on 21 March 2020 for use by the end of the month. The laboratory guidelines were published by the Zhongnan University Hospital in Wuhan under its recommended diagnostic methodology based on the clinical trial model of pandemic risk.
Two-sided glass sub-tipoles with periphral opacities and widely distributed asymmetric posterior are the most common.
Subpleural hyperplasia, severe formation (lobular septal defect in variation), and the same ear can be a painful process.
Little information is available on the prevalence and severity of COVID-19.
The most common pain diagnosed in the laboratory is:
Mascroscopy: pleurisy, pericarditis, pulmonary occlusion and oedema of the lungs
Four more severe strains of the virus have been identified:
Some lung diseases: pulmonary edema, pneumocyte-induced pneumocytosis, a wide variety of other forms of pneumocytosis, inflammation of the intestine with lymphocytic and multinucleated lymphocytes from the cell structure.
severe pulmonary disease: alveolar entry damage (DAD) is excluded.
DAD is caused by acute respiratory distress syndrome (ARDS) and hypoxemia.
tropical lung diseases: what to do with alveolar and intestinal removal of the lungs
Blood: closed muscle distribution (DIC); leukoerythroblastic response
Steps to reduce the transmission of infection include staying in the kitchen, avoiding public areas, washing hands frequently with soap and water and scrubbing for at least 20 seconds, maintaining respiratory hygiene and avoiding contact with eyes, nose, or mouth without provocation.
The CDC recommends removing the mouth and nose cloth when coughing or sneezing and recommends using the insole if there is no cloth.
The correct amount of pleasure after a cough or sneeze.
The CDC recommends the use of clean cloths and face coverings in outdoor settings to reduce contact with personal friends. Social distancing is intended to reduce transmission by crowding out schools and workplaces, restricting movement and stopping mass gatherings.
The recommendations for social distancing include that people should stay 6 feet (1.8 meters) apart from each other.
There is no known cure for COVID-19. A vaccine is not expected to be available until early 2021, a key part of controlling COVID-19 is to reduce the rise in transmission, known as "flow reduction".
The CDC recommends frequent washing with soap and water for at least 20 seconds, especially when the hands are wet or exposed to the air, before handling food and after handling, chewing or eating meat.
It is also recommended to use hand sanitizers with at least 60% alcohol, but only when soap and water are not available. Where hand sanitizers are not commercially available, WHO provides a procedure for customization.
In this case, the antimicrobial activity comes from ethanol or isopropanol.
Hydrogen peroxide is used to remove bacterial activity in alcohol; it is not an "active substance".
Glycerol is added to humectant.
People are administered supervised care, which includes fluid therapy, oxygen support, and support to other cells affected by the virus.
The CDC recommends that people suspected of having the virus wear a face mask.
Extracororeal oxygen uptake (ECMO) is used as a response to respiratory distress, but its usefulness is still being investigated.
Personal hygiene and a healthy lifestyle and diet are said to boost immunity.
Supportive therapy may be helpful for people with mild symptoms in the early stages of the disease.WHO and the National Health Commission of India have issued recommendations for the protection of hospitalized people with COVID-19.
Gastrointestinal and pulmonary physicians have combined the recommended American treatments from various organizations to create a free resource, IBCC.
As of April 2020, there is no specific treatment for COVID-19.
For symptoms, some health professionals recommend that acetaminophen be given first instead of ibuprofen.
Care should be taken to reduce the risk of transmission of the virus, especially in health care settings when performing treatments that may involve inhalation, such as intubation or hand ventilation.
For healthcare professionals caring for people with COVID-19, the CDC recommends that people be admitted to the AIIR in addition to taking normal precautions, social distancing, and ventilation precautions.The CDC said the guidelines for using personal protective equipment (PPE) during the pandemic.
The recommended precautions are: wearing a PPE, respirator, eye protection, and hand washing.
The N95 mask was approved for this purpose but the FDA issued an Emergency Use Approval (EUA) mask for use.
It is intended to protect against respiratory infections such as the common cold but is not guaranteed for any use.
When masks are not available, the CDC recommends that the mask be worn, or, if not otherwise available, that a mask be made at home.
In most cases, COVID-19 is not very severe or does not change its pattern, but in some cases it is.
The respiratory support modes for COVID-19 are associated with respiratory failure which is well studied in people in hospital, with evidence suggesting that nasal or dual nasal airway tubes can be avoided.
Whether these two are equally useful to the patient is unknown.
Some doctors prefer to stay at home with a respirator when available, as this method limits the spread of the respiration compared to a nasal.In more severe cases, it is common in adults (people over 60, and especially over 80).
Many developing countries do not have enough hospital beds for their population, limiting the capacity of health systems to deal with a sudden increase in the number of people with severe COVID-19 who require hospitalization.
One study in Jaina found that 5% of people in the intensive care unit, 2.3% required a respiratory support machine, and 1.4% died.
In fact, an average of 30% of people hospitalized for COVID-19 were later transferred to the ICU.
The respiratory system is complicated by the acute respiratory distress syndrome (ARDS) when COVID-19 increases and oxygen intake becomes more difficult.
A respirator capable of pressure-management mode and high PEEP was required to maximize oxygen delivery to reduce the risk of respiratory injury associated with lung and preumothorax.
The PEEP is not available on the front of the respirator.
A study suggests that treatment will begin in January 2020, and the antiviral drugs will be clinically tested.
Remdesivir seems to be the most effective.
While new drugs will be available for use until 2021, several of these drugs have already been tested and approved for other uses or for advanced use.
Viral medicines can be tested in people with severe pain.
The WHO said that people with convalescent plasma will participate in trials of the efficacy and safety of future treatments.The FDA has granted provisional approval for convalescent plasma as an experimental treatment when a person's condition is severe or requires immediate treatment.
There are no clinical trials of the drug to demonstrate its effectiveness against pain.
In February 2020, Jayna developed an app for working with pandemic pain.
Users are required to enter their name and personal identification number.
The app is able to track 'close contacts' using surveillance information and potential self-harm.
Each user can also view the status of three other users.
If a potential threat is detected, the app not only recommends a place to connect, but also alerts local authorities. It edits a lot of data including phone calls, facial recognition, mobile tracking and technology is used to keep track of infected people and people who have been in South Korea, Taiwan and Singapore.
In March 2020, the Israeli government approved the Mind Agency to monitor mobile phones of suspected coronavirus cases.
Measures have been taken to enforce quarantine and protect people who have been in close contact with infected people.
Also in March 2020, Deutsche Telekom shared phone location information with the German federal government agency, Robert Koch Institute, to investigate and prevent the spread of the virus.
Russia has developed facial recognition technology to track people who have violated quarantine orders.
Italian regional health commissioner Giulio Gallera told the telephone company that "40% of people go as they please".
The German government conducted a 48-hour computer-based study over the two-day holiday with more than 42,000 participants.
Also, the president of Estonia, Kersti Kaljulaid, has made a global call for solutions to the spread of the coronavirus.
People may be anxious about quarantine, immigration restrictions, adverse health effects of treatment or fear of contracting the disease.
"The rise in isolation, loneliness, news, panic and financial closures are a storm of negative effects on people's mental health and safety", the BBC quoted Rory O'Connor as saying.
It may also reduce the symptoms of other respiratory illnesses, such as the common cold.
Mild cases usually take two weeks to recover, while severe cases can take up to six weeks.
Pregnant women may be at higher risk of contracting COVID-19 as determined by information from similar viruses, such as SARS and MERS, but information on COVID-19 is still scarce. In some people, COVID-19 may affect the underlying cause of lung disease.
In severe cases, COVID-19 can cause acute respiratory distress syndrome (ARDS) that can cause respiratory distress, blood pressure dizziness, or muscle paralysis.
COVID-19-related complications of blood toxicity, abnormal blood clotting and damage to the heart, kidneys, and liver.
An abnormal blood clot usually increases the time it takes for a blood sample to be drawn, and is reported to affect 6% of people hospitalized with COVID-19, while abnormal kidney function is seen in 4% of this group.
On average, 20-30% of people who have been diagnosed with COVID-19 have elevated levels of liver enzymes (transaminases).
The same report says that the time between the onset of symptoms and death is about ten days, with five days in hospital.
However, the time between hospitalization and death for patients transferred to the ICU is seven days.
In a study of early cases, the time from the appearance of mild symptoms to death is 14 days, with a maximum of 41 days.
According to a study by the National Health Commission (NHC) in Geneva, men have a mortality rate of 2.8% while women have a mortality rate of 1.7%.
Histopathological laboratory analysis of lung samples from alveolar fubromycoid lesions that have been removed from the lungs.
The mutation of the virus has been mutated to the causative disease.
The lung scan showed acute respiratory distress syndrome (ARDS).
In 11.8% of deaths reported by the National Health and Medical Research Council, heart damage was found to be caused by troponin increase or heart failure.
According to data from March in the United States, 89% of hospitalized patients had a pre-existing illness. Available drug resources and local economic culture may influence mortality.
Estimates vary because of the circumstances and environments, but also because of the complexity of the design.
The reduction in the number of minor cases of death has been exaggerated.
However, since the deaths were caused by the delay in time, the potential for a decrease in the number of deaths is now reduced.
Smokers are 1.4 times more likely to develop severe COVID-19 illness and an average of 2.4 times more likely to improve their health or die than non-smokers.
Hong Kong hospital management found a 20% to 30% decrease in lung capacity in people recovering from the illness, and lung imaging showed cellular damage.
This can also lead to adverse health effects.
As of March 2020, it is unknown whether other long-term illnesses and immune system defects have been overcome by infection.
Infertility may occur, based on other coronavirus behaviour, but the recovered cases of COVID-19 were followed by laboratory tests for coronavirus and subsequent reporting.
These cases are considered to be more severe than a kidney infection that could become another infection.
The virus is considered to be of natural animal origin, transmitted by infection.
The official origin is unknown, but by December 2019 the spread of the disease was completely inter-human.
A study of 41 first confirmed cases of COVID-19, published in January 2020, The Lancet, stated that the earliest date of onset of symptoms was 1 December 2019.
An official report by the WHO said that the symptoms started on December 8, 2019.
Several popular measures have been developed to justify the death penalty.
These figures vary by location and duration and may be influenced by the size of the laboratory, health care quality systems, treatment options, time to onset and patterns of infection such as age, sex and general health.
In late 2019, WHO classified ICD-10 as a case code U07.1 for deaths from laboratory-confirmed SARS-CoV-2 infection and U07.2 for deaths in clinical or laboratory-confirmed COVID-19 infection from laboratory-confirmed SARS-CoV-2 infection. The case fatality rate is expressed as the number of deaths divided by the case wave received over a specific time period.
According to Hopkins University statistics, the mortality rate for cases of influenza was 6.9% (153,822/2,240,191) as of 17 April 2020.
Other measures include the CFR, which indicates the number of people who have died as a result of the disease, and the IFR, which indicates the percentage of people (with or without testing) who have died as a result of the disease.
These statistics may not be timed and do not follow a specific sample of cases.
Although not all people have antibodies, the presence of antibodies can provide information about the number of people who have contracted the disease.
In the most prevalent area in Italy, Castiglione d'Adda, a small village of about 4,600 people, 80 (1.7%) died.
Galgelt, the disease spread through the Carnival event, and spread to a smaller population, which resulted in a relatively low number of deaths, not all COVID-19 deaths were attributed to the disease.
Also, the German healthcare system is not very flexible.
Of those, about 3% had antibodies, according to the blood donor.
69 (0.004% of the population) were confirmed to have died from COVID-19.
The impact of pain and depression is not significantly different for men and women.
Mortality is higher among men in the studies conducted in Germany and Italy.
The risk is higher for men in their 50s, with the gender gap being only 90 years.
In addition, the mortality rate was reported to be 2.8 percent for men and 1.7 percent for women.
The exact reason for the gender difference is unknown, but it is thought that genetic and behavioral factors may be involved.
Gender-based differences in immunity, lower smoking among women and the fact that men have erectile dysfunction less often than women have contributed to higher mortality among men.
In Europe, 57% of the individuals who contracted the disease and 72% of those who died from COVID-19 were men.
As of April 2020, the US government is not tracking the data on the national death toll from COVID-19.
Studies show that viral diseases such as Ebola, HIV, influenza and SARS affect men and women differently.
A high proportion of health workers, especially health care assistants, are female, and they are more likely to be infected with the virus.
The World Health Organization announced on 11 February 2020 that the official name of the disease is "COVID-19".
WHO chief Tedros Adhanom Ghebreyesus says CO stands for corona, VI stands for virus, and D stands for disease 19 when the pandemic was first detected: 31 December 2019.
The name was chosen to avoid referring to a specific locality (such as a place), an animal species or a group of people, in line with international naming guidelines to avoid discrimination. The virus that causes COVID-19 is called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
WHO also uses "COVID-19 virus" and "virus causing COVID-19" in its reports.
Both the disease and the virus are called "coronavirus".
During the early outbreak in Wuhan, China, the virus and disease were known as "coronavirus" and "Wuhan coronavirus".
In January 2020, WHO recommended that 2019-nCov and 2019 nCoV acute respiratory illness be temporary names for viruses and illnesses in accordance with 2015 guidelines not to be used in place when naming illness and virus.
The official names for COVID-19 and SARS-CoV-2 were created on 11 February 2020.
As there were limitations on the level of sales, some digital manufacturers printed health care products such as a tissue sample brush and components of respirators.
For example, when an Italian hospital urgently ordered respirator systems, and lacked the necessary supplies at the time, a local startup developed and printed 100 faucets in one night.
Since the first outbreak of COVID-19, there has been a lot of misinformation and misinformation about its origin, extent, prevention, treatment and other aspects of the disease that need to be urgently addressed online.
Humans seem to be more capable than some other animals.
It has not been detected in studies as a virus from pigs, turkeys, and chickens.
There are no approved medicines or vaccines to treat it.
Global studies on COVID-19 vaccines and medicines are being conducted by government agencies, academic groups and research departments.
In March, the World Health Organization launched a "PREMISE trial" to evaluate the efficacy of a prescription antiviral drug that was then said to be effective.
Probably not, but various organizations are working on vaccination.
Early work on SARS-CoV was facilitated as the SARS-CoV and SARS-CoV-2 pairs are used to bind to the ACE2 receptor that enters the cell without human interference.
There are three stages of vaccination that are being investigated.
First, researchers are aiming to develop a vaccine for all viral strains.
The use of this type of virus, which is either inactivated or dead, is intended to inhibit the immune system's response to the novel COVID-19 infection.
The second stage, the emergence of the vaccine, seeks to determine the vulnerability of the immune system to certain viruses.
In the case of SARS-CoV-2, these studies focus on the S-receptor protein that assists the virus in binding to the enzyme ACE2.
The third component of the vaccine is nucleic acid (DNA or RNA vaccine, novel technique for making the vaccine).
A pilot vaccine developed at a cost of one will be tested for safety and efficacy. On 16 March 2020, the first clinical trial of the vaccine began with four volunteers in Seattle.
The vaccine contains a harmless copy of the virus that causes the disease.There is an increasing number of antibodies that claim to be a challenge to the SARS-COV-2 vaccine, but this is disputed.
There are over 300 active clinical trials in progress as of April 2020.
Several trials have been evaluated and pre-approved for malachite, including studies on hydroxychloroquine or chloroquine.
The reuse of antiviral drugs was the focus of the Jaynes study, which underwent nine phase III trials of remdesivir in several countries, according to a report released in late April.
Widespread criticism of the clinic's development of the COVID-19 vaccine and the drugs developed, April 2020. Several early antiviral drugs have been studied for the treatment of COVID-19, including remdesivir, chloroquine and hyroxychloroquine, lopinavir/ritonavir and lopinavir/ritonavir in combination with interferon beta.
Cadaymayan is tracking the remdesivir decline, as of March 2020.
There has been a marked improvement in the health of patients after the compassionate use of remdesivir.
Phase III clinical trials were conducted in the United States, China, and Italy. Chloroquine, previously used as a malaria antibiotic, was studied in China in February 2020, with preliminary results coming out.
But there is something that fellow researchers should be looking at.
The Korean Health Administration and the Chinese government recommend the use of chloroquine.
However, the Wuhan Virology Institute, despite recommending a daily dose of one gram, states that a double dose is more than the risk of adverse effects.
On 28 March 2020, the FDA issued emergency use approval for hydroxychloroquine and chloroquine approved by a doctor treating people with COVID-19. The 7th edition of the FDA guidelines also includes interferon, ribavirin or umifenovir for use against COVID-19.
Preliminary data suggests that ribavirin is being administered nasally in vitro for SARS-CoV-2.
Nitrozoxanide was proposed for future use in vivo studies after detection of mild respiratory depression in SARS-CoV-2.Studies of the early-onset protein sequence-transfer protease 2 (TMPRSS2) are essential for the entry of SARS-CoV-2 into the ACE2 receptor.
Studies of chloroquine and hydroxchloroquine with and without azithromycin are very limited in the community health prevention of these treatments without study.Oseltamivir does not restrict SARS-CoV-2 transmission in vitro and its role in the treatment of COVID-19 is unknown.
Cyroquin cyclones can be a problem in the later stages of severe COVID-19.
There is evidence that hydroxychloroquine may have anti-cytokine activity.Tocilizumab is also on the National Health Board's treatment guidelines after the study is complete.
The current phase 2 is not a nationally randomized Italian clinical trial after a randomized controlled trial of patients with severe pain.
The addition of serum ferritin to the blood test for cyclonic cytokine detection, results in a synthetic antibody, which is considered to be lethal in some people.
An interleukin-6 receptor antagonist was approved by the FDA based on the results of clinical studies that induce cytokine-induced steroidal infection, CAR T cell in patients, 2017.
To date, there is no evidence of any human-controlled treatment of CRS infection.
Transmission of the purified and concentrated antibodies produced in the immune system of people recovering from COVID-19 to people in need is being investigated in a non-vaccine and immunological method.
This person was treated for SARS with incomplete results.
Viral strains with the desired mode of action of the sleep-dependent antibody can be rapidly transmitted to SARS-CoV-2.
Other methods, such as antibody-dependent cell cytotoxicity and/or phagocytosis, are possible.
Other forms of anti-wrinkle therapy, for example, using monoclonal anti-wrinkle, are being developed.
Convalescent material in serum, which consists of a liquid fraction of blood taken from a patient containing specific antibodies to the virus, can increase rapid formation.
Coronavirus, a group of closely related diseases
Li Wenlian, a doctor at Wuhan Central Hospital, who later contracted COVID-19 and died after reporting the virus outbreak.
Li Wenlian, a doctor at Wuhan Central Hospital, who later contracted COVID-19 and died after reporting the virus outbreak.
